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RÉSUMÉ 
Les Inuits du Nunavik regroupent des peuples autochtones de l'Arctique qui au fil de 
l’histoire ont formé une petite population isolée dans la région du Nunavik (nord de la province 
de Québec, Canada). Le profil génétique unique des Inuits du Nunavik est le résultat d’une 
adaptation à leur milieu de vie et il est considéré comme lié à certaines de leurs susceptibilités 
pathologiques. Une évolution neutre, ainsi qu’une suite d’événements adaptatifs, ont façonné le 
génome de ces Inuits et indirectement engendré leur prédisposition accrue à certains troubles 
cardio-vasculaires et cérébro-vasculaires (ex : hypertension et anévrismes intracrâniens (AI)). 
Les AI sont des faiblesses cérébro-vasculaires localisées pouvant mener à des dilatations 
et renflements localisés de la paroi vasculaire. De telles distorsions sont susceptibles de 
perturber les vaisseaux et entrainer des hémorragies sous-arachnoïdiennes. Les AI sont un 
désordre complexe dont la prévalence est élevée (4-8%) et différentes populations (non reliées 
aux Inuits) ont aussi un risque accru de développer des AI. Le développement des AI est associé 
à la fois à des facteurs environnementaux et génétiques; plusieurs études génomiques ont 
identifié des régions associées aux AI. Une grande part de l'héritabilité génétique des AI 
demeure encore inexpliquée, en particulier dans des populations autres que les finnois et les 
japonais. Toutefois il est à noter que peu d’études génétiques des AI ont tenu compte de la 
contribution de variations génétiques spécifiques à la population étudiée. 
Pour améliorer nos connaissances sur la part encore inexpliquée de l'héritabilité des AI 
(qui implique une grande hétérogénéité génétique et des variations peu pénétrantes), nous avons 
combiné le séquençage à haut débit au génotypage des polymorphismes sur puces afin d’établir 
la signature génétique des deux populations fondatrices du Québec prédisposées aux AI (Inuits 
du Nunavik et Canadiens français). Comme ces populations ont des caractéristiques distinctes, 
nous avons utilisé des approches différentes pour tenter d’identifier des facteurs de risque 
génétiques. Les Inuits du Nunavik représentent une population autochtone et de nombreux 
aspects de leur signature génétique diffèrent de celles des principales populations, nous avons 
choisi d’approfondir leur histoire et profil génomique avant de vérifier si des associations 
génomiques pouvaient être établies avec les IA. Nous avons tout d'abord examiné les régions 
codantes du génome et observé de nombreuses composantes génétiques spécifiques aux Inuits 
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du Nunavik qui reflètent que la population s’est adaptée à son environnement (ex: ascendance 
Inuit homogène, augmentation du déséquilibre de liaison et signature génétique). Des signes de 
sélection naturelle, jusqu’alors non-identifiés, ont révélé une accumulation de variations 
génétiques dans des gènes impliqués dans le processus d'adhésion cellulaire et de la réponse 
immunitaire (ex. CPNE7 et ICAM5). D'autres analyses ont révélé un variant dans le gène CCM2 
qui présente une sélection positive et est significativement associé aux AI chez les Inuits du 
Nunavik. En ce qui concerne l'étiologie génétique des AI dans la population des Canadiens 
français, nous avons adopté une approche différente et utilisé des variations spécifiques aux 
Canadiens français, qui ont été identifiées par le séquençage complet de l'exome. Ces variations 
ont permis de générer une liste de gènes à risque potentiel, qui ont ensuite été priorisés en 
utilisant un test d'association par gène de type « burden ». RNF213 est apparu comme le meilleur 
gène candidat; il est vraisemblablement la conséquence d’une dérive génétique. Les mesures 
génétiques et fonctionnelles subséquentes ont validé la contribution possible de RNF213 au 
développement des AI chez les Canadiens français. Les résultats présentés dans cette thèse 
soulignent l'importance de prendre en compte le contexte génétique spécifique apporté par 
l'évolution lorsqu'une maladie complexe est étudiée. Il a également été montré que les variations 
d’un gène spécifique (ex. CCM2 et RNF213) peuvent contribuer au développement de 
différentes pathologies lorsqu'ils sont observés dans des populations distinctes. D'une manière 
générale, nos découvertes génétiques ont permis d’identifier de nouvelles « pièces » génétiques 
et pour avancer le « casse-tête » incomplet de l'héritabilité génétique des AI ; la génétique des 
populations a été un élément clé pour cette avancée. 
 
Mots-clés : Inuits du Nunavik, Canadiens-français, anévrismes intracrâniens, séquençage 
complet de l'exome, adaptation, maladies cérébrovasculaires, génétique des populations  
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ABSTRACT 
Nunavik Inuit is a group of Arctic indigenous people, who have historically regrouped 
as a small and isolated population across the Nunavik region of northern Quebec (Canada). The 
unique genetic profile of Nunavik Inuit is the result of years of adaptation to their living 
condition, and it is likely responsible for their increased susceptibility to certain pathological 
conditions. Prior studies have shown that as a consequence of neutral evolution or past adaptive 
events, today’s Inuit are predisposed to cardio-cerebrovascular disorders, e.g. hypertension and 
intracranial aneurysm (IA).  
IA is defined as localized cerebrovascular weakness which leads to vascular dilation or 
ballooning, and such distortions are susceptible to disrupt the affected vessels and lead to 
subarachnoid hemorrhage. It is a complex disorder with a high prevalence (4-8%) and certain 
populations have been observed to present an increased risk of developing IA. Both 
environmental and genetic factors are deemed to contribute to the development of IA and in 
regards to the latter, independent genome-wide association studies (GWAS) have identified 
multiple loci associated with IA. Nonetheless, there is still a large portion of the genetic 
heritability of IA, especially in different populations other than Finnish and Japanese that 
remains unexplained. However, fewer IA genetic studies have taken in consideration the 
contribution of population specific genetic variants. 
To address some of the IA missing heritability that is deemed to be accountable to its 
genetic heterogeneity and low penetrance, we have combined high throughput sequencing 
(HTS) with SNP-chip genotyping to examine the genetic signatures of two founder populations 
from Quebec that are predisposed to IA, including Nunavik Inuit and French-Canadians (FC). 
Because these populations have distinct genetic characteristics, we used different approaches 
for the identification of genetic risk factors. Nunavik Inuit is an indigenous population and many 
aspects of its genetic signatures differ from those of separate world-wide major populations; 
therefore we chose to conduct extensive population genetic studies in regards to their genetic 
history and genomic profile before we undertook to test if any association could be established 
between genomic loci and disease susceptibility. We observed many genetic components that 
are specific to the Nunavik Inuit population, including its homogeneous Inuit ancestry, increased 
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linkage disequilibrium (LD) and genetic signatures which reflect the population had a long 
history of adaptations to their environment. Previously unidentified signals of natural selection, 
which focused on coding regions of the genome revealed an accumulation of genetic variants in 
genes involved in the processes of cell adhesion and immune responses (e.g. CPNE7 and 
ICAM5). Further analyses revealed a variant in CCM2 to be under positive selection and 
significantly associated with IA in Nunavik Inuit. In regard to the genetic etiology of IA in the 
French-Canadian population, we took a different approach and used French-Canadian specific 
variants that were identified by whole exome sequencing to generate a list of potential risk 
genes; which were further prioritized using a gene based burden association test. RNF213 
emerged as a prime candidate gene that had undergone possible genetic drift and the follow-up 
genetic and functional examinations further supported its potential contribution to the 
development of IA among French-Canadians. The results presented in this thesis highlighted 
the importance of taking into consideration the specific genetic background brought by natural 
selection or genetic drift, both are driving forces of evolution, when a complex disease is being 
studied. It also further confirmed that variants in a specific gene (e.g. RNF213 or CCM2) may 
contribute to the development of different pathogenesis when examined in distinct populations. 
Overall as our genetic findings identified new genetic “pieces” that further completed the 
missing heritability “puzzle” of IA genetics; evidence for these “pieces” were interestingly 
highlighted through population genetics.  
Keywords: Nunavik Inuit, French-Canadians, intracranial aneurysms, whole exome 
sequencing, adaptation, cerebrovascular disease, population genetics 
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CHAPTER 1: INTRODUCTION 
1.1: PREFACE 
Gaining an understanding of genetic profiles across the full length of genomes has proved to be 
critical to our understanding of human genetic history and local adaptation; it has concomitantly 
helped to delineate the genetic etiology for a number of complex human disorders. The recent 
advancements made for high-throughput sequencing and genotyping technologies have greatly 
enhanced our present ability to identify the genome-wide genetic signatures of specific 
populations, as it eased the unravelling of disease risk factors. The literature reviews presented in 
the introduction section will cover two seemly unrelated area of studies, nonetheless both areas are 
essential for the question to be explored in this thesis: 1) recent advances of the population genetic 
studies about Inuit and related Arctic indigenous populations; and 2) genetic studies of IA, a 
complex cerebrovascular disorder with increased prevalence in certain populations including 
French-Canadian and Inuit. 
Chapter 1.2 will essentially be dedicated to findings recently published by a number of 
genetic and genetic anthropological studies of Greenland Inuit and indigenous Siberians. This 
chapter will provide details about the genetic history, local adaptations and predisposition to 
diseases of these Arctic indigenous inhabitants. The chapter will also highlight the importance of 
disease gene discovery through historically small and isolated founder populations.  
Chapter 1.3 will review and discuss a number of hypotheses regarding IA etiology by 
highlighting recent findings from studies that aimed to identify IA predisposing genetic risk 
factors. In regard to this last element the chapter will emphasize the importance of whole exome 
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sequencing (WES) and genome-wide association studies (GWAS). Interestingly, a number of 
recent large-scale IA association studies were conducted using IA predisposed populations (e.g. 
Finnish and Japanese), these raised points that are critical when addressing the relationships 
between complex diseases and population-wide genetic signatures, which have been introduced 
throughout the process of human evolution.  
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1.2: THE GENOMIC LANDSCAPE AND DISEASE RISKS OF 
INUIT PEOPLE 
 
Manuscript: The genetic history, adaptation and disease predisposition of Inuit and Arctic 
peoples 
 
Authors and Affiliations: 
Sirui Zhou,1,2  Patrick A. Dion,1,3 Lan Xiong 2,4, Guy A. Rouleau1,3,* 
 
1Montreal Neurological Institute and Hospital, McGill University, Montréal (Que), Canada. 
2Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal (Que), Canada. 
3Department of Neurology and Neurosurgery, McGill University, Montréal (Que) Canada. 
4Centre de recherche, Institut universitaire en santé mentale de Montréal, Université de Montréal, 
Montréal (Que) Canada 
 
Abstract 
The arctic aboriginal peoples, especially Inuit, are interesting for their way of life and for being 
the last branch in the “Out of Africa” migration. They are also noteworthy for their distinctive 
genomes, their adaptation to a distinctively harsh environment, and their characteristic disease 
predispositions. This review will provide the emerging conclusion regarding a series of recent 
genetic studies that examined Inuit or other present or ancient arctic populations. It will summarize 
what has been established about the Inuit population, and also highlight critical elements for future 
research directions based on reconstruction of population history, discoveries of genetic signatures 
 4 
 
in positive selections, and population specific disease profiles associated with specific founder 
variations. 
  
Introduction  
According to Reich et al.1, three-waves of migration populated the Americas starting 15,000 years 
ago through the Bering Land Bridge: First Americans, which most of the Native Americans 
descended from; second, the Eskimo-Aleuts from the arctic, with half of their ancestries from the 
second stream of Asian gene-flow; and Saqqaq-NaDene speakers, which partially consists of the 
third stream of gene-flow. 
The arctic circumpolar regions are inhabited by many indigenous people (Fig 1), such as 
the Siberians, Samis, Indians and Inuit. The Inuit originated from East Asia and crossed the Bering 
Strait as part of a final wave of migration about 6,000 years ago, with the present population have 
an approximate 170,000 individuals in the circumpolar region. Arctic Inuit populations, most of 
the Inuit population, live in Canada, Greenland and Alaska2, namely Greenland and Canadian 
Inuit, Alaska's Yupik and Iñupiat, and Siberian Yupik3. 
Throughout the years of their inhabitation, especially after 1950s, Inuit populations have 
undergone changes that led them to abandon their traditional life style. The diet of modern Inuit 
now contains more carbohydrate than their traditional diet which was based on unsaturated fat and 
protein to fulfill their energy requirements. In recent history the climate of the Canadian Arctic has 
been undergoing through drastic changes and these negatively impacted the health of some of its 
inhabitants4. Indeed a higher incidence of complex diseases has become noticeable (e.g. 
cardiovascular disease5, infectious diseases6, and even cancer7). Metabolic and cardiovascular 
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diseases are now a major public health concern for in the 21st century indigenous Arctic 
populations5. This review aims to systematically discuss the genetic history of Inuit and related 
Arctic peoples, as well as to examine how their distinctive genetic architectures contribute to their 
special metabolic and physiological traits and disease predispositions.  
 
 
The Peopling of Arctic Canada and Greenland: the anthropological story 
From Paleo- to Neo-Eskimos 
Ancient Arctic peoples in North America, ancestors of present-day Inuit, are commonly believed 
to comprise two distinct cultures: Paleo-Eskimos and Neo-Eskimos. Early Paleo-Eskimos have 
peopled Arctic Canada and Greenland in the era of 3,000 to 800 BCE, the source of their food was 
essentially caribou and musk ox8, and they had a culture which was very similar to the one of 
Siberian Neolithic peoples. Early Paleo-Eskimos came from two consecutive waves of migrations: 
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1) the pre-Dorset culture and 2) the Independence I-Saqqaq culture in Arctic Canada and 
Greenland, including a small culture of Groswater in Labrador and Nunavik9. During the cold 
period of 800 BCE, the early Paleo-Eskimos developed into late Paleo-Eskimo, namely 
Independence II-Dorset culture in the eastern Arctic, and it was at this point that they started to 
mostly consume the products of sea mammals10. The Dorset culture was further divided into four 
phases11, although whether they represented genetic continuity or not is controversial, and 
eventually ended in around 1,350 CE, replaced by the Neo-Eskimo (Thule) culture, which 
originated from Bering Strait region at the earliest 200 BCE12, during the terminal phase of the 
Dorset culture (Fig 2). 
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Three cultures have led to the Thule culture: starting with the Old Bering Sea stage from 
200 BCE to 500 CE; followed by Punuk and Birnirk stages from 800 to 1,400 CE, which 
distributed along the major Strait islands to shores of the Chukchi Peninsula, and along coastal 
northern and western Alaska, respectively13. Starting at 1,100 CE, the classic Thule culture began 
their movement eastward, during which they gradually changed from mainly whale hunting to 
hunting of walrus and seal, making them the ancestors of the present day Alaskan Yupik/Inupiat 
and Canadian/Greenland Inuit10. There was a coexisting wave of Norse Viking settlement, which 
came around 985 CE, and who mainly occupied the Southwest Greenland and part of 
Newfoundland and Labrador, introducing an ancient admixture to the Inuit peoples in those 
regions, combined with a recent Danish admixture, resulting an approximate 25% European 
ancestry in Greenland Inuit14. 
 
The Population History of Greenlandic Inuit 
The Greenlandic population is a historically small one, as it currently consists of approximately 
only 57,000 individuals. The colonization of Greenland followed its route with the peopling of 
North American Arctic: Paleo-Eskimos entered the Northwest Greenland via Canadian High 
Arctic Island at 2,500 BCE15, which was eventually replaced by the Thule people in the 12th 
century. This hypothesis was further supported by the genome of a 4,000-year-old Saqqaq 
individual retrieved in Qeqertasussuk, Greenland; this sequencing enabled a link to be made 
between the Old World Arctic population and the extinct Greenlandic inhabitants16. Past genetic 
studies have reported evidence that highlighted how modern-day Inuit in Greenland are direct 
descendants of the first Inuit pioneers of the Thule culture9. MtDNA analyses also led to conclude 
that Thule Inuit may have encountered and interbred with concurrent Dorset individuals in Canada 
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and on the east coast of Greenland9; 15, thus suggesting that current Greenland Inuit are the 
descendants of both Thule and Dorset cultures17. This hypothesis is however disputed by other 
groups14. Afterwards, Norse Vikings settled with Dorset and early Thule people in Greenland from 
985 until 1,450 CE18; 19, Thule Inuit started their settlement in the West and Southeast of Greenland 
from 14th century. Analyses of the Greenlandic migration events supports the hypothesis proposing 
a single wave of Inughuit Polar Eskimos to have moved into Northwest Greenland in the 17th 
century20, and then moved southward along the west coast14. In 1721, Greenland became a Danish 
colony until 1979, introducing a large number of European settlements on the island for the second 
time in history21. 
 
Inuit in Canadian High Arctic 
Current Canadian Inuit live mainly in the subarctic region of Nunavut and Nunavik regions of 
Quebec, a small number of them also live in the Nunatsiavut and NunatuKavut regions of Labrador 
and Arctic Ocean of the Northwest Territories. The Nunavik region is 443,685 km2 in size and is 
composed of 14 Inuit communities, with a total population of 12,090. The occupying of Nunavik 
started 4,500 BP by Paleo -Eskimos, at the east coast of Hudson Bay and Ungava Bay, until 2,500 
BP because of the climate changes. During which the Inuit population had gone through several 
declines and a resurgence from 3,000 to 2,800 BP22, until they were eventually replaced by the 
highly cold-adapted Dorset people, who reached Nunavik around 500 BCE. The Dorset people 
were subsequently replaced by Thule around 1,300 CE, during the Medieval Warm Period that 
had a devastating impact on their ways of hunting on sea ice. The contact of Nunavik Thule with 
Europeans, contrary to that of Greenland Inuit, remained near non-existent until the 19th century. 
Modern day Nunavik inhabitants are mostly descendants from the Thule culture, while a small 
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number of late pre-contact Innu sites are also found9. Innu were a nomadic people who likely had 
spent the colder months hunting caribou inland before visiting coastal areas in the spring and 
summer to hunt marine animals, and with ancestors likely to be Paleo-Indians and developed into 
a new culture known as the Maritime Archaic people.  
The peopling of Nunavut from the starting of pre-Dorset culture to the Thule occupying 
was similar to that of Nunavik, but with an earlier inhabitation: when the glaciers in Nunavut 
melted approximately 10,000 BP, Paleo-Indians from the first wave of migration reached this area 
and moved northward following the migration of caribou to the tree line. At around 500 BP, with 
the advancing of Little Ice Age, Nunavut Inuit abandoned most regions of the High Arctic and had 
their first encounter with Europeans12. 
 
The Links between the Past and the Present  
There have been some debates as to whether the Paleo-Eskimos were an offshoot population to 
the one that gave rise to the Native American population. Ancient mtDNA studies suggested that 
the first wave of migrations, which colonized the New World Arctic, originated neither from the 
Native American populations started 14,350 BP nor from the populations that gave rise to the later 
Neo-Eskimo expansion from Alaska around 1,000 BP23. Several studies also aimed to establish if 
there was genetic continuity between Paleo-Eskimo and today’s Inuit. Raghavan et al. pointed out 
that all Paleo-Eskimos appear to be a continuum of a single-source population9, although gene 
flow between the Dorset and the Thule Inuit could not be excluded. A recent mtDNA study 
reported Alaskan North Slope being the starting point for both Paleo- and Neo- Eskimo migrations 
further east-ward into Canada and Greenland, and thus there were some degree of genetic 
continuity between Paleo-Eskimos and contemporary Inuit peoples24. An independent mtDNA 
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analysis showed that Neo-Eskimos were mainly of the Arctic Canada origin, whereas the direct 
ancestors of Paleo-Eskimos were primarily drawn from Chukotka25. It has also been suggested by 
Dulik et al.26 and Olofsson et al.17 that there has been past gene flows between Dorset and Thule 
Inuit, at least in Greenland, which bear traces of both Thule and Dorset descent. Therefore, the 
current populations of the North Circumpolar Region share a common origin with Native 
American populations. 
 
The Genetic History of New/Old World Arctic Peoples: evidence from DNA 
Reconstructing Greenlandic genetic history 
The genetic structure of Greenland Inuit has recently been extensively described, through large 
scale studies using both high density SNP genotyping array and high-throughput sequencing 
methods14; 27. The Greenlandic Inuit population came from small founder populations and they 
encountered a series of bottlenecks in history, consequently they would have had relatively small 
effective size and are expected to harbor less genetic variations; the latter has been proved by a 
number of subsequent studies. Pereira et al. focused on X chromosomal markers of 477 males 
from Greenland (N=312) and Denmark (N=165)27 reported that Greenland Inuit have a reduced 
diversity and a higher level of LD by comparison to the Danish and Asian populations. Their study 
showed a significant difference between Danish with all Greenlandic sub-populations, especially 
the Ammassalik. Ammassalik and Nanortalik (Fig 1) presented the most significant genetic 
distances to the reference populations compared with the other Greenlandic populations. Moltke 
et al.14 further advanced the study of Greenlandic LD by reporting that in the ancestral Inuit 
population, their LD was markedly higher than the present-day Greenlandic population, where the 
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recent European admixture has reduced the LD of the Greenlanders. The high level of genetic 
distinction in Greenlandic populations was also observed in a study from Tomas et al. where the 
pairwise FST between multiple populations (including Somalis and Danes) showed a clear 
displacement of the Greenlandic population versus the others28. Identical by descent (IBD) 
analyses suggested that approximately 84% of the genetic differentiation inside the Greenlandic 
sub-populations may be due to genetic drift, and a different degree of non-Inuit gene flow within 
the different subgroups14. Admixture analysis also revealed that Greenlanders present a low level 
of the European/Danish ancestry and also a low level of Asian ancestry.  
Moltke et al. conducted a more extensive modelling in the Greenland Inuit by genotyping 
4,674 Greenlandic individuals with a MetaboChip that contained 196,224 SNPs14. Their first 
finding was consistent with the previous findings of European ancestry admixture as they observed 
that there has been gene flow from Europeans into most of Greenland. Over 80% of Greenlanders 
have European ancestry, but the distribution is not even across Greenland (individuals from 
Ammassalik, the South Villages and Qaanaaq in the Northwest Thule region have less European 
ancestry or only Inuit ancestry). The findings could be interpreted with a scenario where Greenland 
was settled by Inuit who entered North Greenland and migrated to South Greenland along the west 
coast and later to East Greenland. Nonetheless the Greenlandic gene flow is reported to be sex-
biased, which was correlated with an earlier finding of Bosch et al.21. Although as much as 50% 
of Greenlanders have European male ancestry, only 1% of the female ancestry were European. 
There is also population differentiation even within the Greenlandic Inuit population – as the 
observed FST between Upernavik villages and South villages is smaller than the estimated between 
Upernavik villages or other locations, thus suggesting that Upernavik villages are genetically 
closer to South villages (Fig 1). Ammassalik from Southeastern Greenland are genetically furthest 
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away from Qaanaaq in Northwestern Greenland (FST=0.04), as they are closest to the villages in 
South Greenland (FST=0.02). This slight decay of genetic variation following a north-west-south-
east gradient of Greenland further supports the aforementioned hypothesis proposing a single wave 
migration along the coast. 
Additionally, the genetic-drift tree topology and D statistics relating Greenlandic sub-
groups also inferred the existence of a single coastal route migration, in which each location 
sequentially split off along the coastline. On the other hand, the D statistic test also suggested that 
there had been only limited amount of gene-flow from the Dorset to the modern east Greenlanders, 
when compared with the ancient Saqqaq genome16. The last question that Moltke et al. addressed 
in their study was if there were Norse Viking admixture in the Greenlandic genome by analyzing 
the length of ancestry tracts, as ancient admixture tends to have shorter tracts. Unfortunately, they 
reported no significant differences when comparing the tract-length distributions of Northwest 
villages and South Villages, where little recent European admixture was found and large 
settlements of Norse Viking once took place. 
Beringia peoples lived in cold climate conditions and their diet was rich in fat and protein 
from fish and marine mammals. It is likely that all Native Americans and related groups like Inuit 
descent from populations originally have adapted to such conditions, since the migration route into 
the Americas for all of these groups was through Beringia. Fumagalli et al.29 thus followed up the 
previous population structure study of Greenland14 by analyzing the environmental adaptation of 
Greenlandic Inuit. Through analyzing the same SNP-chip dataset14; 30, they selected 191 
Greenlandic individuals who have less than 5% estimated European ancestry and applied 
population branch statistic (PBS) for the detection of positive selection signals. As a result, they 
found the strongest signal of selection on chromosome 11, which comprises multiple genes 
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(TMEM258, MYRF and FADS1, FADS2 and FADS3). They also reported other loci that appeared 
to be associated with selection signal, e.g. on chromosome 1 (encompassing WARS2 and TBX15) 
and chromosome 17 (FN3KRP). To supplement the SNP-chip data, they generated WES data on 
18 Greenlandic Inuit and observed two additional genes, DSP and ANGPTL6, representing the 
strongest signals of selection. Although the selection signal for FADS cluster was reduced using 
the WES dataset (PBS=1.145, FADS2), the report by Fumagalli et al. provided additional 
evidences that highlighted the selected alleles in genes known to modulate fatty acid composition 
and affect the regulation of growth hormone, which would have been critical for the adaptations 
to a diet rich in PUFAs.  
 
The Genetic Structures and Selection Signals in Siberians 
Studies of the Old World peoples can also be informative in analyzing contemporary Inuit 
populations who have adapted to the cold climate before they evolved through their own courses, 
possibly due to the result from the bottleneck drift that New World peoples experienced during 
their period of migration. Some Siberians appear to have different cardio-metabolic disease risks 
than other circumpolar groups31; and other studies observe lower serum lipid levels in indigenous 
Siberian peoples32.  
Several mtDNA studies examining Siberians preceded the era of genome sequencing and 
these provided the first genetic evidence supporting archeological findings that led to believe that 
the High Arctic populations originated in Siberia. These mtDNA studies found the latest 
inhabitants of Beringia to be genetically linked with the Chukchi-, Eskimo-Aleut- 33, and Na-Dene-
speaking Indians as well as Paleosiberian-speaking Yukaghir in the high arctic since early 
Postglacial34. These studies also established the founding population of Eskimo-Aleut to have 
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originated in Beringia/Southwestern Alaskan during the early postglacial period35, and today’s 
Greenlandic individuals to essentially be the descendants of Alaskan Neo-Eskimos36. 
Studies that included Siberians for the identification of selection signals showed that the 
most strongly selected signals across worldwide populations are associated with pigmentation, 
autoimmune diseases and genes related to UV radiation, infection, immunity, cancer and metabolic 
adaptations37; 38. In 2014, Cardona et al. conducted a study describing the population structures of 
indigenous Siberian peoples and their selection signatures39. They used a SNP-chip that contains 
730,525 SNPs in 200 individuals from 10 Siberian groups. The initial assessment using principal 
component analysis (PCA) and ADMIXTURE showed different ancestry profiles that enabled 
distinctions to be made across native Siberian populations. Among those distinctions it appears 
that Chukchi, Eskimo and Koryaks were predominately of Inuit ancestry; also Yakuts, Evens and 
Evenks came mainly derived from another ancestry; and finally Altai, Teleuts, Shors and Buryats 
all shared a third. The clustering of different predominant ancestries into different groups was 
fitting with their respective geographical locations. Subsequently, two haplotype-based tests (iHS 
and XP-EHH) were used to examine the positive selection, and seven genes (THADA, ITPR3, 
GNGT1, PRKG1, RELN, CPT1A and LRP5) were observed to be positively selected; furthermore 
a locus on chromosome 11 containing the last two genes was delineated and shown to be the most 
significant. Interestingly, this region was close to the region that had been found to be positively 
selected in the earlier Greenlandic Inuit study by Fumagalli et al.29. Cardona et al. demonstrated 
that this region contained the strongest signal in the Northeastern Siberian gene pool39, the ancient 
ancestors of today’s Greenland and Canadian Inuit.  
A followed-up study by Clemente et al.40 based on the aforementioned chromosome 11 
region generated whole genome sequencing (WGS) data from 25 individuals from Chukchi, 
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Eskimo and Koryaks39. After a careful variant filtration, 148 SNPs with both a >0.5 derived allele 
frequency in subjects of the study and a MAF<0.01 in published populations were retained. From 
which they reported three variants with possible functional consequences to the encoded proteins, 
which located in two genes, CPT1A and IGHMBP2, within the previously found chr11 region39. 
iHS test focused on this region with the inclusion of other populations mapped chr11:66-69 Mb 
region to be the significantly selected locus only in Northeast Siberians. Tajima’s D scans further 
narrowed down a region of 68.2-68.6 Mb, which contains genes LRP5, PPP6R3, GAL, MTL5 and 
CPT1A. This study eventually established that a variant in CPT1A (c.1436C>T) drove this 
selective sweep, and this will be further discussed in the following section.  
 
Discovering Selection Signals in FADS and CPT1A in Arctic Populations 
Fumagalli et al. suggested that in Greenlandic Inuit, the strongest selection signals are in the FADS 
gene cluster29. The family of FADS genes are known to be associated with long chain 
polyunsaturated fatty acids (PUFA) metabolism, type 2 diabetics (T2D) and coronary artery 
disease41-43. Using the inferred demographic model by Approximate Bayesian Computation 
(ABC), the divergence time between Han Chinese and Greenland Inuit was estimated to have 
occurred 23,250 years ago with an effective population size of 1,550. The chromosome 11 region 
was thus established to be a strong outlier and the selection starting time of the most significant 
SNP (rs74771917) from the FADS cluster was occurred approximately 19,751 BP (selection 
coefficient s=0.0313), when the common ancestors of Inuit and Native Americans still lived 
around Beringia, and before the first migration wave to the New World started.  
A positive selection of the FADS cluster has been reported in many other populations 
because of its involvement in n-3/n-6 PUFA metabolism, a key component for the diet evolvement 
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of Homo sapiens44, (e.g. in Africans45; 46 and Alaskan Eskimos43). A very recent study reported a 
22bp insertion-deletion (rs66698963) in FADS2 that was positively selected in Asian populations, 
more particularly in South Asians47. FADS2 was positively selected in both vegetarians, such as 
South Asians; and meat eaters, such as Greenland Inuit. Interestingly, the ancestral allele of 
rs174570 in FADS2, which was positively selected in Greenland Inuit, also exhibited positive 
signals in South Asians. The differences being that the derived allele was under adaptation in 
Greenland Inuit, while in South Asians, the ancestral allele was better adapted. It is tempting to 
suggest that the ancestral haplotype of FADS2 variants has been selected towards dairy-vegetable 
diet while the derived haplotype has contributed to the adaptation to a marine-fat-rich diet.  
Another interesting gene is CPT1A for which a missense mutation (c.1436C>T, p.P479L) 
was reported in multiple studies; most likely because of its high frequency (possibly due to natural 
selection) across Arctic populations (0.77 in Nunavut and 0.44 in the Northwest Territories)48; 49. 
This Arctic-specific variant was initially thought to be associated with CPT1 deficiency, including 
hypoketotic hypoglycemia50 and sudden infant death syndrome51. A functional characterization of 
the CPT1A c.1436C>T mutation revealed that this mutation decreases the process of fatty-acid 
oxidation and ketogenesis under normal condition. However under conditions of high malonyl-
CoA concentration, the activity of CPT1A c.1436C>T mutation was much greater than what could 
be measured in the cells with the wildtype allele52; which could consequently have a protective 
role against the overproduction of ketone bodies53.  
In order to study the origin of this mutation at the evolutionary level, Clemente et al.40 
performed LD analysis focused on chr11:68-69Mb region that had shown strong selection in their 
previous study39. They found that CPT1A c.1436C>T mutation seem to be the driving selection 
(MAF=0.68) in Northern Siberians as a selective sweep54, as it forms two distinct LD blocks only 
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in Northern Siberians while the pattern is not significant in East Asians and completely absent in 
Europeans. The c.1436C>T variant was thought to be absent from the genomes of most individuals 
worldwide, and to be only presented in Arctic populations. The inferred demographic model of 
Northeastern Siberians yielded an effective population size of 3,000-5,000; under the assumption 
that c.1436C>T variant is the result of directional selection from a de novo mutation, they 
estimated the selection time of this variant to be 3-ka old (selection coefficient s=0.14). The age 
of selection time of a 58kb haplotype around the c.1436C>T variant is around 6.7-ka, supporting 
the hypothesis of a strong selection from a selective sweep, possibly due to a recent and rapid 
adaptation against the cold climate and dietary specialities. To concur with the estimation of the 
age of this mutation, they examined ancient samples for its surrounding haplotype (comprised of 
27 variants in high derived allele frequency in Northeast Siberians). They found that this derived 
haplotype was absent from the Neandertal and Denisovan genomes, regardless of the fact that 
CTP1A was also found to be among the lipid-catabolism-associated genes enriched with 
Neandertal-like sites55. It was also absent from the ancient human genomes more than 10-ka old56, 
but starting to appear in the 4-ka old ancient Saqqaq genome16, then also in Paleo-Eskimo/Neo-
Eskimo samples9. Interestingly, this haplotype was partially presented in Aleutians but completely 
absent from Na-Dene speaking Athapaskans, perfectly consistent with a previous conclusion that 
Eskimoan- and Athapaskan-speaking populations are genetically distinct and came from two 
population expansions that occurred after the initial wave of migration26. It was therefore 
postulated that the c.1436C>T variant (and its surrounding haplotype) could have occurred in the 
Old World Arctic (ancestors to the Northeastern Siberians) and only retained by the selection 
pressures of cold climate, before it was introduced to the New World Arctic, starting with the first 
Paleo-Eskimo wave that populated the Canadian High Arctic and Greenland.  
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Founder Mutations and Disease Risks in Inuit Populations 
The recent changes of Inuit lifestyle, such as drinking and smoking, calorie-dense foods and less 
hunting activities, were believed to have increased their risk of cardiovascular diseases (CVD), 
including atherosclerosis and hypertension, compared to western populations. Parallel studies 
comparing Inuit living in Greenland and Denmark57 also supported this belief. Considering these 
observations it can be hypothesized that variants which neutrally accumulated in the Inuit 
populations may be starting to show deleterious effects under the new selective pressure. On the 
other hand, because of the high degree of genetic differentiation following the separation from 
East Asian or Beringian founder populations58, causal variants that are very rare in other 
populations may segregate at a distinctly high frequency in the Inuit population, making it a 
suitable model for discovering disease susceptible variants.  
 
Metabolic Traits and Diseases 
The best example of this scenario would be the p.R684X variant in TBC1D4, which was discovered 
through a genotyping and WES study examining 2,575 Greenland Inuit, and found to be associated 
with a higher 2h plasma glucose levels30. The discovery phase of the GWAS found the highest 
association to be with an intronic variant (rs7330796) of TBC1D4 and subsequent followed-up 
WES and further genotyping in general Greenlandic cohort and T2D cohort revealed the causative 
variant p.R684X in TBC1D4. This nonsense mutation was shown to be strongly associated with 
mean 2h plasma glucose levels (mainly in homozygous carriers), and with an increased risk of 
T2D, which elevated circulating glucose and insulin levels after the glucose load. The p.R684X 
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variant has a large population impact, with an estimated frequency of 23% in the Inuit cohort, 
possibly due to a weak selection or genetic drift; while it is absent from Europeans and only at a 
frequency of 0.5% in 1KGP Japanese population.  
More studies have focused on the association of Inuit specific lipid-metabolic profiles with 
their genetic background. In the selection study of Greenland Inuit carried out by Fumagalli et al., 
a strong association was observed for a positively selected FADS SNP with body weight 
(p=1.1×10−6; rs7115739) and height (p=0.00012; rs7115739), FADS affects the fatty acid 
desaturases by compensating for a high dietary intake of eicosapentaenoic acid29. In 
Greenland Inuit, a rare haplotype in the gene encodes adipose triglyceride lipase (ATGL) was 
found to be associated with increased plasma triglyceride concentrations59. The allele distributions 
in several ALDH genes, particularly ALDH1B1 and ADH1C, shown to be associated with drinking 
patterns, also differed significantly between Inuit and Danes60. The Inuit also harbor distinct 
variant distributions in other genes (CYP1A1, CYP1B1 and COMT) and this suggests their 
susceptibility to environmental contaminants to be increased61, the same variants may also 
contribute to their predisposition to diabetes62. Additionally, a study of 553 Nunavik Inuit, focused 
on 35 variants across 20 lipid-metabolism related genes pinpointed 7 SNPs as significantly 
associated with plasma lipid parameters63. And genes such as DOCK1, PTPRE and FABP4, were 
highly associated with obesity-related traits and n-3 PUFA interactions in Yup’ik people64; SNPs 
in LPL, TNFRSF10B, and APOJ also had strong statistical evidence of functional effects in the 
fatty acid distributions65. CDKAL1 and HHEX polymorphisms were also reported to be associated 
with glucose homeostasis in Alaska Native population with a low prevalence of T2D66.  
Disrupted profiles of the metabolic genes sometimes could lead to more severe conditions. 
In a large cohort that regrouped Inuit from Alaska, Canada and Greenland67, the LDLR p.G116S 
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variant was observed to be strongly associated with dyslipidemia; a condition found in 
approximately 10% of Inuit and with one of the largest effect sizes (3.02-fold increased risk of 
hypercholesterolemia). In another Nunavik Inuit study examining glycogen storage disease type 
III (GSD-III), a founder mutation, AGL c.4456delT68, was reported to cause the disease in 
individuals who are homozygous carriers. It should however be noted that the same homozygous 
variant was also observed in a cohort of GSD-III cases of North African Jewish heritage, albeit it 
is absent in other present-day populations. The reason why this old variant was somehow preserved 
only in these two very genetically distinct populations is unclear. Finally, a variant 
c.273_274delAG located in the gene encodes Sucrase-Isomaltase (SI) was also found common in 
the Canadian Inuit population (MAF=17.2%) with homozygous carriers develop congenital 
sucrase-isomaltase deficiency69.  
 
Infection and Allergy 
The risk of infectious diseases is another health concern for Inuit populations. For instance, a high 
risk of HPV infection was observed among Nunavik Inuit women70; HLA-G polymorphisms were 
also suggested to affect the host immune recognition and this is supported by the fact that Nunavik 
Inuit women have a distinctive HLA allele frequencies by comparison to other populations71.   
A common Inuit variant IL4RA Ala57Thr, while extremely rare in other populations 
(MAF≤0.6%), was found associated with the risk of atopy in Inuit living in Denmark, but not in 
Greenlandic Inuit72. This finding was not an isolated case as in Inuit populations of Greenland and 
Denmark the same asthma risk allele expresses opposite magnitude and direction of genetic 
associations73. The Inuit population separation time between Greenland and Denmark is however 
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too short for the effect of a genetic drift to have taken place, suggesting that environmental changes 
also play a big part in some of the disease pathogenesis observed in Inuit. 
 
Cancer 
Inuit populations have recently observed to present with an elevated risk of cancer. A founder 
mutation c.2002A>G in PMS2 was observed in a Nunavik Inuit family with constitutive mismatch 
repair deficiency (CMMRD) syndrome, which leads carriers to eventually develop cancer74. The 
intronic variant creates a de novo 5’ splicing site for intron 11 that leads to a frameshift. Nine 
additional Inuit cancer patients were subsequently discovered to be homozygous carriers of the 
PMS2 c.2002A>G; this variant is therefore likely to act in a recessive inheritance manner. The 
variant has an estimated frequency of 0.06 in the Nunavik Inuit populations and is considered to 
be one of the most common cancer-associated risk allele.  
Breast cancer risk is high amongst Greenland Inuit women and reports have highlighted a 
founder mutation, BRCA1 p.C39G, that is observed in 33% of ovarian cancer patients and 10% 
breast cancer patients, the overall frequency of this variant is 1.6%75; 76. However the frequency of 
this variant differs geographically as it is 0.6% on the West Coast to 9.7% on the East Coast, a 
difference that likely resulted from bottleneck drift during the migration. Other polymorphisms in 
CYP1A1 and CYP17A1 can also increase the risk of breast cancer among Inuit women and the risk 
increases with higher serum levels of Perfluorooctane Sulfonate (PFOS) and Perfluorooctanoic 
acid (PFOA), which were consistently shown as risk factors of breast cancer as well77. 
By opposition, Inuit men from Greenland have lower risk of prostate cancer. Several 
SRD5A2 SNPs and androgen receptor repeats were shown to differ significantly between 
 22 
 
Greenland Inuit and Swedish, these differences lead to a lower SRD5A2 enzymatic activity that 
regulates the turnover of testosterone to 5 alpha-dihydrotestosterone78.  
 
Liver Diseases and Others 
An ATP8B1 c.1660 G>A variant was reported to cause cholestasis familiaris groenlandica, a liver 
disease common in Greenlandic Inuit79, the variant causes the disease in a recessively inherited 
manner and it is found in an heterozygote state in 12% of the population80. The observation of a 
BLVRA c.214C>A nonsense mutation in unrelated Inuit women with biliary obstruction during 
cholestasis suggest it might be a founder mutation81. A frameshifting mutation ATP13A2 
c.2473C>AA was also found in a Greenland Inuit family affected with Kufor-Rakeb syndrome 
(KRS)82.  
Inuit hearing impairment, a highly prevalent disorder in this arctic population, was reported 
to be caused by a GJB2 c.35delG mutation, the variant frequency in overall population is found 
vary between 0.5% in the West Coast to 2.3% in the East Coast83.  
 
Cerebrovascular Diseases 
Whether or not related to the high risk of CVD that the Inuit populations recently acquired, there 
is also an elevated risk of cerebrovascular diseases in Inuit5, the genetic underlying of which may 
be combined with heavy alcohol consumption and hypertension, known to increase the CVD risk. 
A report of CVD prevalence among Nunavik Inuit indicated that 2.5% of adults were diagnosed 
with a cerebrovascular disease84. In Alaska, cerebrovascular disease is the 5th leading cause of 
death (4.5%) and the mortality rate is 1.5 times higher than the rate observed in the European 
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descendants85. Lindgaard et al. reported that Inuit IA patients have a much higher rate of familial 
history of subarachnoid hemorrhage (SAH) (23.1%) and IA (9.6%) compared to Danish IA 
patients (4.3% and 1.6%)86. Moreover the relative risk of SAH of Greenlandic Inuit is 4.4 fold 
higher than the one observed for the neighboring Dane population87. The prevalence of IA in 
Denmark is similar to that of Sweden and Finland88, individuals from the latter also deemed to 
present a high risk of IA89. Finally it is noteworthy that Inuit IA cases also tend to harbor multiple 
IAs, the percentage of such cases is two-fold higher than Danes; fitting with a genetic risk factor 
in Inuit since multiple IAs is a marker for the genetic form of IA. Despite this evidence, the 
underlying genetic cause of IA in Inuit and the contribution played of founder mutations 
nonetheless remain to be further elucidated. 
 
Conclusion  
Through several waves of migration, ancient groups of humans began populating the Americas 
nearly 16 millenniums ago. The arctic population is an interesting one as it provides us with an 
extended picture of how ancient human occupied the New World, it also sheds light on how today’s 
global populations came into being. Through examinations of their genomes which were adapted 
to the harsh arctic environment and affected by bottleneck drifts, the arctic indigenous peoples like 
Inuit might lead us to discover not only the genetics that explain specific human traits but also the 
underlying mechanism of certain disease etiology. Canadian Inuit are one of the most important 
residents of the Arctic, but their genetic landscape remained a largely uncharted territory. Further 
studies focusing on this unique population could therefore efficiently link the studies of Siberians 
and Greenlandic Inuit and advance our knowledge of the global population genomic profiles. 
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1.3: THE GENETIC ETIOLOGY OF INTRACRANIAL 
ANEURYSM 
 
Cerebrovascular diseases, stroke and subarachnoid hemorrhage 
Cerebrovascular diseases include a broad spectrum of disorders affecting the blood supply to the 
brain. Stroke, carotid stenosis, IA, artery malformations, including arteriovenous malformations 
(AVM) and moyamoya disease, all belong to this heterogeneous disease group.  
Stroke is the second most common cause of death after coronary artery diseases in the 
western contries90, while in China, it is the most frequent cause of death, with incidence more than 
five folds that of myocardial infarction. It can be categorized into ischemic (blockage) and 
hemorrhagic (bleeding), with 87% being ischemic91. Ischemic strokes are commonly due to 
thrombosis or embolism while hemorrhagic strokes, which are subdivided to intracerebral and 
subarachnoid, are usually caused by an arteriovenous malformation or the rupture of an 
aneurysmal lesion.  
SAH is bleeding in the subarachnoid space, an area between the pia mater of the brain and 
the arachnoid membrane. SAH comprises approximately 5% of all strokes, with an incident rate 
of 6-7 per 10,000 person/year92 and a fatality rate around 50%93. The prevalence of SAH is higher 
in Finnish and Japanese94; 95, and surprisingly this is not due to their prevalence of IA96.  
 
The risk and etiology of intracranial aneurysm 
The risk of IA rupture 
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An IA is a dilatation of part of the intracranial artery and its shape varies from a localized sac-like 
pouch to a long enlargement of the vessel diameter97; these two forms are referred to as saccular 
or berry aneurysm and fusiform aneurysm, respectively. The worldwide incidence of intracranial 
aneurysms has been estimated to be approximately 2-3%98, most IAs are saccular (SIA), which 
typically occur at the arterial branching sites on the Circle of Willis. Common sites of SIA include 
the anterior communicating artery, the bifurcation of posterior communicating artery and internal 
carotid artery, the middle cerebral artery, and the basilar artery bifurcation99. The most common 
clinical symptoms of aneurysmal SAH are a sudden onset of severe headache with stiff neck, 
vomiting, and photophobia100. Unruptured IA (UIA) is usually asymptomatic, however 
retrospective studies have estimated the annual risk of rupture among IA patients to be 
approximately 1-3%101.  
Although ruptured IAs are the cause of 85% patients who had subarachnoid haemorrhage, 
it has been reported that 50% to 80% of all IAs do not rupture during the course of a person's 
lifetime. A recent examination of the prevalence of UIA estimated it to be around 3.2%96, and can 
be as high as 7% in China. The prevalence ratio of UIA is significantly higher in women than men 
(1.61) and in individuals over 50 years versus less (2.2)96. 1.8% of the people with European 
ancestry have SIA102, the incidence usually varies among different populations, with the highest 
in Finnish and Japanese. However, recent studies suggested those statistics to be disputable96; 103.  
The risk of SIA is also higher in some connective-tissue related genetic disorders. 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common disease associated 
with SIA, with a relative risk of 6.9 (95% CI 3.5-14). Approximately 5% to 40% of patients with 
ADPKD have IA, and 10% to 30% of patients have multiple IA96. Other associated disorders 
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include neurofibromatosis type I104, Ehlers-Danlos syndrome105, Marfan syndrome106, hereditary 
hemorrhagic telangiectasia107 and endocrine neoplasia type I108.  
The risk of UIA to rupture increases with the aneurysm size, location (particularly in the 
posterior circulation), irregular shape, and history of previous aneurysmal SAH109. Other studies 
suggested smoking and female sex increase the risk of IA rupture, size of the IA lesion, on the 
other hand, is not a significant risk110. Controversies always follow the size of aneurysm: small 
aneurysms have low annual risk of rupture111; however, 85-90% of the ruptured aneurysms are 
small112. A more recent study reported the risk of SAH depends predominantly on smoking, sex 
and blood pressure113. Excessive alcohol consumption also increases the risk of SAH114.  
The exact etiology of IA is still unclear, albeit several hypotheses highlight the contribution 
of maladaptive vascular remodeling115 triggered by hemodynamic stress116 and inflammatory 
response117, such chain of events would ultimately damage the blood vessel wall, which is the key 
process in the pathophysiology of IA.  
 
Intracranial arteries and IA pathology 
Intracranial arteries have two major differences compared to other arteries: 1) there is no elastic 
lamina and the adventitia is thinner in the vascular walls118; 2) there are gaps in the muscular media 
layer in the bifurcations119. These special characteristics may help to explain the site of the 
aneurysm formation.  
IAs have different arterial wall types that characterized by their specific histopathology: 1) 
perturbations of homeostasis in the cerebrovascular wall, characterized by a lack of internal elastic 
lamina in the IA wall120, which occurs early in the course of the disease; 2) decrease in tissue 
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cellularity along with changes in the extracellular matrix composition, with the number of smooth 
muscle cells (SMC) decreasing and wall thinning121, as well as apoptosis and necrosis122; and 3) 
hyperplasia of the tunica intima and disarray of vascular smooth muscle cells; followed by an 
increased risk of rupture in thicker walls with myointimal hyperplasia and thrombus123. 
Changes in composition of the vessel wall are also observed in IA tissues as the levels of 
collagen, laminin and several extracellular matrix components are decreased124. Type I collagen 
and fibronectin appear dispersed in IA wall while in normal artery the expression of type I collagen 
is restricted to the adventitia and fibronectin to the media125; type III and IV collagen and laminin 
also appear to have decreased expression in IA wall124. Atherosclerosis is another common 
pathological feature in IAs and it is noteworthy that the progression of atherosclerosis correlates 
positively with aneurysmal growth126.  
 
Hemodynamic stress 
IAs tend to occur at regions of sharp vessel curvature, and also occur more frequently at certain 
bifurcations, such as the anterior communicating artery and middle cerebral artery. Because those 
regions experience high wall shear stress and other hemodynamic forces, it is assumed that local 
hemodynamic environment is critical to IA formation127. Animal studies have demonstrated that 
elevated hemodynamic stress could trigger aneurysm-type remodeling at a bifurcation site128 and 
at the basilar terminus129.  
Endothelial cells can undergo significant changes, both in function and morphology under 
hemodynamic stress130. In response to shear stress, endothelial cells may elongate, change 
alignment while developing actin stress fibers and may change cell migration131. Hemodynamic 
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stress may also relate with changes in molecular signaling, such as mediating pathway of 
inflammation, within the endothelium and amplifying chronic inflammation132. 
Studies focusing on correlating hemodynamic stress and IA formation established the 
following facts: 1) IA occurs more often in locations experiencing higher wall shear stress (WSS) 
and wall shear stress gradient (WSSG); 2) the susceptibility of IA reflects a threshold-type 
response to hemodynamics, which increases drastically at high level of WSS and WSSG127.  
 
Vascular remodelling  
Vascular remodelling is carried out when the vascular endothelium reacts to blood flow, in which 
the morphology of the endothelia cells (EC) varies corresponding with blood flow patterns133. The 
reaction of EC is thought to be regulated by different factors such as calcium channel activation134, 
gene expression differentiation induced by shear forces135, mechanical events136 and EC 
realignment137. 
The vascular smooth muscle cells (VSMC) in IA walls have been observed to migrate into 
the intima and proliferate to produce myointimal hyperplasia126, an early event in IA formation. 
VSMC modulation appeared to be the most pronounced in ruptured IA: a transition of VSMC from 
a differentiated to a modulated phenotype and eventual loss of both in ruptured IA. Thus 
phenotypic modulation of VSMC in the IA wall appears to be related to the aneurysmal wall 
formation and to a rupture mechanism138. 
WSS is also thought to be one of the most important factor to regulate vascular structure 
and remodelling139, usually through the endothelium’s response. Low level of WSS tend to induce 
atherosclerotic lesions140 and high level of WSS has been implicated in expansive or outward 
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vascular remodeling in response to a sustained flow increase141. High WSS contributes to the 
adaptive outward remodelling by 1) endothelial responses; 2) an increased stimulation of 
endothelial cells and smooth muscle cells proliferation; 3) an increased stimulation of matrix-
degrading proteins; and 4) atherosclerotic wall remodeling142.  Bifurcation apices and outer curve 
of arteries in the Circle of Willis tend to have flow impingement, which will cause high WSS and 
positive WSSG, thus are subject to remodelling and the predisposition to IA.   
 
Inflammatory response 
Vascular inflammation has shown to be involved in the pathogenesis of IA, although it is not yet 
clear if those inflammatory responses contribute directly to IA formation. Many of the pathological 
changes underlying IAs are related to the chronic inflammation in the vessel walls, especially in 
IA VSMC that has shown to undergo phenotypic modulation to a pro-inflammatory phenotype143.  
It was reported in several studies that low-density lipoproteins in VSMC are oxidized144; 
145 to produce inflammatory response in IA walls which will lead to the degeneration of vessel 
wall. Macrophages are probably the most important histologic indicator of the inflammatory 
reaction of IA walls. A recent study revealed the functions of macrophages in IA: they are critical 
for hemodynamically induced outward vascular remodeling and elaboration of inflammatory 
cytokines146. Macrophages contribute to the extracellular matrix remodelling by increasing the 
expression of matrix metalloproteinases (MMP)147, which digests arterial wall extracellular matrix 
and leads to further damage via upregulation of angiogenic factors148 and will eventually cause IA 
rupture149. Macrophages are also participants in the elaboration of the inflammatory signaling by 
secreting inflammatory factors implicated in the IA pathogenesis117; 150, as macrophage-depleted 
mice were found to have a substantially lower risk of developing IA146. In addition, damage-
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associated molecular patterns151, immunoglobulins144, lymphocytes123, T and B cells144; 152, 
cytokines153 and growth factors154 are all reported to be involved in the pathogenesis of IA via 
inflammatory infiltration. A study also found an increased number of leukocytes during the 
formation of IA and an induction of MMP in VSMC after mast cell degranulation155. Worth noting, 
modest hemodynamic changes might be sufficient to induce IA if the vascular wall is compromised 
by inflammation.  
 
Diagnosis and treatment of IA and SAH 
UIAs are often found either through screening high-risk individuals or as incidental findings of 
magnetic resonance imaging (MRI), particularly magnetic resonance angiogram (MRA) or 
computerized tomography (CT) studies for other neurological symptoms. The diagnosis of SAH 
is primarily by CT, CT angiography (CTA), or catheter angiography156.  
IA are usually treated either by microsurgical clipping or endovascular coiling. Both work 
by the occlusion of the aneurysm neck, which prevents the risk of possible re-bleeding from 
secondary complications. Endovascular treatment has developed in the past 20 years, which aims 
to reduce the operative risks of microsurgical treatment157. The advantage of microsurgical 
clipping is good durability, and can successfully treat most aneurysms158. The advantage of 
endovascular coiling is minimally invasive, decreases procedural and anesthesia time, and 
multiple, simultaneous treatments159. However, endovascular treatment requires more follow-up 
imaging, has increased recurrence rates, and a greater need for retreatment compared with 
microsurgical clipping. There are also some aneurysms with features that are not suitable for 
endovascular coiling. Both procedures have their benefits, although there is a study suggested that 
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in patients with a ruptured IA, the outcome in terms of survival free of disability at one year is 
significantly better with endovascular coiling158. 
 
The genetic susceptibility of IA  
One of the major IA risk factor is genetic predisposition, which is supported by the fact that 8-9% 
of UIAs are familial160 and 10% of the SAH cases are associated with a family history of SAH161. 
The prevalence ratio is also significantly higher (3.4, 95% CI 1.9-5.9) in patients with positive 
family history of SIA or SAH96. IA seems to be a disease with incomplete penetrance when occurs 
in families and in general with late age onset, and also appears to be multifactorial, with 
environmental and stochastic risk factors162. Throughout the years, genetic researches of IA have 
identified multiple risk genes and loci; however the genetic risk factors and pathogenic 
mechanisms for IA are far from being fully understood.  
 
Traditional approaches: linkage and candidate gene screening 
Being the earlier method of utilizing genome-wide data, linkage studies performed on the sparsely 
distributed markers have been applied on multiple IA families or a single large IA family. A 
collection of 13 major loci were found in these studies, and among those are the following: 1p34.3-
36.13163, 7q11164 and 14q23-31165 in North American IA families; 1p36.21-36.13166, 19q13167 and 
Xp22166; 167 in Dutch and Finnish families, 5q22-31, 7q11, 14q22168, 8p22169, 17cen170, 19q13 and 
Xp22170; 171 in Japanese and Korean families; 5p15.2-14.3172 and 13q14-21173 in French-Canadians 
and 4q32174; 175, 12p12.3175 and 11q24-25165 in mixed ethnicity families. Six genomic regions 
(1p34–36, 4q32, 7q11, 14q22-23, 19q13, and Xp22) were replicated by two or more independent 
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linkage studies. Three large studies focusing on multiple IA families of different ethnicities 
included 346 Finnish IA families162; 176 and 542 FIA families177. 
Candidate genes involved in vascular wall and endothelia cell functions have been tested 
in case-control association studies of IA, especially those also discovered in previous linkage 
studies. Positive associations were found in SNPs located in ELN (rs8326, p=1×10-6)178, 
SERPINA3 (rs4934, p=1×10-5), COL3A1 (rs1800255, p=1×10-5), IL6 (rs1800796, p=1×10-5), 
VCAN (rs251124, p=7×10-4), COL1A2 (rs42524, p=9×10-4), HSPG2 (rs3767137, p=0.002)179, 
JDP2 (rs175646, p=0.004)180, KLK8 (rs1722561, p=0.008)181, TCN2 (rs1801198, p=0.002)182,  
LIMK1 (rs6460071, p=0.026)183, ACE (rs4646994, p=0.03)184 and TNFRSF13B (rs4985754, 
p=0.048)185.  
 
IA Gene expressions  
Microarray based mRNA expression comparing IA and control tissues is a relatively unbiased 
approach to discover IA candidate genes and pathways. One of the first studies discovered 
enrichments in adherent junction, MAPK, and Notch signaling pathways186. A follow-up study 
focused on inflammatory response, discovered that histocompatibility class related genes played 
an important role in IA formation187. More studies that compared IA tissue with superficial 
temporal artery tissues found distinctively differentially expressed genes on certain pathways, 
including adhesion, proliferation and migration, extracellular matrix receptor interaction, and cell 
communication; as well as atherosclerosis, inflammatory response and apoptosis in SMCs188-190.  
The expression profiles of the ruptured and unruptured IA were also examined in a number 
of studies. A study reported that in ruptured IA, genes encode MMPs and genes involved in 
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apoptosis were upregulated; when compared of unruptured and ruptured IA, the matrix 
metalloproteinases 3 (TIMP-3) was significantly downregulated in unruptured IA, while nitric 
oxide synthase (iNOS) appeared to be overexpressed in ruptured ones191. Other studies reported 
inflammatory response related genes and anti-inflammatory regulators seemed to be 
upregulated190; 192 in the ruptured IA. There was a similar observation with the transcription 
factors193, such as Toll-like receptor signaling and nuclear factor-kappaB, hypoxia-inducible 
factor-1A, and ETS transcription factors were all significantly enriched in ruptured IA151. 
However, there were also other studies that have made different observations189; 194, for instance, 
genes coding for MMPs, genes coding for adhesion proteins of the extracellular matrix (ICAM1) 
and cytoskeleton (WIPF1, TUBA4A) were reported to be significantly under-expressed in the 
blood of ruptured IA patients195, suggesting the mechanism of rupture is not regulated by 
degenerative process of the arterial wall.  
MicroRNAs were also found to be potential biomarkers of IA formation and rupture. 
Differential expression of microRNAs have been linked to apoptotic cells and vascular wall 
activation pathways196, phagocytes migration, mononuclear leukocytes proliferation197, vascular 
smooth muscle cell modulation and even protein translation machinery198. 
A recent RNA sequencing (RNA-seq) study identified 229 differentially expressed genes 
in IA tissues by comparison to controls, and 1,489 genes were also found to be expressed in 
ruptured IA tissues by comparison to unruptured wall tissues199. The pathways of the differentially 
expressed genes in IA includes extracellular matrix (ECM), transmembrane transporter activity 
and blood vessel regulation, with top overexpressed genes as collagen COL10A1, cartilage 
intermediate layer protein CILP2, secreted frizzled-related protein SFRP2, RNA-binding family 
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member MEX3B; and underexpressed genes as FAM134B, transporter protein SLC13A3, 
coagulation gene SERPIND1, growth regulation gene GREB1 and gap junction protein GJB6.  
Several meta-analyses on IA gene expression have summarized the genes that were 
observed to be involved in independent studies. It was suggested that BCL2, COL1A2, COL3A1, 
COL5A1, CXCL12, TIMP4 and TNC showed differential expression in more than three 
independent studies200. Another study using weighted gene co-expression network analysis 
suggested that FOS, CCL2, COL4A2 and CXCL5 enriched in immune response and extracellular 
matrix pathway contribute to the rupture of IA201.  
Recent studies also focused on expression levels on previous IA candidate genes 
discovered in previous GWAS and within functional CNVs. A CNV containing oxidoreductase 
WWOX, which previously was associated with cancer development, was found have significantly 
lower expression in IA tissues in Chinese202. Two GWAS significant genes CDKN2A192 and 
SOX17203 were both found to be downregulated in IA tissues.   
It is interesting to note that there were large overlaps in the genes showing a differential 
expression profile in blood samples of IA204, ischemic stroke205 and AVM206, especially with genes 
in the pathways of immune function and hematopoiesis, suggesting a potential continuity in the 
genetic etiology of different cerebrovascular diseases.   
 
Genome-wide association study in IA risk gene identification 
Following the extensive research of microarray expression data, genome wide association studies 
(GWAS) came into focus for the next stage of IA genetic research, using a dense SNP array 
(500,000 to 1,000,000 SNPs) covering the whole genome; an approach which is still deemed to be 
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the most successful method for the identification of IA risk gene. The first GWAS of IA was 
conducted in 2008207, which comprised 2,100 IA patients and 8,000 controls across a discovery 
cohort of Finnish and Dutch, and a Japanese replication cohort. The study discovered significant 
signals on 2q (PLCL1), 8q (SOX17) and 9p (CDKN2A). A follow-up study increased number of 
European and Japanese IA study cohorts (5,891 cases and 14,181 controls) and identified three 
new loci: 18q11.2 (RBBP8), 13q13.1 (STARD13) and 10q24.32. The previous GWAS loci of 
8q11.23-12.1 (SOX17) and 9p21.3 (CDKN2BAS) were also replicated, and the potential risk genes 
in those loci are involved in cell-cycle progression208. It is noteworthy that the 9p21.3 
(CDKN2BAS) gene cluster has been identified as a GWAS hotspot for many other common 
diseases (e.g. coronary diseases, T2D, gliomas and basal cell carcinomas)209.   
After these two major GWAS, several small studies mainly focused on Japanese cases were 
conducted. A GWAS on Japanese IA cohort discovered other risk loci that related to the 
ELN/LIMK pathway, namely 9q31.3 (rs1930095, p=1.31×10-5), TMEM195 (rs4628172, 
p=1.32×10-5), ARHGEF11 (rs7550260, p=4.93×10-5) and IQSEC1 (rs9864101, p=3.63×10-5)208. 
The additional risk loci of the second GWAS were also followed up in two independent Japanese 
IA cohorts and a new loci 4q31.23 (rs6841581, p=2.2×10-8) near the endothelin receptor type A 
(EDNRA) was highlighted in the discovery, along with the increased evidence of two additional 
loci 12q22 (rs6538595, p=1.1×10−7) and 20p12.1 (rs1132274, p=6.9×10-7)210. Association with 
genes EDNRA (4q31.22) and CDKN2BAS (9p21.3) were replicated in another larger Japanese 
GWAS (rs6842241, p=9.58×10-9; rs10757272, p=1.55×10-7), and the functional assessment of 
EDNRA SNP rs6841581 showed that it affects the expression of EDNRA211. A study following 
previous IA GWAS risk loci and found that among which PRDM6 (5q23.2) was significantly 
associated with elevated blood pressure in Europeans (p=8.13×10-7)212.  
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A meta-analysis study on all major GWASs further concluded that the IA consistent risk 
loci are 8q11 (rs10958409, p=1.78×10-15), 9p21 (rs10757278, p=1.59×10-13), and 4q31.23 
(rs6841581, p=1.95×10-8), followed by 12q22 (rs6538595, p=1.12×10-7), 20p12 (rs1132274, 
p=8.29×10-7), 2q33 (rs1429412, p=1.07×10-6) and 7q13 (rs4628172, p=4.04×10-3)179. The GWAS 
risk SNPs rs6841581 (4q31.23), rs10958409 (8q11.23), rs9298506 (8q12.1), rs1333040 (9p21.3), 
rs12413409 (10q24.32), rs9315204 (13q13.1), and rs11661542 (18q11.2) were also investigated 
in another study of genetic risk scores (GRS) based on the site of IA; the results showed that GRS 
of IA were higher at the MCA in both Dutch and Finnish and combined cohort. However, the GRS 
of previous GWAS loci were not associated with familial IA in all cohorts, indicating that risk loci 
of familial IA may be different from the results of previous GWAS results213.   
Correlated with the GRS finding, another GWAS study focusing on populations of 
European descents was conducted with the inclusion of familial and sporadic IA cohorts. The two 
discovery cohorts yielded different risk loci, but meta-analysis confirmed the previous risk loci in 
9p21.3 (rs6475606, p=3.59×10-8) and 8q (rs1072737, p=8.7×10-5). The suggestive loci of familial 
discovery cohort were different to any previously reported loci: PDE1A (rs1897472, p=6.66×10−7) 
and BTBD16 (rs911774, p=6.69×10−6); however, the two loci were not significant after the 
inclusion of sporadic discovery cohort, which suggests again that familial IA may have different 
underlying genetic causes214. 
Focusing on population specific, low frequency variants, an IA GWAS on Finnish familial 
IA discovered high IA risk loci with low-frequency (MAF<0.05) variants on 2q23.3 (p=1.42×10-
9), 5q31.3 (p=3.17×10-8), 6q24.2 (p=1.87×10-11) and 2q33.1 (p=1.87×10-12), while 7p22.1 was 
associated with the number of IAs89. Other GWAS focused on different populations also yielded 
new risk loci. A recent one focused only on European descendants identified new IA risk loci on 
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7p21.1 (rs10230207; p=4.14×10−8)215, close to the SNPs previously associated with ischemic 
stroke216. However, this region failed to show replication in the Finnish cohort, suggesting the 
genetic heterogeneity of IA may be linked with population diversity. Subsequently, another multi-
staged GWAS in Portuguese IA also suggested new loci in their population - rs4667622 (2q31.1, 
p=7.13×10-5), rs6599001 (3p22.2, p=6.05×10-5), rs3932338 (5p14.2, p=2.02×10-4), and 
rs10943471 (6q14, p=5.50×10-4)217, further lengthening the list of GWAS risk loci, however this 
study had limited power due to its sample size. 
Despite of the successful findings of IA GWAS, the accounted heritability in those GWAS 
risk SNPs is extremely low. For instance, in the Finnish study89, all five newly discovered risk loci 
accounted for only 2.1% of the heritability. Additionally, the six SNPs identified in the previous 
GWAS study explained only 2.5% of the heritability in the Finnish. Besides the possibility of lack 
of power, all these results may also suggest that the genetic etiology of a heterogeneous disease 
group such as IA could be population specific and/or differs in familial form.  
 
IA risk gene discovery using whole exome sequencing (WES)  
The implementation of high-throughput sequencing and WES, which started in 2010, opened a 
major era of genetic research and has led to many successful discoveries, especially in rare 
Mendelian disorders. As a systematic way of exploring rare coding variations, the success rate of 
WES relying on how much of the disease can be explained by those variants and how many of the 
diseases exhibit Mendelian inheritance. Despite its wide application in disease gene discovery, the 
number of WES studies in IA is surprisingly limited, with only two such studies were reported up 
to date.  
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The first WES study of IA was reported in 2015 which examined Japanese families218. 
Twelve families with a total of 42 cases were included in the discovery cohort and validated in 
more familial and sporadic IA cases. The study identified 78 risk variants; and 10 variants from 9 
genes (GPR63, ADAMST15, MLL2, IL10RA, PAFAH2, THBD, IL11RA, FILIP1L, and ZNF222) 
were further prioritized based on their functions. These ten variants were genotyped in a validation 
cohort and only the variant in ADAMTS15 (rs185269810, p.E133Q) showed a significant 
association with familial IA (p=0.001). Functional assessment of this variant also highlighted its 
role in endothelial migration. A subsequent and independent WES study that focused on seven IA 
families of European American descent identified 68 potential risk variants219. Linkage analysis 
and RNA sequencing were applied as additional steps in order to further filter variants. Disease 
segregating variants were observed in 8 genes (KLF11, ABCC3, TANC2, ALMS1, ARHGEF17, 
SMEK2, HTRA2, and NDST1) and RNA-seq only revealed TMEM132B to be differentially 
expressed. Furthermore, none of the candidate variants were located in genes reported in the 
previous GWASs.  
It is not surprising that there is no replication between the two IA WES studies. Genetic 
heterogeneity, phenocopies, or gene-environment interactions are all likely be factors that 
introduce complexities to WES discovery efforts. IA being such a common disease with many 
underlying factors that contribute to its predisposition, based on the findings from large amounts 
of data that generated by previous genetic studies (especially GWAS and WES), it is naturally to 
assume that a successful design of IA genetic study needs to rely on increasing the effect sizes of 
potential risk variants. As a result, the selection of a particular founder population with high IA 
prevalence and familial aggregation might lead to the enrichment of such variants with a higher 
heritability.  
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1.4: RATIONALE AND OBJECTIVES 
Since the very beginning of applying genome-wide sequencing and genotyping methods in the 
complex disease genetic studies, the collection of large cohorts has been critical. However, an 
alternative approach involving founder populations also works well to increase the power of 
detection of disease genes. IA is such a complex disease with a low penetrance that it can be 
affected by environmental factors and genetic background. Moreover, in the case of familial 
aggregations, certain populations seem to present higher genetic predispositions110; 211.   
Many two-staged studies have successfully combined the uncovering genetic architecture 
of founder populations with risk gene discovery to the disease predisposed in such populations; 
this yielded significant findings in the two areas: such as in Ashkenazi Jewish peoples with Crohn's 
disease220; 221, Greenlanders with T2D14; 30, Sardinians with multiple sclerosis222; 223 and Indians 
with cardiomyopathy224; 225. French-Canadians and Nunavik Inuit are two important, yet very 
distinctive, founder populations in Quebec, a high prevalence of SAH and IA is observed in both. 
The genetic causes behind this increased IA prevalence are not well understood, while in the case 
of Nunavik Inuit, their underlying genomic landscapes are equally intriguing. In order to shed 
some light on these questions we conducted a series of studies which are described herein. 
The first objective of this thesis was to reconstruct the genetic history and uncovering 
genomic signature of adaptations in Nunavik Inuit. For this purpose, we have used a WES and 
Illumnia Omni SNP-chip tandem approach on a cohort of Nunavik Inuit and performed analyses 
regarding their genetic structure, admixture, patterns of migration and natural selection. The genes 
located in the selection signals were further assessed by qPCR and tested for associations between 
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Inuit individuals affected with IA and controls. This study aimed to reveal the genetic architecture 
of a Canadian aboriginal population while also attempted to apply results from the population 
genetics analyses to a complex disease association. Subsequently, the genetic burdens of a family 
of lipid metabolism genes were also investigated in Nunavik Inuit, including CPT1A, which harbor 
the most significant variant under selection sweep in the Arctic indigenous population. The 
combination of the two methods (WES and SNP-chip) has helped to provide a full picture of the 
genomic landscape of Nunavik Inuit, which can be used in future studies aiming at analyzing other 
diseases for which this population is observed to be predisposed.  
The second objective of this thesis was to identify genetic factors that could explain some 
of the missing heritability of IA in the French-Canadian founder population. The first part of this 
study was mainly high-throughput sequencing (HTS) based. WES data was generated from a 
discovery cohort comprised of large French-Canadian families in which multiple members 
affected with IA. Subsequently, genes that presented an increased burden of rare, functional 
variants in IA patients were re-sequenced in a larger French-Canadian replication cohort, with 
newly discovered potential risk variants from the candidate gene, and further assessed using 
functional assays. Our hope was that using a strategy that both minimize the population 
heterogeneity and acquiring unbiased genetic data would increase the power of identifying the 
genetic risk of IA. Moreover, we complemented the French-Canadian WES study by using high 
density SNP-chip to perform a GWAS analysis for familial IA cases and a large cohort of French-
Canadian control individuals. This complementary approach have enabled us to identify low 
frequency variants associated with IA that would have been overlooked by previous GWAS 
focused on mixed populations. 
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CHAPTER 2: THE GENETIC SIGNATURES OF 
NUNAVIK INUIT 
 
2.1: PREFACE 
Nunavik Inuit represent an important and unique population. The harsh Arctic environment 
has shaped their genomes to harbor unique genetic variants that have enabled their adaptation. 
They are also the descendants of the third wave of human migration into the New World and, 
unlike other Native Americans, they have remained largely isolated until very recently. However, 
the recent changes towards a western lifestyle are thought to have brought increased prevalence of 
cardio-/cerebrovascular diseases among them, including IA, and genetic risks factors lay 
undiscovered in their unique genomes. Until recently, population epidemiological and genetic 
studies aiming to identify genetic risk factors were limited to studies examining disease candidate 
genes or focused on mtDNA and Y-chromosomal DNA. With the recent advances of high-
throughput sequencing (HTS) technologies and the completion of 1KGP phase III data, which has 
included high quality whole genome sequencing data of 26 present-day populations, genome-wide 
population genetic studies have become feasible.  
Here we have used a parallel HTS and genome-wide SNP-chip genotyping approach to 
obtain unbiased genetic data from Nunavik Inuit. Chapter 2.2 presents the first study characterizing 
the genetic history and structure of the Canadian Inuit population. Interestingly this study yielded 
findings different from those of an earlier one, where a neighbouring Greenlandic Inuit population 
was examined14. Unlike their Greenlandic counterpart, Nunavik Inuit have almost no European 
admixture, and some even harbor ancestries that closely resemble those of the ancient Native 
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Americans. These results not only indicate that Nunavik Inuit is an old and isolated population, 
but also suggest that a higher percentage of their genome is unique to the major worldwide 
populations. However, while the Nunavik Inuit genome became adapted to a harsh environment 
and living conditions, it also brought about some genetic predisposition to certain “new” diseases. 
The evidence for this came from both the identification of selection signals, which are essentially 
embedded within the coding portion of the Nunavik Inuit genome and expression level analysis of 
the genes harboring variations of these selection signals29. These genes, which encode protein 
products associated with various biological processes (e.g. cell adhesion and immuno-response), 
and deemed to be indicators of the predisposition to cardio-/cerebrovascular conditions. Moreover, 
an association study aiming to identify variants under selection regions and IA identified a 
common variation in CCM2, which showed a significant association when in a homozygous state.  
Chapter 2.3 focuses mainly on estimations of accumulated genetic burdens to profile 
CPT1A as well as other members of this gene family in Nunavik Inuit. The CPT1A p.P479L loss 
of function variant was initially discovered in Inuit who had CPT-I deficiency52 that was linked to 
infant mortality226; it was subsequently determined that it is within a selective sweep particularly 
in Arctic indigenous peoples40. We found that the frequency of this variant has increased with the 
proportion of Inuit ancestry, and in Nunavik Inuit, the deemed derived allele of p.P479L reached 
a near fixation of 96%. We also found increased mutation burden in other genes encoding carnitine 
acyltransferases including CPT2 and CRAT, in Nunavik Inuit compared to the Asian and European 
populations, highlighting the importance of fatty acid oxidation in Nunavik Inuit’s adaptations.  
Overall this chapter presents a series of studies of reconstructing genetic architecture of 
Nunavik Inuit, in which we have addressed multiple points, from the population genetic struture 
and admixture to migration to genes positively selected for the adaptations. The studies have also 
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suggested the possibilities of identifing disease risk genes based on population genetic approaches. 
Such methods might be applied in different populations as alternative means to carry out genetic 
study of complex diseases.  
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Abstract 
The Canadian aboriginal population has a distinct history and some health risks are known to 
specifically affect its individuals. Nonetheless the number of genetic studies examining this 
population is limited and much remains to be uncovered regarding its genetic characteristics. In 
this study we generated whole exome sequences and genome-wide SNP-chip genotypes for 170 
Nunavik Inuit that belonged to a small and isolated, yet important, founder population of Canadian 
Arctic indigenous people. Our results revealed that the genetic background of Nunavik Inuit is 
distinct from the ones of present-day world-wide population. The majority of Nunavik Inuit are 
with un-admixed Inuit ancestry; only individuals from the Ungava Bay villages have certain 
admixtures found with the ancient Native Americans. The Inuit live in the Hudson Bay area are 
also seemly distinct than the ones located next to Ungava Bay; and the colonization of Nunavik 
appear to have consisted of two southward migrations from the Northwest corner, neighboring 
Nunavut. Furthermore, we observed certain genomic signatures that are distributed across different 
loci of coding regions which are supportive of the adaptation pressure unique to Inuit. The 
strongest selection signal and the significant level of gene expression changes are related to genes 
involved in cell adhesion and immune response processes (CPNE7, ICAM5, STAT2 and RAF1), 
which suggests adjustment of their functions during the development of the cardiovascular system. 
A subsequent analysis aimed to establish if any association could be observed between these 
signatures and the risk of intracranial aneurysms (IA) in Nunavik Inuit revealed a splice variant 
(rs2289367) in cerebral cavernous malformations gene (CCM2); with much higher frequency in 
Nunavik Inuit than general populations (0.83 vs 0.22), which was significantly associated with IA, 
especially in homozygous state (OR=0.23). 
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Introduction 
Considering that the migration of Aboriginal Canadians occurring during the settlement of the 
Arctic population took place over a period of approximately 6,000 years1, it is noteworthy that 
present-day Nunavik Inuit are the descendants of a long line of different occupants with genetic 
discontinuity among most of them. The occupation of this territory started with the early Paleo-
Eskimos (at some point between 3,000 to 800 BCE), who subsequently replaced by Dorset culture 
(1,100 CE) when the Thule people began to occupy the territory9 and became the ancestors of all 
modern Inuit. The different Arctic population changeovers have mostly followed distinctive 
climate shifts in history, and it is assumed that both environment and isolation have played a large 
part in shaping the Inuit genome. In the past decades, changes of the Nunavik Inuit’s lifestyles 
were believed to have increased their risk to several complex disorders227, such as cardiovascular 
diseases (CVDs)84; 228, metabolic disorders229, infection71 and cancer74.  
A number of recent studies have genotyped the Siberians and the Greenlandic Inuit using 
high-density SNP arrays and genomic profiles of these arctic indigenous peoples have emerged. 
An analysis on cold adaptations of the Siberian populations revealed that the genes involved in 
lipid metabolism and vascular smooth muscle contraction were being selected39, with strong 
selective sweep of a CPT1A deleterious variant described in a follow-up study40. Another study of 
the Greenlandic population subsequently revealed that there has been a substantial recent European 
gene flow into the Greenlandic Inuit, and that the populating of Greenland came from a single 
migration from northwest towards southeast14; Subsequently a strong selection signal was reported 
in a cluster of fatty acid desaturases (FADS1-3), which determine polyunsaturated fatty acid 
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(PUFA) levels29. Another team independently reported a TBC1D4 founder mutation related to the 
increase of prevalence of T2D in the Greenlandic Inuit30. 
Despite these recent advances there are various aspects of the genetic profile of the Inuit 
populations that remain to be explored. While significant genetic divergences exist between the 
Nunavik and Greenlandic Inuit, the latter are nonetheless genetically closest to the Nunavik Inuit, 
in particular to the contribution of European gene flow. The underlying genetic factors potentially 
associated with higher prevalence of cardiovascular and related disorders in Arctic indigenous 
peoples are poorly understood5; 230, especially in the evolutionary and genome-wide scale. Through 
a combined analysis of high density SNP-chip genotyping and whole exome sequencing (WES) 
across an Inuit cohort that sampled over 1% of the population of Nunavik, our study provides clues 
that will help to clarify questions about the susceptibility of the underlying genetic factors. 
 
Results 
Population structure of Nunavik Inuit 
Principle Component Analysis (PCA) of the panel ALLPOP containing a total of 5,422 present-
day and ancient individuals showed that Nunavik Inuit were largely separated from the other 
worldwide populations, while being the closest to the Siberian Eskimos and the ancient New 
World/New World Arctic populations (Figure S1). After exclusion of the Africans and other 
populations, which have little relation with Nunavik Inuit (panel NUIrelate), and with most of the 
ancient humans removed as outliers because of their low sequencing qualities, the PCA results 
suggest that the closest relatives to the Nunavik Inuit are the Eskimos and the Greenlandic Inuit. 
However, the Paleo-Eskimo (Saqqaq)16 individuals are shown to be the closest to the Siberian 
 48 
 
Koryaks and do not resemble much the Inuit from either Nunavik or Greenland (Figure 1A). 
146,668 SNPs within the high-confidence (HC) regions were derived from the WES data of the 
Nunavik Inuit and the publicly available WGS data of 649 individuals, including four Native 
American populations from the 1000 genome project (1KGP) and several indigenous populations 
and ancient individuals described in Table S1. CHB and CEU from the 1KGP were also included 
to help determining the ancestries. With further elimination of possible SNP with ascertain bias, 
the Nunavik Inuit still appear to have a distinctive ancestry when compared to other populations, 
including the Greenlandic Inuit and the Northeastern Siberians (Figure 1B). There were also slight 
genetic differentiations within the Nunavik: the two Ungava Bay villages (Kuujjuaq and 
Kangiqsualujjuaq) seem to be separated from the rest of the villages located near Hudson Bay 
(Figure 1C). 
ADMIXTURE analyses231, using the same WES HC dataset, similar results were obtained. 
When assuming the scenario of four estimated ancestries (Han, Native-American, European and 
Inuit), individuals from the Ungava Bay villages seem to contain Native American ancestry 
admixture: among 27 Inuit individuals from Kuujjuaq and Kangiqsualujjuaq, six of them were 
found to have more than 15% of the Native American ancestry (Figure 2A). We preformed further 
analyses using the SNP-chip dataset (NUIrelate) which contains a total of 103 world-wide 
populations. When the number of estimated ancestries was increased to 8 (Euro1, Euro2, Central 
Asian, Siberian, Han, ancient New World, Native-American, Inuit), we found a major non-Inuit 
ancestry that existed only in the Ungava Bay villages, with an average of 16% of admixture in the 
Kangiqsualujjuaq Inuit. Interestingly, this admixed ancestry was found mainly in the genome of 
ancient humans, mostly from the New World Arctic (Figure 2B). Furthermore, 21 out of 170 
Nunavik Inuit showed European admixture (>1%), which seems to be introduced by very recent 
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admix events (10 individuals have >25% European ancestry). Conversely, 87% of the Nunavik 
Inuit showed no evidence of European admixture. Our results also showed that the present-day 
Inuit ancestry first started appearing around Altai regions and then increased drastically from the 
Western Siberia to Northeastern Siberia, which was significantly decreased in the Native American 
populations. Only several groups of Aboriginal Canadians (Athabascans, Algonquins, 
Chipewyans, Crees and Ojibwas) still have some admixture similar with the Inuit ancestry (Figure 
2B). 
PCAdmix232 was used to infer genome-wide local ancestries of admixed Inuit individuals 
and Arctic indigenous peoples. The Inuit individuals from Kangiqsualujjuaq were estimated to 
have an average of 2.0-3.8% of their ancestry from the ancient New World populations, inferred 
from genomes of Saqqaq, Clovis233 and Kennewick234 (Figure 3). The Saqqaq individual shared 
67% of the ancestry with today’s Nunavik Inuit; however, the ancient ancestry inferred from the 
ancient Arctic genome9 only accounted for 6.9% of the Kangiqsualujjuaq genome, suggesting the 
low sequencing quality of the ancient Arctic genome may have caused bias in the ADMIXTURE 
inferring process (Figure S2). Among the 21 Nunavik Inuit who have European admixture, the 
European ancestry accounted from 12.2% to 97.6% of their genomes. In other aboriginal 
populations, Greenland Inuit shared the most of the ancestries with Nunavik Inuit (83.4%), 
followed by Naukan (72.7%), Eskimo (64.4%), Chikuchi (46.8%), Chipewyan (26.3%), Koryak 
(24.3%), Algonquin (12.3%), Evens (11.7%), Yukagir (9.75%), Cree (9.5%) and Ojibwa (9.1%) 
(Figure S2). 
 
History of populating of Nunavik 
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To investigate the effect of isolations on the Nunavik Inuit, we estimated the linkage 
disequilibrium (LD) in individuals from several Nunavik Inuit villages and compared them with 
other Arctic populations (Naukan, Eskimo, Chukchi, Western and Eastern Greenlanders) and 
aboriginal Americans (Chipewyan and Athabaskan). Because sample size affects the accuracy of 
LD estimation, we only included samples from five villages (Inukjuak, Puvirnituq, Ivujivik, Salluit 
and Kaniqsualujjuaq) which have more than 15 individuals. The results showed Nunavik Inuit had 
the highest degree of LD compared to the Arctic indigenous peoples and the 1KGP major 
populations, and they also had significantly higher LD than the Greenland Inuit. Since the presence 
of gene flow reduces LD, we concluded that Nunavik Inuit is the most historically isolated 
population in the Arctic indigenous peoples, including Greenlandic Inuit. Within Nunavik, the 
Kangiqsualujjuaq villagers had a higher LD compared to the Inuit from the Hudson Bay villages, 
suggesting it was the most isolated sub-population in Nunavik Inuit (Figure 4). These observations 
are correlated with the result of the runs of homozygosity (ROH) analyses, in which 27.7% of the 
ROHs are longer than 10 Mb in the Kangiqsualujjuaq Inuit (Figure 5). The Inuit from Salluit and 
Kuujjuarapik have a much smaller percentage in the long segments of ROH, which may be due to 
the inclusion of several highly European-admixed individuals. 
In the Treemix235 analysis, Yoruba was set as outgroup in rooting the tree to infer the 
maximum-likelihood genetic-drift topology relating the Nunavik villages to other artic 
populations. The result of the tree shows the root split between Nunavik Inuit and Greenlandic 
Inuit, with the two Inuit populations subsequently split off with the New World Arctic indigenous 
peoples and the Northeast Siberians. There was also a split between the Ungava Bay Inuit and the 
Hudson Bay Inuit. A potential migration route from the Salluit to both the Southwestern villages 
and the Ungava Bay villages along the coastline could also have be established, with the Inuit from 
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Salluit seemed to be the closest to the New World Arctic indigenous peoples, suggesting the 
ancestors of Inuit entered Nunavik at the northwest point from Nunavut (Figure 6). Furthermore, 
there were migration events from Kangiqsualujjuaq to Kuujjuaq, indicating the history of 
connections between these two villages. No evidence of migration events appeared in other 
Nunavik Villages, while many occurred in aboriginal Canadians, correlated with our previous 
findings of little admixture existed in Nunavik Inuit. 
 
Genes under natural selection in Nunavik Inuit 
Population branch statistics (PBS)236 were calculated for a total of 387,339 single nucleotide 
variants (SNVs) generated from WES data between the Nunavik Inuit and the CHB with the CEU 
as outgroup. 38,116 SNVs with PBS >0.1 was shown in a Manhattan plot (Figure 7), from which 
9,883 were coding SNVs (red), 784 located in or near splicing sites, 1,936 were in UTRs and the 
rest were non-coding, intronic or intergenic SNVs. Variants with an empirical threshold of 99.9th 
(PBS>1.0) were selected as potentially under natural selection. 132 SNVs from 79 genes met the 
aforementioned criteria, including 38 coding and UTR SNVs (Table S2). In result, rs80356779 in 
CPT1A (p.P479L) showed the highest PBS score (3.11), which correlated with our previous 
study49. This Arctic-specific allele had a frequency of 68% in the Northeastern Siberian 
populations40. It was also absent in the ancient Siberian individual Mal’ta56 from 24-kya BP and 
two ancient Native Americans: the Clovis from 11-kya BP and the Kennewick man from 8-kya 
BP. However, the SNV was presented as heterozygous in current day Nivkhs, Athabascans and 
Aleutians237, as well as the 4-kya Saqqaq and a late Dorset individual 1.6-1.4-kya BP. It could 
therefore be assumed that this SNV occurred in the Neolithic Siberia after the first wave of 
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migration into the New World, and it only reached an even higher frequency around the Arctic 
sea. 
Besides CPT1A, we also confirmed the selection signals previously found in the 
Greenlandic Inuit29 around the FADS cluster (chr11: 61,543,499- 61,647,427), which included 
MYRF, TMEM258, FADS1, FADS2 and FADS3, with the highest PBS at 1.17 in FADS1. Several 
new regions with at least one SNV highly selected (PBS>1.5) and within the 500 kb window 
included chr16: 89.6 Mb- 90.1 Mb (CPNE7, DPEP1, CDK10, TCF25 and PRDM7, with the 
highest PBS at 1.74 in CPNE7); chr3: 12.6 Mb- 12.9 Mb (TSEN2, RAF1, MKRN2 and CAND2, 
with highest PBS at 1.76 in TSEN2); chr8: 143.9 Mb- 144.0 Mb (GML, CYP11B1 and CYP11B2 
with highest PBS at 1.52 in CYP11B1) and IMPDH1 at chr7 with highest PBS at 1.65. A single 
missense SNV in STAT2 had also been highly selected (PBS>1.53), however it was the only SNV 
found in this region (Figure 7). 
According to the previous selection signals based on the WES data of the Greenland Inuit, 
there was a strong correlation between the Nunavik and the Greenland Inuit populations. Among 
132 SNVs (79 genes) with PBS>1.0 that we found in Nunavik Inuit, 61 were also found in 
Greenland Inuit with PBS>0.3, from which 25 were also being strongly selected (PBS>1.0).  
We also calculated the WES-based PBS between the Nunavik Inuit and the Northeastern 
Siberians with CHB as outgroup to detect more recent selection. One missense SNV 
(rs180768267) had the highest PBS located in CAND2 (PBS=1.09), followed by ATP10D 
(rs16851681, PBS=1.07) and ICAM5 (rs1056538, PBS=1.04). Both SNVs in CAND2 and ICAM5 
were predicted to be deleterious according to their combined annotation dependent depletions 
scores (CADD >15), suggesting the SNVs may have important function in certain biological 
progresses. However, the CPT1A rs80356779 SNV was only moderately selected between the 
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Nunavik Inuit and the Northeastern Siberians (PBS= 0.84), followed by the aforementioned 
missense SNV in STAT2 (PBS=0.84); both of them were predicted to be highly deleterious 
(CPT1A, CADD=18; STAT2, CADD=25) (Table S3).  
RT-qPCR was used to test the expression levels of genes under selection between the Inuit 
and controls who live in close geographic area but without selection, i.e., the French-Canadians 
(FCs). Thirty genes (Table I) were selected from the SNVs with top PBS and met the following 
criteria: 1) 2 or more SNVs have PBS>1 and in the same region or located in the abovementioned 
selected regions; 2) the gene also showed sign of selection (PBS>0.5) in Greenlandic Inuit29; and 
3) the gene expression in lymphoblastoid cell lines (LCL) cells is predicted to be measurable by 
GTEx (www.gtexportal.org). Two genes, EDAR and SLC24A5 were previously shown under 
selection among worldwide populations, which therefore were not tested in this study238.  
Among the genes tested, GML, CYP11B1, CYP11B2 on chr8, IMPDH1, NCR1, DSP, 
LECT1 and IGHMBP2 showed very limited expression in LCL, therefore were excluded from the 
subsequent analyses because of their low confidence in the expression measurements. Within the 
rest of 21 genes, 11 of them showed the same trend of expression in relative quantification (RQ) 
compared with the FC controls across three independent experiments. Two genes in particular, 
CPNE7 (P = 0.045, Wilcox test) and ICAM5 (P = 0.041, Wilcox test), had significant differences 
in the expression levels (measured by delta CT) in the Nunavik Inuit compared with the FCs; while 
the level of expression of another three genes STAT2 (P = 0.051, Wilcox test; P = 0.03, T-test), 
RAF1 (P = 0.063, Wilcox test; P = 0.05, T-test), and FADS1 (P = 0.051, Wilcox test) suggested 
borderline significance for each gene (Figure 8). 
 
Genes under natural selection in Nunavik Inuit potentially contributed to the risk of IA  
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GO enrichment test on 1,596 genes with one or more coding SNVs with weak signals of selection 
(PBS>0.3) revealed significant enrichment of biological processes in cell adhesion (GO:0007155) 
(P = 6.52e-03); localization (GO:0051179) (P = 3.79e-03) and response to stimulus (GO:0050896) 
(P = 7.46e-05) (Table S4), from which 124 genes are categorized under cell adhesion process, 
including the ICAM family genes, ICAM-1 to ICAM-5, which showed the top selected signals. 
Forty-nine SNVs from the WES data predicted to be both protein-damaging (missense and 
splicing) and also under potential selection in Nunavik Inuit (PBS>0.8). The result of the 
association tests of these 49 SNVs between the Inuit IA patients and the matched population 
controls revealed three SNVs spanning 35kb on chr7 to be significant, with one SNV in the gene 
CCM2 remained to be significant after multiple correction (rs2289367, p=0.000952) (Table S5). 
 
Discussion 
In this study, we combined the datasets of WES and dense SNP-chip genotyping and applied 
statistical methods developed for population genetics; and then investigated the genetic history 
and signatures of Nunavik Inuit. To our knowledge the WES dataset presented here is the largest 
one generated for a single indigenous population. Moreover, the combination of this WES data to 
high quality genome-wide SNPs genotyping data represents an unbiased approach to study the 
largely unknown genetic profile of this unique population. We also associated the Inuit genetic 
profile with a population-characteristic disease phenotype as a portion of the Nunavik Inuit 
samples examined here were ascertained as IA patients. IA is a complex cerebrovascular disorder, 
where there is a thinning and bulging of the intracranial vascular walls, and the prevalence of IA 
is increased in the Nunavik Inuit and the Canadian aboriginal peoples. Our results suggest that the 
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distinctive genetic signature of the Nunavik Inuit population is the result of natural selection or 
genetic drift, and some element of this signature could also explain the increased IA risk. 
 
Genetic structure and migration history of Nunavik Inuit 
Our observations show that the isolated Nunavik Inuit population has no admixture from other 
ancestries and is distinctive from other Arctic populations, such as Greenlandic Inuit, Alaskan 
Athabaskans, Canadian Chipewyan and Northeast Siberians. The component of Inuit ancestry is 
almost exclusive in Nunavik Inuit, which makes it an ideal “reference” population for future 
genetic studies of Arctic indigenous peoples. Apart from the fact that Nunavik Inuit are genetically 
different from other indigenous populations, there was also a genetic isolation between the Inuit 
living at the West Coast of Nunavik (Hudson Bay) and the East Coast (Ungava Bay), where 
Ungava Bay village Inuit seem to have part of their ancestry came from the 4-11 kya BP ancient 
New World. This evidence may suggest two scenarios: 1) Nunavik Inuit at Ungava Bay had once 
admixed with late pre-contact Innu of Labrador, whose ancestors were Paleo-Indians9; and 2) there 
had been genetic continuity between Dorset and Thule Inuit in Nunavik, which correlates with the 
findings of Helgason et al.15, although the study in Greenland Inuit14 suggested otherwise. 
Regardless of the conflict findings, there were evidences indicate that Dorset people remained in 
part of the eastern Arctic Canada until much later (1,350 CE), when Thule people already had 
occupied Greenland at 1,100 CE239. However, the percentage of this ancient Arctic ancestry is low 
(<5%), suggesting an ancient admixture. On the other hand, only 12% of the Nunavik Inuit have 
European admixture (>10%), with ten of them (out of 170 studied individuals) having high 
percentage European ancestry (>50%), which is correlated with the documented history that only 
until 19th century Nunavik had European encounters. 
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We also found evidence suggesting that Thule Inuit came into Nunavik through the Sugluk 
Inlet at Salluit, followed by costal migrations towards the east and west of Nunavik. The 
Greenlandic Inuit split off with the rest of Nunavik Inuit, correlating with the Thule migration split 
off at the Canadian high Arctic in 1300 AD into Greenland and Eastern Canada (Nunavik and 
Labrador)9. We have also discovered a closer split between West Greenland and Ungava Bay Inuit, 
which could be related with a small group of Inuit from Baffin Island arrived in the Northwest of 
Greenland in 1864240, who might bear close genetic resemblance with the Ungava Bay Inuit. 
Similar to that of Greenlandic Inuit, Nunavik Inuit have elevated LD; and this trend seems 
to increase from the West to the East. There was also a higher percentage of large ROHs (>10 Mb) 
in the Ungava Bay villages, which indicates higher levels of isolation and less admixture. The 
increased LD and higher levels of genetic differentiation (indicated by FST) in Nunavik Inuit may 
suggest an increased probability that deleterious variants may reach high frequencies due to many 
generations of genetic drift or hitchhiking with the nearby variants of natural selection. 
 
Genetic signatures of Nunavik Inuit highlighting genes involved in cardiovascular risk 
Genes involved in lipid metabolism are known to be under positive selection in Arctic indigenous 
populations, especially in Inuit29; 40. In addition to confirming the two regions (CPT1A, FADS1-3) 
on chromosome 11 which were previously identified to have high level of selection signals, we 
have also discovered additional loci with unique genetic signatures in Nunavik Inuit, by mainly 
focusing on the protein coding regions of their genomes. 
A strong selection signal in the Nunavik Inuit was identified within a 105 kb region on 
chr16 (chr16: 89,656,156-89,760,474), in which variants in three genes CPNE7, DPEP1 and 
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CDK10 showed the highest PBS. CPNE7 is the most prominent gene, which showed significant 
expression level changes (p<0.05) between LCL cells of Nunavik Inuit and FCs (European 
descents); and had another variant also being positively selected in Greenlandic Inuit 
(rs139901937, PBSGI = 1.39). An alternative splicing variant rs12445560 (PBS=1.74) in CPNE7 
had an extremely high frequency in Nunavik Inuit (F = 95%), while gradually decreasing in 
Northeast Siberians (F = 74%) and Native Americans (F = 40%). The frequency of rs12445560 is 
much lower in Europeans and East Asians (F = 10-12%) and even rarer in Africans (F = 1%). The 
frequency changes of this splicing variant is interesting and seems to be correlated with the out-
of-Africa migration, and has reached near fixation in Nunavik Inuit. CPNE7 is a member of the 
copine family that bind phospholipids in a calcium-dependent manner and also belong to von 
Willebrand factor A-domain-containing proteins241, which is known to be important in cell 
adhesion and migration events. Copines are a family of protein with similar structure and 
biological functions, although their functions are not fully described, there were studies suggesting 
that variants in CPNE4 may be associated with coronary artery disease in East Asian population242. 
Another locus with significant selection signal is located on chr19, containing genes 
ICAM5 and ICAM1 (intercellular adhesion molecules). In our experiment, ICAM5, with two 
missense variants (in LD) under selection, showed significant changes in gene expression between 
the Nunavik Inuit and FC controls. The common haplotype of these two SNPs also seems to be 
present in higher frequency in the indigenous populations (0.19 in CHB, 0.38 in CEU, 0.6 in Native 
Americans, 0.56 in Northeast Siberians), and has again reached near fixation in Nunavik Inuit 
(0.98). ICAM5 is neuronal specific, and ICAM1 is a critical molecule secreted by endothelium 
during vascular inflammation and is responsible for formation of atheroma243. ICAMs also encode 
a family of adhesion proteins, which are involved in oxidative stress and inflammatory response, 
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while highly expressed in the brain and being crucial in the endothelium remodeling, make them 
potentially very important players in cardio- and cerebrovascular diseases244-246. 
Other interesting genes with variants under selection in the Nunavik Inuit include STAT2, 
which encodes a critical component in the type 1 interferons signalling247, and is a well-studied 
inflammatory mediator and important factor in antiviral defense, especially in the brain248. Other 
studies indicated STAT2 is a prominent modulator of inflammation in vascular cells and during 
atherosclerosis249, which makes it a potential marker for CVD250. RAF1 also encodes an 
inflammation regulator and activated by fibroblast growth factor (FGFB) and vascular endothelial 
growth factor (VEGF)251, making it critical in endothelial cell survival during angiogenesis252. 
RAF1 expression was seen to be altered in patients with arterial hypertension253. The selection 
signal on chr8, containing genes CYP11B1-CYP11B2, which function in steroidogenesis and are 
known to be involved in hypertension and increased cardiovascular risk254. 
Besides FADS1, four other genes, CPNE7, ICAM5, STAT2 and RAF1, which contain 
variant(s) most likely under positive selection, and which also have shown high levels of 
differential expression in the Nunavik Inuit and the FC controls, all function in cell adhesion and 
inflammatory response, suggesting that they are also possibly involved in the cardiovascular 
development. The variants, which have reached near fixation (>80%) in Inuit, were predicted to 
be highly damaging according to their CADD scores, thus their impact on the proteins’ functions 
and the metabolisms they act upon might be differently in Nunavik Inuit by comparison to other 
populations. Genes involved fatty acid metabolism were also known to be associated with the 
increased risk of CVD255, which have shown the most positively selected signals in the Inuit 
populations. However, we have discovered genes associated with vascular remodelling and 
inflammatory response – other features of CVD could also be associated with the altered frequency 
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and the differential expressions in Nunavik Inuit. The accumulation at high frequency of 
potentially deleterious variants is usually due to less selective disadvantage in an isolated, small 
founder population with increased LD (genetic drift). However, because of the drastic frequency 
changes, the scenario that we discovered here resembles more of natural selection, in which these 
genetic signatures were essential in the adaptation to the Inuit living environment. Nevertheless, 
the recent switch to Western life style and diet may have diminished the beneficial effects that 
brought by those adaptations in the Nunavik Inuit and made them predisposed at high risk to 
cardiovascular diseases. 
 
Splicing variant in CCM2 under strong selection is associated with the risk of IA in 
Nunavik Inuit 
Intracranial aneurysm (IA) shared pathological similarities with some other cardiovascular 
diseases, such as the damaged vascular remodelling process and maladapted immunological 
responses. It was also demonstrated that lipid metabolic process could contributed to the 
pathogenesis of IA256. We hypothesized that among those highly selected genetic signatures, which 
we previously reported, some may also be associated with increased prevalence of IA in Nunavik 
Inuit. 
As a result of an association test on variants which showed strong selection in Nunavik 
Inuit, a synonymous variant (rs2289367) in gene CCM2, predicted to affect canonical splicing, has 
shown to be significantly associated with the increased IA risk in this population. rs2289367 is 
common in populations worldwide, with similar frequencies from the lowest in East Asians (0.2) 
to the highest in Africans (0.26). However, the derived allele of rs2289367 is much more prevalent 
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in Inuit populations from Nunavik to Greenland (0.82 to 0.88). Furthermore, none of the Inuit IA 
patients were homozygous of the reference allele (G) and 86% of the IA patients were homozygous 
of the derived allele (A); while in controls only 53% were homozygous state (allelic OR=0.23). In 
comparison, only 1-4% of the general population are homozygous of the derived allele, which 
might possibly correlate with the overall worldwide prevalence of unruptured IA (3.2%)96. 
CCM2 is a well-established gene with mutations known to cause cerebral cavernous 
malformations (CCM), which are brain vascular malformations and characterized by abnormal 
enlarged capillary cavities without intervening parenchyma257, likely to result in hemorrhage and 
consequent strokes. The two-hit mutation events leading to the complete loss of function in 
CCM2258 are considered to be the main cause of CCM. In our study, most of the Nunavik Inuit IA 
patients were shown to have a homozygous, potential splicing variant on exon 8, which may lead 
to the complete functional changes of CCM2. CCM2 functions through the regulation of 
endothelial cell integrity259. A recent study suggested the gain of MEKK3 signalling, which CCM2 
binds to, affects endothelial cell migration260 and cardiovascular development261. The KO of 
Mekk3 in mice is lethal due to multiple intracranial haemorrhages262. CCM2-knockdown human 
umbilical vein endothelial cells (HUVECs) has shown lack of the formation of lumens263; and the 
depletion of this gene was also known to induce a response similar to hemodynamic shear stress 
on endothelium remodeling264 and vascular dilation with the thinning of vessel walls 265. All of 
these observations seem to correlate with the well-accepted hypothetical pathogenic mechanisms 
and characteristics for IA266, further suggesting the etiologic continuity between brain vascular 
disorders. 
In summary, we have presented a systematic characterization of the genetic history, 
genomic signatures suggesting adaptations and the susceptibilities of IAs in Nunavik Inuit. 
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Utilizing of the WES data has fully taken account of the unbiased protein coding sequences of this 
important indigenous population. We have discovered new evidences that had not been revealed 
in previous Greenlandic Inuit studies. We have found that Nunavik Inuit is a unique ancestral 
population with potential minor Native American admixtures; and that they have distinct genetic 
signatures showing adaptations to their life styles and reflecting in their cardiovascular 
development in extreme environment; and that a splicing variant in the CCM2 gene showing strong 
natural selection is also associated with the risk of IA. All of these have demonstrated the great 
value underlying the genetic and medical research in isolated founder populations. 
 
Subjects and Methods 
Subjects and genetic data 
Nunavik Inuit 
One hundred and seventy Inuit individuals from Nunavik (Québec, Canada) (Figure S3) were 
included in this study, 155 of them were coming from ten villages: 38 individuals from Kuujjuaq 
(9) and Kangiqsualujjuaq (29) were recruited from Eastern Nunavik villages around Ungava Bay 
and 117 individuals were recruited from Ivujivik (19), Salluit (23), Puvirnituq (28), Inukjuak (32), 
Akulivik (5), Kuujjuarapik (2), Umiujaq (3) and Whapmagoostui (5) in Western Nunavik villages 
around Hudson Bay. The rest 15 individuals were from unknown village origins. Written informed 
consent was obtained from all participants and the study was approved by McGill University 
Ethics Committee and the Nunavik Nutrition and Health Ethics Committee. 
 
SNP-chip genotyping and WES for Nunavik Inuit 
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Illumina HumanOmniExpress 12 and 24 were used to genotype 165 Nunavik Inuit, each contain 
730,525 and 716,503 SNPs, respectively; with WES performed on 114 selected genotyped 
Nunavik Inuit. Illumina GenomeStudio was used for the SNP-chip genotype calling. For exome 
sequencing data, steps regarding to the unaligned bam-to-fastq conversion by picard, adaptor 
trimming, alignment, sam-to-bam conversion, removal of PCR duplicates, recalibration, variant 
calling and annotation were described in the previous study49. Genomic VCF (g.vcf) files for each 
sample were generated by Genome Analysis Tool Kit (GATK) haplotype caller to ensure the 
coverage of non-variant sites267.  
 
Population control panel 1 (structure panel) 
SNP-array data: We obtained array-based data from the publicly available populations from the 
Siberians and the Native Americans, which included 10 Siberian populations (Eskimo, Altai, 
Shors, Koryak, Chukchi, Teleuts, Evens, Yakut, Evenk, Buryat) from Cardona et al.39; 114 
worldwide populations (including 15 Siberian populations and 51 New World populations) from 
Reich et al.1; 9 Sakha-Siberian populations from Fedorova et al.268; 13 Caucasus populations from 
Yunusbayev et al.269; 32 Turkic related populations (Siberians, Middle-Easterners, Central Asians 
and Caucasus) from Yunusbayev et al.270; 11 Siberians, Greenlanders and Athabascans from 
Rasmussen et al.16; 9 Altai region populations from Raghavan et al.56 and 5 Siberian populations 
from Raghavan et al.237 (Table S1).  
 
Whole genome sequencing data: Whole genome sequencing data were also obtained from the 
1000 genome project (1KGP) phase III, which included 26 populations271, the Northeastern 
Siberian populations from Clemente et al.40 and 9 current Old/New World populations237. We also 
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obtained ancient genomes from Siberia and the New World, which included a 4-kya Saqqaq 
genome16; a 24-kya Mal’ta Siberian genome56; a 11-kya Late Pleistocene human from Clovis233; 
34 ancient Arctic people’s genomes: including three from PreDorset culture, 14 from Middle 
Dorset, two from Late Dorset, two from Birnirk culture, one Norton and five Thules9; five Bronze 
age genomes from ancient Altai region272; the genome of the 8-kya Kennewick Man234 and 23 
ancient Native American genomes237 (Table S1).  
 
Population control panel 2 (selection panel) 
European (CEU) and Han Chinese (CHB) populations from the 1KGP phase III271 as well as the 
Northeast Siberian populations, including Chukchis, Eskimos, and Koryaks40 were used in 
combination with the WES data from Nunavik Inuit to calculate the PBS.  
 
Data merging and quality control 
Merging genotype data: The genotype data of the aforementioned array-based population controls 
were merged with Nunavik Inuit using Plink 1.9273 based on GRCh37/hg19 reference and dbSNP 
131 database, with strand correlate with the 1KGP. SNPs without chromosomal positions and 
mitochondrial SNPs were removed. A total of 1,230,877 SNPs were included after the final 
merging, and were used as intervals for variant calling from the bam files of the ancient whole 
genome data aforementioned, as well as the 1KGP phase III data. After the removal of sex-
chromosomal SNPs, the final merged data comprised of array-based contemporary populations, 
ancient populations and the 1KGP populations, which include 1,198,992 SNPs (1,198,070 SNVs) 
and a total of 5,422 individuals from 197 populations. 
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Quality control of the sequencing data: Variants from the g.VCF files of Nunavik Inuit were 
combined with the variants of CHB and CEU samples from the 1KGP phase III VCF files. High 
quality intervals of both datasets were generated and intersected with each other to provide high 
confident regions to obtain high quality exome variants. For the Nunavik Inuit WES data, high-
confidence regions were considered to be that 80% individuals have 100% of reads in the refseq 
gene regions above 10X coverage, which contain 25,941,861 base pairs in the autosomal regions. 
The exome targets of the 1KGP phase 3 were also considered to be the high-confidence regions 
for this dataset, which contain 44,584,105 bp in the autosomal regions. GATK CombineVariants 
function was used to merge the datasets between the Nunavik Inuit (NUI) and the 1KGP phase3 
CHB and CEU and the Northeast Siberians; and variant selection and merging were performed 
within the intervals of HC regions of both datasets. Indels and SNVs, which covered less than 10X 
in each population, were further removed in the combined dataset, non-polymorphic variants were 
also excluded. 
A round of variant re-calling using GATK were performed on NUI, CHB and CEU BAM 
files using variants of the NUI-CHB-CEU merged dataset as intervals. This step was used for the 
calculation of population branch statistics (PBS) to ensure the accurate calling of homozygous 
reference genotypes in outgroup (CEU) and sister population (CHB).  
Variant calling of WGS controls, including 25 North Siberians, 59 ancient genomes and 16 
genomes from Old/New World populations, were also performed by GATK within the exome HC 
region described above. The VCF file was merged with four Native American populations (AMR) 
from the 1KGP and NUI-CHB-CEU variant recall file, using positions in NUI-CHB-CEU recall 
dataset as intervals. 
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Population Structure and Admixture 
PCA and ADMIXTURE 
Principle component analysis (PCA) implemented in Eigensoft 6.1274 was performed on 1) a total 
of 5,422 individuals from the aforementioned structure panel (ALLPOP); 2) 4,611 individuals with 
the removal of African populations (NoAfr); and 3) 3,130 individuals selected from Siberian, 
Middle Asian, East European and Native American populations located along the migration path 
of the ancestors of today’s Nunavik Inuit (NUIrelate). Each set has excluded the SNPs with the 
genotype missing rate over 0.5, 0.55 and 0.6, respectively; and LD-pruned to ensure that no pair 
of SNPs with r2 greater than 0.5 in windows of 50 SNPs. The first 10 eigenvectors were calculated 
and maximum number of outlier removal iterations was set to 5 in the NoAfr and NUIrelate 
datasets.  
The ancestry analysis was also performed on the three aforementioned datasets using 
ADMIXTURE software231. K=8 was used for ancestry estimation for each dataset based on pruned 
data used for PCA analysis. An additional PCA and ADMIXTURE analysis were also performed 
using the WES data of Nunavik Inuit and WGS controls to minimize ascertainment bias induced 
by SNP-chip. 
PCAdmix232 was used for the local ancestry estimation for individual genomes selected 
from highly admixed Inuit individuals and each of the populations with high level admixture of 
the Inuit ancestry. 12 populations were selected, including Naukan, Chikuchi, Eskimo, Yukagir, 
Koryak, Evens, Chipewyan, Cree, Ojibwa, Algonquin, Greenland Inuit and the Paleo-Eskimo. The 
data before applying PCAdmix analysis was phased using BEAGLE 4.1275 with the 1KGP phase 
III as reference panel. We inferred three ancestral populations (ancient New World, European and 
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Inuit) based on the results from ADMIXTURE when preforming PCAdmix on highly admixed 
Inuit individuals. For each of the other 12 admixed individuals, three ancestral populations were 
inferred: for the Siberian populations (Naukan, Chikuchi, Eskimo, Yukagir, Koryak and Evens), 
the ancestries were inferred as Nunavik Inuit (NUI), Han Chinese (CHB) and Native American 
(NAT); for the Canadian-Arctic populations (Chipewyan, Cree, Ojibwa, Algonquin and Greenland 
Inuit), the ancestries were inferred as Nunavik Inuit (NUI), European (CEU) and Native American 
(NAT). The three ancestries for the Saqqaq individuals were ancient New World, Han and Inuit. 
The results were illustrated on the chromosomal ideographs.  
 
LD decay and Runs of Homozygosity (ROH)  
Genome-wide Linkage disequilibrium (LD) can be affected by genetic drift and natural selection; 
and admixture could also affect the length of LD thus causing faster LD decay. It is assumed that 
historical demography has an effect on LD in the isolated populations, such as Nunavik Inuit.  
We calculated the D’ from SNP-chip data of 14 indigenous and other present-day 
populations in order to compare the patterns of their LD decay. Each population contains 20-50 
individuals to minimize the inflation. The five Nunavik villages (Inukjuak, Puvirnituq, Ivujivik, 
Salluit and Kangiqsualujjuaq) with more than 20 peoples were selected; along with three Northeast 
Siberian populations including Naukan, Eskimo and Chukchi; Athabaskans from Alaska; 
Chipewyans from NWT in Canada; West/East Greenlanders; CHB and CEU populations. 
LD measured by D is   
D=Frequency(AB)-Frequency(A)Frequency(B) 
Or D=Frequency(AB)Frequency(ab)-Frequency(Ab)Frequency(aB) 
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The AB alleles are in LD if D≠0 
And for the calculation of D’ 
If D>0,  
D’=D/Dmax(min(Frequency(A) Frequency(b), Frequency(a) Frequency(B))) 
If D<0,  
D’= D/Dmin(max(-Frequency(A) Frequency(B), -Frequency(a) Frequency(b))) 
The result of the LD decay for each population was plotted in R. 
Runs of Homozygosity (ROHs) were used in estimating individual genome-wide 
autozygosity, with 5,000 kb of sliding window and homozygous SNPs spanning 1,000 kb used to 
define the homozygous segment. The SNP-chip data of Chukchi, Naukan, Eskimo from Siberia, 
Athabascan and Chipewyan from Alaska and Canada, East and West Greenlandic populations and 
YRI, CHB and CEU populations from 1KGP were compared with the Nunavik individuals from 
different villages. The proportion of each population with one or more ROH up to 1.5 Mb, between 
1.5-2.49 Mb, 2.5-4.99 Mb, 5.0-9.99 Mb and more than 10 Mb in length was calculated 
respectively.  
 
Treemix 
We used Treemix235 to infer population splits and mixtures from genotypes of SNP-chip data in 
selected populations that closely related to Nunavik Inuit (NUIrelate). The algorithm used 
Gaussian approximation to estimate genetic drift between populations. Thirty-four ancient Arctic 
people’s genomes and 23 ancient Native American genomes were excluded from the tree 
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generation because of their low sequencing quality. Different populations focusing on the Old/New 
world peoples were included in the constructing of trees with or without high quality ancient 
genomes (Saqqaq, Mal’ta, Clovis, Kennewick and four ancient Bronze Age Altai peoples) because 
they were shown as outliers. 50 trees were generated for each dataset with 0-10 migration events, 
the trees with the highest likelihood were presented. 
 
Detection of Selection by Population Branch Statistics (PBS) 
PBS 
Population-wide site variant frequencies were calculated from the NUI-CEU-CHB exome HC 
variant dataset described above. Variants with no frequency in one population was assigned a 
minimum MAF to reduce the bias introduced by a limited population size. Fixation index (FST) 
value for each variant was calculated between each of the two populations, and the classical 
transformation was used as follows,  
T = -log (1 – FST) 
The value T was calculated between the Inuit and CEU populations (TIE), the Inuit and 
CHB populations (TIH) and CEU and CHB populations (TEH). PBS values, representing the lengths 
of the branch leading to the Nunavik Inuit population since its divergence with Han Chinese, were 
calculated as  
PBSI = (TIE + TIH − TEH)/ 2 
when using Europeans as outgroup236. 
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The results were shown in Manhattan plot and all variants with PBS > 0.1 were plotted 
against concatenated chromosomal locations. The exome variants with PBS > 0.1 were shown in 
red. We also calculated the PBS values between Nunavik Inuit and Northeastern Siberians, with 
CHB as outgroup to identify more recent selections. 
 
Expression analyses of the genes under selection 
Genes under potential natural selection were chosen for real-time quantitative PCR (RT-qPCR) 
analysis to detect whether their levels of expression are significantly changed among the Nunavik 
Inuit samples. EBV-transformed lymphoblastoid cell lines (LCL) were selected from 15 unrelated 
Nunavik Inuit and 14 unrelated French Canadians (FCs) as controls. RNA was extracted from each 
LCL and cDNA was prepared using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). RT-
qPCR was performed using the TaqMan Gene Expression Assay on QuantStudio 7 Flex Real-
Time PCR System (Applied Biosystems). For each assay, RNA polymerase II polypeptide A 
(POLR2A) was used as endogenous control to normalize the gene expression level. Three analyses 
were done with independent RNA extractions and each sample was tested in triplicate. The 
triplicates were valid if the delta Ct standard deviation was smaller than 0.25, and the mean delta 
CT value over three replications was used and with delta delta CT calculated using one FC 
individual as the calibrator. Relative quantification (RQ)276 for each gene was calculated for 14 
Nunavik and 14 FC individuals using the formula of: 
RQ = 2-ΔΔCt 
And were compared by non-parametric Mann-Whitney U test with the RQ of each gene 
subsequently plotted. 
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Susceptibility of IA in Nunavik Inuit 
Among the Inuit individuals recruited in this study, forty-two of them were also diagnosed to have 
definite IA, a cerebrovascular disorder affects the brain vascular walls (thinning and bulging) 
therefore leading to subarachnoid hemorrhage277. We sought to discover if the gene(s) that have 
undergone natural selection in Nunavik Inuit would potentially influence their susceptibility of IA, 
because the changes of life style of today’s Nunavik Inuit may have possibly introduced new 
selective pressure on specific genetic variants that they have carried over through their population 
history. 
Gene ontology (GO) enrichment analyses were performed on a number of genes under 
selection (PBS>0.3) between Nunavik Inuit and CHB using Panther (http://geneontology.org/). 
SNPs with batch bias (<0.05 after multiple correction) in Nunavik Inuit dataset were removed; and 
we performed association tests in 42 un-admixed Nunavik IA cases and 62 un-admixed Nunavik 
controls focused on the high quality, potential protein altering variants which are under strong 
selection (PBS>0.8). Bonferroni correction was applied to adjust the results with P < 0.05 as 
significance. 
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Figures 
 
Figure 1. Principal component analysis (PCA) of Nunavik Inuit and other populations. 
A. PCA using SNP genotyping panel “NUIrelate” showing the Nunavik Inuit and selected indigenous populations. B. PCA using WES 
data showing the Nunavik Inuit and selected Arctic and Native American indigenous populations. C. PCA using WES data showing the 
Inuit from the Hudson Bay and the Ungava Bay of Nunavik.  
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Figure 2. Estimated admixture proportions for Nunavik Inuit with Arctic and 
Native American indigenous populations. 
The ancestry components are estimated with ADMIXTURE using A. the WES data of the Nunavik 
Inuit (by villages) and 1KGP Native American populations and the ancient populations (K=4); and 
B. the SNP-chip genotyping data, selected populations with Inuit ancestry are shown (K=8). 
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Figure 3. Local ancestry inference of an individual from Kangiqsualujjuaq.  
The individual genome potentially come from the Saqqaq ancestry are shown in red (3.8%).   
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Figure 4. LD decay for different populations.  
The figure depicted the LD decay for Nunavik Inuit villages (01-05), Northeastern Siberians (06-
08), Greenlandic Inuit (09-10), Canadian Arctic indigenous peoples (11-12) and two reference 
populations, CHB and CEU from 1KGP (13-14). 
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Figure 5. Estimated Runs of Homozygosity (ROH) lengths of different populations.  
Including Nunavik Inuit from different villages, Arctic indigenous peoples and 1KGP populations. ROH in windows of different sizes 
were shown in proportion in each population.  
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Figure 6. Maximum-likelihood genetic-drift tree topology relating people from 
Nunavik Inuit and other Arctic indigenous populations.  
Estimated by Treemix, with 10 migration events.   
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Figure 7. Manhattan plot displaying Population Branch Statistics (PBS) of Nunavik Inuit. 
This figure shows the FST based PBS results, which measures the variant frequency changes of each site. CHB is used as the sister 
population and CEU is used as outgroup, variants with PBS>0.1 are displayed, with red (pink) dot represent exonic variants. 30 genes 
marked on the figure were also included in the subsequent expression analysis.  
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Figure 8. The relative quantification (RQ) scores of genes with significant expression level changes between Nunavik 
Inuit and FC.  
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Tables  
 
Table I.  Candidate genes under positive selection based on top PBS scores in Nunavik Inuit using WES data 
Gene Top SNP Top PBS 
in NUI-
CHB-CEU 
Function(CADD) MAF.NUI MAF.CHB MAF.CEU Top PBS in NUI-NES-
CHB 
Top SNP (PBS>1) in GI-CEU-CHB No. SNPs 
with PBS>1 
in NUI 
CPT1A rs80356779 3.11191 missense(18.21) 0.9567308 0 0 0.839809 NA 1 
TSEN2 rs735640  1.75609 3'-UTR(NA) 0.8300971 0 0 NA rs735640 (1.386817257) 1 
CPNE7 rs12445560 1.74435 near-splice(9.53) 0.9471154 0.126214 0.09596 0.48916 rs139901937 (1.386817257) 4 
IMPDH1 rs72624969 1.65097 intronic(NA) 0.9759615 0.286408 0.07071 NA rs4731447 (1.074576366) 3 
STAT2 rs2066815 1.526 missense-near-
splice(25) 
0.7932692 0.009709 0 0.839179 NA 1 
TASP1 rs11697393 1.52427 intronic(NA) 0.8300971 0.048544 0.0202 NA rs11697393 (1.145574318) 3 
CYP11B1 rs4534  1.51184 missense(0.09) 0.9615385 0.446602 0.01515 0.495403 rs57589970 (1.42684416116379) 1 
SREBF2 rs2228314  1.48112 missense 0.9951923 0.194175 0.25253 NA rs2228314 (1.052002479) 1 
NCR1 rs2278428 1.45223 missense(5.939) 0.9567308 0.320388 0.06566 0.510609 rs2278427(0.801) 3 
ATP10D rs16851681 1.43361 missense(0.09) 0.9807692 0.194175 0.23232 1.073339 rs13152689 (1.01525329436256) 5 
CAND2 rs180768267 1.38952 missense(16.91) 0.7884615 0.021739 0 1.094545 rs181307051 (1.067382254) 2 
RAF1 rs5746223 1.34431 intronic(NA) 0.8267327 0.033981 0.09596 NA rs5746223(0.72) 3 
LECT1 rs62637607 1.28517 intronic(NA) 0.7355769 0 0.0101 NA rs62637607 (1.376472464) 1 
AIM2 rs2276405 1.27947 missense(16.34) 0.75 0.029126 0 0.634696 rs2276405 (2.536097555) 1 
CYP11B2 rs6432  1.26684 intronic(NA) 0.9509804 0.519608 0.01515 NA rs4536 (1.30937734894169) 1 
SGSM3 rs55844816 1.25915 intronic(NA) 0.8798077 0.169903 0.09596 NA rs55844816 (1.413484817) 4 
GPR133 rs1212936 1.24033 intronic(NA) 0.9663462 0.160194 0.32828 NA rs1195923(0.671033087505734) 2 
GML rs3764795 1.23792 missense(15.17) 0.038835 0.504854 0.95455 0.368187 rs3750247(0.238465870959858) 1 
NDUFA10 rs77816205 1.19479 intronic(NA) 0.7548077 0 0.06633 NA rs77816205 (1.427053791) 1 
ALG11 rs17480245 1.18738 missense(0.017) 0.7058824 0 0.0101 0.532059 rs17480245 (1.212805669) 1 
FADS1 rs174556 1.16915 intronic(NA) 0.0048077 0.664706 0.68966 NA rs174547(0.763990036106579) 3 
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ICAM5 rs1056538 1.16354 missense(16.96) 0.0192308 0.81068 0.61616 1.038068 rs2228615(0.546499505209769) 3 
FADS2 rs174602  1.14054 intronic(NA) 0.9326923 0.257282 0.19192 NA rs174602 (1.14510508) 1 
CHERP rs12460141  1.09348 intronic(NA) 0.6923077 0.005952 0.00549 NA rs12460141 (1.508902039) 2 
MYRF rs174536 1.08532 intronic(NA) 0.0096154 0.674757 0.67677 NA rs108499(0.770196821564124) 4 
DSP rs7741957  1.07435 intronic(NA) 0.8543689 0.315534 0 NA rs7741957  (1.907001643) 2 
NSUN2 rs506416 1.05426 intronic(NA) 0.0148515 0.650485 0.70202 NA rs6887702(0.781014952248378) 4 
IGF2BP1 rs4265867  1.05156 intronic(NA) 0.6634615 0 0 NA rs4265867 (1.735874019) 1 
IGHMBP2 rs560096 1.02829 missense(1.24) 0.0480769 0.538835 0.88384 0.15293 rs1249463(0.954137807645166) 1 
ICAM1 rs5498 0.99744 missense(0.754) 0.0192308 0.737864 0.58586 0.881544 rs5498(0.424053850741787) 1 
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2.3: INCREASED MISSENSE MUTATION BURDEN OF FATTY 
ACID METABOLISM RELATED GENES IN NUNAVIK INUIT 
POPULATION 
 
Manuscript: Increased missense mutation burden of fatty acid metabolism related genes in 
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Abstract:  
Background: Nunavik Inuit (northern Quebec, Canada) reside along the arctic coastline where 
for generations their daily energy intake has mainly been derived from animal fat. Given this 
particular diet it has been hypothesized that natural selection would lead to population specific 
allele frequency differences and unique variants in genes related to fatty acid metabolism. A group 
of genes, namely CPT1A, CPT1B, CPT1C, CPT2, CRAT and CROT, encode for three carnitine 
acyltransferases that are important for the oxidation of fatty acids, a critical step in their 
metabolism. Methods: Exome sequencing and SNP array genotyping were used to examine the 
genetic variations in the six genes encoding for the carnitine acyltransferases in 113 Nunavik Inuit 
individuals. Results: Altogether ten missense variants were found in genes CPT1A, CPT1B, 
CPT1C, CPT2 and CRAT, including three novel variants and one Inuit specific variant CPT1A 
p.P479L (rs80356779). The latter has the highest frequency (0.955) compared to other Inuit 
populations. We found that by comparison to Asians or Europeans, the Nunavik Inuit have an 
increased mutation burden in CPT1A, CPT2 and CRAT; there is also a high level of population 
differentiation based on carnitine acyltransferase gene variations between Nunavik Inuit and 
Asians. Conclusion: The increased number and frequency of deleterious variants in these fatty 
acid metabolism genes in Nunavik Inuit may be the result of genetic adaptation to their diet and/or 
the extremely cold climate. In addition, the identification of these variants may help to understand 
some of the specific health risks of Nunavik Inuit.  
 83 
 
 
Introduction: 
Modern Inuit are descendants of the Dorset peoples from the second wave of migrations which 
took place over 1,000 years ago278. Previous studies have established that these Inuit are 
genetically closest to the contemporary north-east Siberian populations16, and belong to one of the 
three native ancestral groups that populated the Americas. The ancestors of today’s Nunavik (a 
region of northern Quebec) Inuit had migrated from Alaska to the east across the far north. With a 
population of barely 10,000 individuals, Nunavik Inuit form a very isolated population whose 
ancestral genetic profiles are likely to be well preserved until today. The Inuit enrolled in this study 
were recruited from 13 of the 14 inhabited villages, and they represent over 1% of the Nunavik 
Inuit population. As a part of their unique lifestyle, Nunavik Inuit derive approximately 75% of 
their daily energy intake from animal fat279. The traditional diet (high in fat and low in 
carbohydrates) of Nunavik Inuit suggests that they have high rates of gluconeogenesis, which is 
supported by their larger liver size compared to other populations. 
The oxidative processing of fatty acids is critical for generating energy from a diet enriched 
with animal fat. Several enzymes are involved in the metabolism of fatty acids, including the 
carnitine acyltransferases. The carnitine acyltransferase gene family is comprised of six members 
which encode for three types of enzymes: (1) carnitine palmitoyltransferases (CPTs) encoded by 
CPT1A, CPT1B, CPT1C and CPT2; (2) carnitine acetyltransferase (CrAT) encoded by CRAT; and 
(3) carnitine octanoyltransferase (CrOT) encoded by CROT280. The genomic features of these six 
genes are listed in Table II. CPTs include two members, CPT-I and CPT-II. As a rate-limiting 
step in fatty acid oxidation, CPT-I converts long-chain fatty acyl molecules into their 
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corresponding acylcarnitines, which are then transported across the inner mitochondrial membrane 
for beta-oxidation. CPT-II is responsible for the reversal of this process281. CrOT and CrAT 
catalyze the reversible transfer of fatty acyl groups between CoA and carnitine, and therefore 
determine the acetyl-CoA/CoA ratio282. 
CPT-I and II deficiencies are genetic disorders that are characterized by the reduced CPT 
enzyme activity which can lead to severe consequences, such as liver failure and renal problems283; 
284. Although these deficiencies are commonly caused by autosomal recessive mutations in CPT1A 
and CPT2, heterozygous carriers of CPTs mutations can also be symptomatic285.  
Considering their critical roles in lipid metabolism and energy generation, the six genes 
encoding carnitine acyltransferases may be subjected to evolutionary pressure, especially in 
populations such as the Inuit, which require an increased enzyme activity because of their special 
diet and extreme living conditions. Recent studies have shown that the diet of Nunavik Inuit led to 
changes in specific biomarkers. For instance, Nunavik Inuit have very high levels of n-3 
polyunsaturated fatty acids (PUFA), especially in the elderly286, as well as high levels of plasma 
LDL cholesterol287. It is possible that these changes may be partially due to the variations in the 
carnitine acyltransferase genes, which can affect their enzymatic activity. Because of these 
biochemical characteristics, it is important to study the genes that are critical to fatty acid 
metabolism. In addition to providing insight about the Nunavik Inuit adaptation, the identification 
of variants in these genes may also help to understand some of their specific health risks. To 
examine this hypothesis, we used exome sequencing and SNP array genotyping to investigate 
genetic variants across these six genes in a cohort of Inuit from Nunavik.  
 
Materials and Methods: 
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Subjects 
We recruited 113 Inuit individuals (62 males and 51 females, mean age 52 years) from 13 inhabited 
villages of Nunavik. The study was approved by Comité d'éthique de la recherche du Centre 
hospitalier de l'Université de Montréal (ND 04.101) (Québec, Canada) and the Nunavik Nutrition 
and Health Committee (Québec, Canada). Individual written consent was obtained from each 
participant before entering this study.  
 
Exome sequencing and coding variant identification from six carnitine acyltransferase genes 
The genomic DNA of 113 Nunavik Inuit individuals was extracted from peripheral blood 
lymphocytes using Gentra Systems PUREGENE DNA purification kit (Qiagen). A 50 µl DNA 
sample at a concentration of 100 ng/µl from each sample was captured by Agilent SureSelect 
50mb/V4 capture kit. The library was subsequently sequenced at 100 bp pair-end using Illumina 
Hiseq 2000, with 3 samples per lane to ensure an average coverage depth of 100-fold.  
Raw fastq files were aligned to NCBI human reference GRCh37 using Burrows-Wheeler 
Aligner (BWA)288, with all PCR duplicates removed from the alignments. The aligned reads were 
converted to binary format for further analysis using Sequence Alignment/Map (SAM) tools288. 
Single nucleotide variant (SNV) and insertion/deletion (indel) calling were performed using 
Genome Analysis Toolkit (GATK) version 2.7267. Variant annotation was performed using 
ANNOVAR program289 with references to GRCh37/hg19, dbSNP version 132, 1000 Genomes 
project (1KGP) (2012 data release)290, 69 Complete Genomics (2012 update) and exome variant 
server (EVS) with approximately 6,500 exomes (NHLBI-ESP project, 2013 update)291. Finally, 
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variant segregation analysis was performed using an in-house segregation program, using more 
than 1,000 exomes of different ethnicities from our lab as controls.  
In the variant analysis, intronic, intergenic and non-coding variants were excluded because 
of insufficient coverage. Quality filters were set at sequencing depth ≥20x and variant frequency 
≥25%, with genotype quality ≥10. Rare variants were defined as variants with minor allele 
frequency (MAF) ≤0.01 in the aforementioned public databases. All potential missense and 
splicing site variants from the genes CPT1A, CPT1B, CPT1C, CPT2, CRAT and CROT were 
examined, and were further validated by manual inspection using the Integrative Genomics Viewer 
1.4 (IGV)292 and Sanger sequencing. 
 
SNP genotyping and common variant identification from six carnitine acyltransferase genes 
SNP genotyping was performed on 113 Nunavik Inuit, using Illumina HumanOmniExpress-12 
SNP array, which contains 730,525 SNPs. Raw data was processed and analyzed using Illumina 
GenomeStudio and quality control was performed by PLINK 1.07293. SNPs within each gene 
region and 2,000 bp up/downstream flanking regions were extracted from all individuals. Variant 
concordance within these regions was calculated between data from exome sequencing and SNP 
array genotyping. Allele frequencies and Hardy–Weinberg equilibrium (HWE) of all selected SNP 
were calculated using PLINK. Calculation of linkage disequilibrium (LD) and haplotype analysis 
were performed using Haploview 4.2294.  
 
Statistical analysis 
 87 
 
Multidimensional scaling (MDS) and Admixture analyses231 were performed on the Nunavik Inuit 
genotype data against HapMap genotype data from Asian (CHB and JPT), European (CEU) and 
African (YRI) populations to assess the mixture of Nunavik Inuit population.  
Missense variations of the carnitine acyltransferase genes were retrieved from 286 Chinese 
(CHB) and Japanese (JPT) from the 1KGP database and European descendants from EVS, to serve 
as controls. 
Mutation burden is defined as the average number of rare (MAF ≤0.01) missense variant 
alleles per person. To examine whether there is an increased mutation burden in the selected genes 
in Nunavik Inuit compared to other populations, we performed a binomial test to compare rare 
allele frequencies between Nunavik Inuit and 1KGP Asians. The Adaptive Permutation test was 
also performed to compare the mutation burden in Nunavik Inuit with Asians. The Permutation 
test was performed five times based on the number of variant-containing genes, with Bonferroni 
correction for multiple comparisons applied and p <0.01 was set as statistically significant. 
We also calculated two F-statistics (FST and FIS) scores based on variants identified in the 
carnitine acyltransferase genes. The FST value provides an indication about the population genetic 
difference that is due to the genetic drift between subpopulations. The FIS value measures the 
proportion of total inbreeding within a population that is due to non-random mating within 
subpopulations295. To further compare the impact of these variants in Nunavik Inuit to other 
populations, we generated a scatterplot using the R package “ggplot2” of all functional variants 
identified in CPT1A, CPT1B, CPT1C, CPT2 and CRAT in Nunavik Inuit, 1KGP Asians and EVS 
Europeans. Mann-Whitney U test was performed to compare the PolyPhen-2 scores of all rare 
missense variants found in Nunavik Inuit and 1KGP Asian populations, with p<0.05 as significant.   
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Results: 
Data quality control 
Using the data from the HumanOmniExpress SNP array, four individuals with sex mismatch were 
identified by PLINK and removed from the subsequent analysis. After MDS testing, the genomes 
of nine additional individuals were found to have a mixture of both Inuit and European genomes 
and were therefore also removed from subsequent analysis. This mixture is probably the results of 
intermarriages between Nunavik Inuit and French-Canadians. Therefore a total of 100 Inuit 
samples were included in the genetic/statistical analysis (Figure 9). 
Based on GATK's DepthOfCoverage Walker267 program, the average coverage depth of 
the coding regions of CPT1A, CPT1B, CPT1C, CPT2, CRAT and CROT were 102X, 134X, 107X, 
102X, 101X and 80X, respectively. The percentage of targeted region with coverage depth of more 
than 20X for each gene were 92.7%, 97.3%, 99.6%, 94.1%, 98.6% and 90.2%, respectively 
(Figure S1).  
Of the 6 carnitine acyltransferase genes, coding variants were identified only in CPT1A, 
CPT1B, CPT1C, CPT2 and CRAT in Nunavik Inuit. Since no coding variants were found in CROT, 
all subsequent analyses and discussions were focused on the other 5 genes. Across these genes, 16 
variants were identified by both the exome sequencing and SNP array, 4 of which were exonic 
variants. The concordance rate of the exonic variants between the two platforms was 100%, while 
for the intronic variants it was 77% (Table S1).  VCF (Variant Call Format) files of the exome 
sequencing data and PLINK genotype files of the SNP array covering the carnitine acyltransferase 
gene regions can be found in supporting information-Compressed/ZIP File Archive.    
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Missense variants of the carnitine acyltransferase genes in different populations 
In the 100 individuals included in the analysis, 10 missense and 3 synonymous variants were found 
in 5 carnitine acyltransferase genes. Three missense variants, CPT1C p.T265M, CPT2 p.R477W, 
CRAT p.S78F and one synonymous variant CPT1A p.V616V, were unique to the Nunavik Inuit 
population (Table III and Table S2). In addition, an Inuit specific variant CPT1A p.P479L was 
also observed. These five variants and a rare synonymous CRAT p.A575A variant were validated 
by Sanger sequencing (Figure S2). The frequencies of the 10 missense variants were compared 
between the Nunavik Inuit, Asian, European and African populations. In silico prediction using 
PolyPhen-2296 and MutationTaster297 suggested that the 4 Inuit specific missense variants are 
potentially deleterious (Table IV). Even with the exclusion of the Inuit high frequency variant 
CPT1A p.P479L (rs80356779), the Polyphen-2 scores of all the rare variants found in Nunavik 
Inuit and 1KGP Asian population were still significantly higher (Mann-Whitney U test, p=0.02) 
for Nunavik Inuit (Table V and Figure S3).  
 
Mutation burden test and F-statistics of variants in the carnitine acyltransferase genes in 
Nunavik Inuit 
In order to characterize the genetic profile of the carnitine acyltransferase genes in Nunavik Inuit, 
the mutation burden for each gene was calculated in the Inuit and compared to the mutation burden 
in 286 Asians (CHB and JPT) from 1KGP. Nunavik Inuit had significantly more mutated alleles 
per individual in the CPT1A, CPT2 and CRAT genes than Asians (Binomial test, p<0.01). 
Permutation test showed similar results with marginally significant p values in CPT2 and CRAT 
(not significant after Bonferroni correction) (Table VI).  
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FST and FIS scores were calculated for 100 Nunavik Inuit and 83 HapMap Asians (CHB 
and JPT). The CPT1A p. P479L variant had the highest FST value (0.92), and the mean FST of the 
4 Inuit specific variants was also statistically significant (0.84, p<0.01). However, the mean FIS of 
all variants did not significantly deviate from zero after 1,000 randomizations (-0.0092) (Table 
VII).  
Figure 10 depicted the frequencies and deleterious scores of the functional variants of the 
carnitine acyltransferase gene in different populations. The allele frequencies of all missense 
variants in European descendants (EVS database), Asians (1KGP) and the Nunavik Inuit were 
plotted against the PolyPhen-2 score of each variant. Variants with PolyPhen-2 score>0.8 
(predicted to be highly deleterious) were presented at higher frequencies in the Nunavik Inuit 
compared to Asians and European descendants (Figure 10). 
 
Common missense variants in the carnitine acyltransferase genes 
HWE testing did not show a significant deviation for any of the exonic variants identified in the 5 
genes. Haplotype analysis found that 3 common Nunavik Inuit CPT1B missense variants 
(rs470117, rs8142477 and rs3213445) were in an 8 kb LD block. The frequency of this haplotype 
in the Inuit (0.66) was significantly higher than in Asians (0.46) (Binomial test, p=7.501e-05). In 
CPT2, two common missense variants rs2229291 (p.F352C) and rs1799821 (p.V368I) are in a 1 
kb LD block (Figure 11). These variants along with the Nunavik Inuit specific variant p. R477W 
form four major haplotypes in the studied cohort: T-G-C (45%), T-A-C (24%), G-A-C (28%) and 
T-G-T (3%), respectively. While in Europeans and Africans, only the T-G-C and T-A-C 
haplotypes were found. In Nunavik Inuit the G-A-C haplotype frequency is 28% compared to 10% 
in Asians298, and absent in Europeans (Binomial test, p=3.481e-07).  
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Discussion: 
Carnitine acyltransferase gene variants in the Nunavik Inuit  
Our results indicate that Nunavik Inuit are genetically distinct from European, African and Asian 
populations, with the closest relationship to Asians. In 100 Nunavik Inuit we found three novel 
missense variants and a known Inuit specific missense variant in 4 carnitine acyltransferase genes. 
The rare missense mutations are significantly more deleterious and their frequencies are 
significantly higher in Nunavik Inuit, compared to other populations. Interestingly, we didn’t find 
CROT missense variants in either Nunavik Inuit or Asians. 
Mutation burden testing shows that mutations in the CPT1A, CPT2 and CRAT genes are 
significantly more frequent in Nunavik Inuit compared to Asians. The mean FST value (0.18) of all 
variants indicates a great genetic differentiation between Nunavik Inuit and Asians (FST >0.15); it 
is also noteworthy that the 4 Inuit specific variants are indicating an even higher degree of 
differentiation for this population (FST >0.25) (Table VII). However the FIS value shows no 
statistical significance, which may due to the limited number of variants available. Nevertheless, 
the negative mean FIS value suggests that there could be an excess of heterozygotes within the 
populations.   
 
Nunavik Inuit population specific variants 
CRAT and CPT2 
The CRAT p.S78F mutation is located at the splicing site and is predicted to affect splicing, 
potentially to leading to a loss of function of CrAT and carnitine acetyltransferase deficiency. 
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Moreover, in a muscle-specific CrAT knockout mouse model, CrAT acts as a modulator of whole-
body glucose homeostasis and metabolic flexibility299. The Inuit appear to tolerate drastic changes 
in metabolic homeostasis, hence the loss of CrAT function may be beneficial to them. 
Symptomatic CPT-II deficiency is usually caused by homozygous or compound heterozygous 
mutations in CPT2. The CPT2 p.R477W mutation found in the Nunavik Inuit is likely to lead to 
the loss of function as it is located in a highly conserved region where mutations known to cause 
CPT-II deficiency occur300; 301. It is possible that heterozygote loss of function mutations in CPT2 
may have a beneficial effect on the enzyme activity in Nunavik Inuit.   
 
The high frequency CPT1A p.P479L variant 
In general, missense mutations are rare in CPT1A; yet in some Inuit populations, the p.P479L loss 
of function mutation has a high frequency, ranging from 44% to 83% from Alaska to Greenland48; 
226. In our study of the Nunavik Inuit, the p.P479L mutation has an allele frequency of 95.5%, the 
highest reported to date. The frequency of this variant seems to increase from the west to the east 
along the arctic tree line and from inland to the shore (Figure S4), correlating with the migration 
timeline and with the higher consumption of animal fat of residents near the shore. The CPT1A 
p.P479L mutation is significantly more frequent among Nunavik Inuit compared to 243 Kivalliq 
Inuit (western Nunavut) (χ2=15.629, p=0.0004)48. Interestingly, the CPT1A p.P479L mutation is 
absent from all other worldwide populations, including East Asians (Table IV). This variant was 
initially believed to cause CPT-I deficiency, since the first discovery was made in a Canadian First 
Nation man with myopathy52, a typical subtype of CPT1A deficiency. Therefore, this variant has 
been included in the Alaska newborn screening protocol302. In addition, in Canadian Inuit and First 
Nation families with severe CPT-I deficiency, the only missense mutation found in the CPT1A 
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gene was the homozygous p.P479L variant53. It was further demonstrated that the presence of the 
p.P479L variant in both CPT1A alleles resulted in reduced CPT-I activity in cultured fibroblasts 
and affected malonyl-CoA interaction with CPT1A303. However, other studies of this variant in 
Yup'ik Eskimos and Greenland Inuit yielded different results. In these studies, the L479 allele was 
reported to be associated with infant mortality51, with impaired fasting tolerance50, reduced 
adiposity304 and with higher levels of HDL-cholesterol and apoA-I cardioprotective factors305. 
Nevertheless, it is important to note that Yup'ik Eskimos and Canadian Inuit are genetically 
different26. The reduced CPT1A activity associated with the homozygous state of p.P479L variant 
in Inuit may indicate two scenarios: A) lower activity of the p.P479L variant is beneficial for a 
state of permanent ketoadaptation in Inuit53 or B) another Inuit specific variant in the regulatory 
region may serve as a rescue factor to the enzyme activity.   
Although different disorders and traits associated with this variant were reported in 
different studies, the presence of this variant in very high frequency in Nunavik Inuit suggests that 
it is likely to be beneficial in this population. For example, it may help the arctic residents to adapt 
to the extremely cold environment and/or their ketogenic diet. This assumption is supported by the 
mean age difference found in previous studies and in the current study. Previously, it was reported 
that the p.P479L variant frequency is higher among Inuit newborns and children48; 51. However, 
the current study shows that among older populations (mean age of 52 years at enrollment) the 
L479 allele remains predominant. Furthermore, infant mortality rates are higher in Nunavik than 
in Nunavut (25 vs 14.6 per 1,000 live births) and Quebec (5 per 1,000 live births), but lower in 
Kivalliq (32.3 per 1,000 live births)306. These conflicting data suggest that further investigation is 
needed to determine whether there is an association between the p.P479L variant and infant death. 
Since the p.P479L variant is absent from Chinese and Japanese populations, it probably occurred 
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more recently, after the migration across the Bering Strait of their Asian ancestors. Genotyping the 
p.P479L variant in Siberian and Mongolian populations will be interesting to trace the origin and 
the occurrence of this variant.  
CPT1B and CPT2 haplotypes in the Nunavik Inuit population 
The mutation burden and tolerance tests did not show any excess of rare missense CPT1B variant 
in Nunavik Inuit. Nevertheless, the relative frequencies of different CPT1B locus 
rs470117/rs8142477/rs3213445 containing haplotypes found in the Nunavik Inuit are different 
from those seen in Asian populations. Interestingly, this haplotype is in the same LD block as the 
SNP rs5770917, which was reported to be associated with narcolepsy in the Japanese 
population307; 308. Given that the Inuit live in the far north with the midnight sun and the polar 
night, variants in this locus may therefore have some roles in sleep, possibly benefiting the Inuit 
while predisposing to narcolepsy in Japan.  
CPT2 missense mutations are rare in the general population, suggesting that the variations 
in the CPT2 gene seen in Nunavik Inuit may be functional, possibly related to the energy 
metabolism requirements unique to this population. The haplotype containing p.F352C and 
p.V386I variants was previously named as a thermolabile CPT-II variant309 with decreased CPT-
II activity. It was further reported as a risk factor for infection-induced acute encephalopathy and 
for continuous high-grade childhood fever, which leads to a systemic and metabolic energy crisis 
in Japanese and Chinese populations298; 309; 310. The CPT2 p.F352C variant was also reported in 
three individuals from one Inuit family with CPT-II deficiency53. However, there was no clinical 
description of acute encephalopathy in this family. Since this variant is temperature sensitive, it 
may act differently or even lead to higher enzyme activities in cold temperatures, which may 
explain their increase of the thermolabile haplotype frequency in the Inuit. Of note, encephalopathy 
 95 
 
was not reported in the Nunavik Inuit cohort, suggesting that the same genetic variation may be 
associated with different phenotypes in different populations.  
In this study, we observed an increased frequency of rare divergent variants in the carnitine 
acyltransferases family of genes in Nunavik Inuit in Quebec, as compared to other populations. 
There are few missense mutations in these genes, suggesting that they do not tolerate variation. As 
Asians are thought to have common ancestors with the Inuit1, the excess of variants in these genes 
in Nunavik Inuit also suggests an effect of selective pressure. It is possible that these variants are 
related to their high fat diet, as the carnitine acyltransferase genes are essential for fat metabolism.   
Since data on metabolic measurements was not available in our cohort, we could not 
determine whether the high frequency of variations in the carnitine acyltransferase genes in 
Nunavik Inuit affects their enzyme levels and activities. Our cohort was comprised of healthy 
Nunavik Inuit individuals and individuals with a family history of brain aneurysms; none of them 
showed any of the severe symptoms caused by CPTs or CrAT deficiencies. We hypothesize that 
these variants, while being part of the Inuit ‘healthy genomes’, could be harmful in other 
populations. Further studies in other Inuit populations, with the inclusion of measurements of these 
enzymes’ levels and activity are necessary to confirm our results and conclusions.  
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Figures 
 
Figure 9. MDS plot showing the distinctive ethnicity relationships of CEU, YRI, 
JPT-CHB and Nunavik Inuit.  
Individuals in the dashed-line box have a mixture of both Inuit and European genomes.  
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Figure 10. Scatterplot of the frequencies and deleterious scores of CPT1A, CPT1B, 
CPT1C, CPT2 and CRAT missense variants.  
Variants were extracted from 286 Asians from 1KGP, EVS populations comprising 4,294 
European descendants and 100 Nunavik Inuit. 
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Figure 11. Pairwise linkage disequilibrium (LD) diagram for CPT1B and CPT2 in 
Inuit.  
LD block was delineated using confidence intervals (Gabriel et al), and 0.6–0.98 for strong LD. 
Variants of MAF<0.05 were indicated with dashed-line. Variants were extracted from exome 
sequencing and SNP array data, with the asterisk indicated variants only genotyped by the SNP 
array. D value <1 was shown in the box, with red color indicated LOD ≥2. 
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Tables  
 
Table II.  Genomic features of carnitine acyltransferase genes. 
 Encode Genomic region of longest 
isoform (number of isoforms) 
 Number of 
exons 
HGMD** mutation numbers 
from of all isoforms 
Loss of function variant* 
from EVS*** 
CPT1A carnitine palmitoyltransferase -I 
(CPT-I )liver-type 
chr11:68522088-68609399 (2) 20 29 (missense) 
1 (splicing) 
5 (indel) 
3 
CPT1B CPT-I muscle-type chr22:51007290-51017096 (4) 21 2 (missense) 
1 (splicing) 
9 
CPT1C CPT-I brain-type chr19:50194365-50216988 (2) 20 N/A 4 
CPT2 carnitine palmitoyltransferase –II 
(CPT-II) 
chr1:53662101-53679869 (1) 5 65 (missense) 
4 (splicing) 
20 (indel) 
3 
CRAT carnitine acetyltransferase (CrAT) chr9:131857073-131873070 (1) 15 N/A 3 
CROT carnitine octanoyltransferase (CrOT) chr7:86974951-86989425 (3) 18 N/A 12 
*Including nonsense mutations, frameshift mutations, splicing donor and acceptor site mutations. 
**Human Gene Mutation Database, including all published gene mutations responsible to human inherited disease.  
***NHLBI Exome sequencing project exome variant server, including approximately 4,294 European Americans and 2,200 African Americans. 
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Table III.  Coding variants of carnitine acyltransferase genes discovered in Nunavik Inuit. 
Gene Variant Variation type Annotation  
CPT1A p.V616V synonymous  novel 
CPT1A p.P479L missense rs80356779 
CPT1A p.F417F synonymous rs2228502 
CPT1B p.E531K  missense rs470117 
CPT1B p.S427C missense rs8142477 
CPT1B p.I66V  missense rs3213445 
CPT1C p.T265M missense novel 
CPT2 p.F352C missense rs2229291 
CPT2 p.V368I missense rs1799821 
CPT2 p.R477W missense novel 
CRAT p.A603P missense rs17459086 
CRAT p.A575A  synonymous rs375414636 
CRAT p.S78F missense_splicing novel 
 
 
 
 
 
 
 
 
 
 
 101 
 
Table IV.  Variant frequencies and deleterious score predictions of carnitine acyltransferase genes. 
Gene Protein coding 
variants 
SNP MT PP2  Frequency* in 
Nunavik Inuit (100) 
Frequency in 
HCB-JPT (286)** 
Frequency in 
CEU (178)** 
Frequency in 
YRI (250)** 
CPT1A p.P479L rs80356779 0.997899 1 95.5% 0 0 0 
CPT1B p.E531K rs470117 0.606166 0.303 30.5% 48.3% 46.5% 8.8% 
CPT1B p.S427C rs8142477 0 0 67.5% 51.7% 93.3% 25.8% 
CPT1B p.I66V rs3213445 0.251908 0 17.5% 35.8% 4.9% 10.2% 
CPT1C p.T265M  0.999717 0.998 0.5% 0 0 0 
CPT2 p.F352C rs2229291 0.999596 0.999 28.0% 20.0% 0 1.3% 
CPT2 p.V368I rs1799821 0.06145 0.001 52.5% 77.5% 54.9% 25.2% 
CPT2 p.R477W  0.997459 1 3.0% 0 0 0 
CRAT p.A603P rs17459086 0.993409 0.013 9.0% 7.0% 1.7% 0.8% 
CRAT p.S78F  0.999657 0.906 2.5% 0 0 0 
*Based on the derived allele from the reference genome. 
**From 1000 genome database. 
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Table V.  Deleterious scores of all rare missense variants in carnitine acyltransferase genes found in Nunavik Inuit and 1KGP Asians. 
 PolyPhen v2 Derived allele frequency (%) 
Nunavik Inuit (100) 
CPT1A: p.P479L 1 95.5  
CPT1C: p.T265M 0.998 0.5 
CPT2: p.R477W 1 3 
CRAT: p.S78F 0.906 2.5 
1KGP Asians (286) 
CPT1A: p.I491T 0 0.35 
CPT1B: p.C659W 1 0.35 
CPT1C: p.R514Q 1 0.35 
CPT1C: p.Q97H 0.08 0.35 
CPT2: p.S122F 0.018 0.6 
CRAT: p.V411M 0.803 0.35 
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Table VI.  Mutation burden scores of identified rare mutations (MAF<0.01) of carnitine acyltransferase genes in Nunavik Inuit and 
1KGP Asians. 
 
*Binomial test, Bonferroni corrected, significant p<0.01 
**Empirical p-value of permutation test, 105 permutations 
***Variants only identified in Inuit 
 
 
 
 
 
 
 
 
 
 
 
Gene Variants Av # variants alleles/individual Inuit/Asian ration Base-pair 
sequenced 
P* P** 
 Inuit (100) Asians (286) 
CPT1A p.P479L***, p.I491T 1.91 0.007 272.80 2319 2.2e-16 0.000006 
CPT1B p.C659W 0 0.007 0.00 2316 1 0.75 
CPT1C p.T265M***, p.Q97H, 
p.R514Q 
0.01 0.014 0.71 2409 1 1 
CPT2 p.R477W***, p.S122F 0.06 0.017 3.53 1974 0.003 0.03689 
CRAT p.S78F***, p.V411M 0.05 0.007 7.14 1815 0.00076 0.01305 
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Table VII.  The FST and FIS value of 13 variants in the population containing Nunavik Inuit and HapMap Asians. 
Variant SNP FST FIS  
CPT1A: p.V616V  0.0196 -0.04 
CPT1A: p.P479L rs80356779 0.9171* -0.0452 
CPT1A: p.F417F rs2228502 0.0506 -0.1067 
CPT1B: p.E531K rs470117 0.0414 -0.0273 
CPT1B: p.S427C rs8142477 0.034 0.0382 
CPT1B: p.I66V rs3213445 0.0453 0.0114 
CPT2: p.F352C rs2229291 0.0298 -0.0925 
CPT2: p.V368I rs1799821 0.0546 0.0349 
CPT2: p.R477W  0.0146 -0.0297 
CRAT: p.A603P rs17459086 0.0045 -0.0227 
CRAT: p.A575A rs375414636 0.0097 -0.0196 
CRAT: p.S78F  0.0122 -0.0246 
CPT1C: p.T265M  0.0024 -0.0048 
Mean (all variants)  0.1833 -0.0092 
Mean (missense variants)  0.1907 -0.0053 
Mean (Inuit specific variants)  0.8401* -0.0393 
FST: The fixation index, which is the proportion of total genetic variance contained in a subpopulation relative to the total genetic variance. The value of FST ranges 
from 0 to 1, the higher value implies higher degrees of population differentiation.  
FIS: The inbreeding coefficient, which is the proportion of genetic variance in the subpopulation contained in an individual.  
*Statistical significance, 1000 randomizations 
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CHAPTER 3: UNCOVERING MISSING HERITABILITY 
OF INTRACRANIAL ANEURYSM IN THE FRENCH-
CANADIAN FOUNDER POPULATION 
 
3.1: PREFACE 
IA is a common form of the cerebrovascular disorder and a number of populations are known to 
present at higher risks to develop this condition89; 211. In this chapter, we furthered our efforts to 
identify IA susceptible genes. Here we focused on the French-Canadians, an important founder 
population of Quebec. Similar to what has been observed for Nunavik Inuit, French-Canadians 
also present an increased prevalence of IA, especially for the familial form.  
Because of the heterogeneity and complexity of IA, only two studies218; 219 have thus far 
used a WES approach; however, their results failed to explain most IA cases. In Chapter 3.2, we 
describe a study that successfully used WES to identify an IA genetic risk factor, RNF213; the 
study relied not only on WES but also on targeted resequencing and a protein assay. Variants of 
RNF213 were previously established to cause another cerebrovascular condition known as 
moyamoya disease (MMD). In this study, the French-Canadian IA patients from large families 
were chosen as the discovery cohort, and RNF213 was identified to bear significant increased 
genetic variation burden among all genes from WES. Targeted resequencing of RNF213 was 
subsequently performed in a larger cohort of IA cases (70% of which were familial) and additional 
rare missense mutations were identified, in turn representing a higher genetic burden compared to 
controls. ATPase assays were performed to measure two of the IA variants located in the functional 
domain of the protein expressing ATPase activity. The measurements revealed these two IA 
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variants to produce a gain of ATPase activity; and interestingly this was the opposite of what the 
MMD variants produce. Distinct RNF213 variants can therefore affect cerebrovascular 
development in a manner that will lead to distinct cerebrovascular disorders.  
On the other hand, genome-wide association studies (GWAS) are still considered to 
represent the most powerful approach for the identification of IA risk genes. In Chapter 3.3, we 
present a GWAS study focusing on familial IA patients of French-Canadian origin. Unlike 
previous large GWASs, we focused on the French-Canadian founder population to increase the 
detection power. With our cohort aggregated with familial cases, it is likely to discover new 
candidate loci harboring risk genes for IA that could further explain the missing heritability of this 
cerebrovascular disorder. In this study, 257 French-Canadian IA patients and 1,992 controls were 
genotyped using custom designed Illumnia NeuroX SNP-chip of approximately 710,000 variants 
backbone and 24,000 variants focusing on neurological diseases. After imputation, we discovered 
a locus with genome-wide significance at 3p14.2. The SNP within this top association was located 
in an intronic region of FHIT (rs1554600, p=4.66×10-9), previously suggested to be associated 
with the risk of hypertension in Quebec, Canada. Another interesting gene CCDC80 (rs78125721, 
p= 4.77×10-7) was located in another promising locus of 3q13.2; WES of 32 French-Canadian IA 
cases and 106 control individuals revealed a significantly increased exonic variant burden in 
CCDC80 across IA cases. The product of CCDC80 is noticeably expressed in vascular smooth 
muscle cells and is involved in cell adhesion during differentiation of fibroblast. Both genes may 
contribute additionally to the vascular development and risk for IA in French-Canadians. 
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3.2: RNF213 IS ASSOCIATED WITH INTRACRANIAL 
ANEURYSMS IN THE FRENCH-CANADIAN POPULATION 
 
Manuscript: RNF213 is associated with Intracranial Aneurysms in the French-Canadian 
population 
American Journal of Human Genetics, 2016 Nov 3; 99(5):1072-1085. doi: 
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ABSTRACT 
Intracranial aneurysms (IAs) are the result of focal weakness in the artery wall and have a complex 
genetic makeup. To date, genome-wide association and sequencing studies have had limited 
success in identifying IA risk factors. Distinct populations, such as the French-Canadian (FC) 
population, have increased IA prevalence. In our study, we used exome sequencing to prioritize 
risk variants in a discovery cohort of six FC families affected by IA, and the analysis revealed an 
increased variation burden for ring finger protein 213 (RNF213). We re-sequenced RNF213 in a 
larger FC validation cohort, and association tests on further identified variants supported our 
findings (SKAT-O, p=0.006). RNF213 belongs to the AAA+ protein family, and two variants 
(p.Arg2438Cys and p.Ala2826Thr) unique to affected FC individuals were found to have increased 
ATPase activity, which could lead to increased risk of IA by elevating angiogenic activities. 
Common SNPs in RNF213 were also extracted from the NeuroX SNP-chip genotype data, 
comprising of 257 FC IA-affected and 1,988 control individuals. We discovered that the non-
ancestral allele of rs6565666 was significantly associated with the affected individuals (p=0.03), 
and it appeared as though the frequency of the risk allele had changed through genetic drift. 
Although RNF213 is a risk factor for moyamoya disease in East-Asians, we demonstrated that it 
might also be a risk for IA in the FC population. It therefore appears that the function of RNF213 
can be differently altered to predispose distinct populations to dissimilar neurovascular conditions, 
highlighting the importance of a population’s background in genetic studies of heterogeneous 
disease.  
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INTRODUCTION 
Intracranial Aneurysms (IA) (MIM105800) are vascular abnormalities characterized by dilations 
or ballooning of intracranial arteries. The pathology of IA is not clear, however the lesions are 
usually characterized by very thin (or absent) tunica media and internal elastic lamina within the 
arterial walls at the IA sites311. The worldwide prevalence of IA is 1-3%102; 312. Moreover this 
condition entails severe consequences, particularly when subarachnoid hemorrhages (SAH) occur 
(incidence rate 0.5-1%98) as 30-45% of SAH are fatal within 30-days313. The annual incidence of 
SAH is 4-9 per 100,000 worldwide and 80% of all spontaneous SAH are caused by the rupture of 
aneurysm314. The formation and rupture of IA are related to complex risk factors, including 
smoking and alcohol consumption, hypertention315 and other vascular diseases316, a very small 
percentage of them were related with infections317 and trauma318. Many studies provided evidence 
suggesting a large fractions of IA and SAH cases involve underlying genetic risk factors. First-
degree relatives of individuals with aneurysmal SAH have a 4 to 7 fold increased risk of being 
affected by comparison to the general population319. There have been several genome wide 
association (GWA) studies examining sporadic IA and these identified several candidate loci (e.g. 
2q33.1, 8q11.23, 9p23.1207; 214; 18q11.2, 13q13.1, 10q24.32320; 7p21.1215; regions near rs1930095, 
rs7781293, rs7550260, rs9864101208; and 4q31.22211). Unfortunately, follow-up replication 
studies suggests those loci are unlikely to explain a large fraction of IA cases. It has been reported 
that the French-Canadian (FC) population has a higher IA and SAH incidence rates and affected 
individuals usually aggregated in families, especially large pedigrees321. In a study conducted in 
the Saguenay-Lac-Saint-Jean region of Quebec, Canada, it was observed that 30% of IA affected 
individuals had a family history322. It is believed that IA is genetically heterogeneous and therefore 
population specific variants might play a big part of the pathogenesis, especially in familial 
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aggregates. In order to explore those hypotheses, we conducted whole exome sequencing (WES) 
and target sequencing experiment in a group of familial IA subjects of FC descent. We focused 
our attention to the identification of rare, or FC specific, variations as genetic factors that might 
explain the high prevalence and familial aggregation of IA in this population. 
 
MATERIALS AND METHODS 
Discovery cohort 
The discovery cohort of this study included 26 French-Canadians (from 6 families) who had 
received a positive IA diagnosis (Figure 12); diagnostics were confirmed either by magnetic 
resonance angiography (MRA) (1.5T), or by surgical confirmation (clipped or coiled). Subjects 
were excluded if they had received a personal diagnosis, or had a history of polycystic kidney 
disease (MIM173900), Ehlers-Danlos syndrome type IV (MIM130050), neurofibromatosis type 1 
(MIM162200), Marfan syndrome (MIM154700) or other intracranial vascular malformations 
including moyamoya disease (MIM607151). 
Written consent was obtained for all the participants and the study was approved by Comité 
d'éthique de la recherche du Centre hospitalier de l'Université de Montréal (ND 04.101, Québec, 
Canada). 
Population control cohort 
Exome population controls for this study were selected from our in-house exome database, which 
includes 189 healthy FC individuals. Additionally, the SNP-chip genotype data for 1,988 unrelated 
FC control individuals with no obvious cerebrovascular disease were also included for this study. 
Whole exome sequencing (WES) and variants prioritization 
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Genomic DNA for each individual was extracted from peripheral blood lymphocytes using Gentra 
Systems PUREGENE DNA purification kit (Qiagen). A 50 µl DNA sample at a concentration of 
100 ng/µl from each sample was captured by Agilent SureSelect V4 capture kit. The library was 
subsequently sequenced at 100 bp pair-end using Illumina Hiseq 2000, with 3 samples per lane to 
ensure an average coverage depth of 100-fold. All high-throughput and Sanger sequencings were 
performed at the McGill University and Génome Québec Innovation Centre. 
Raw fastq files were aligned to NCBI human reference GRCh37 using Burrows-Wheeler 
Aligner (BWA)323, with all PCR duplicates removed from the alignments. The aligned reads were 
converted to binary format for further analysis using Sequence Alignment/Map (SAM)288 tools. 
Single nucleotide variant (SNV) and insertion/deletion (indel) calling done by UnifiedGenotyper 
from Genome Analysis Toolkit (GATK)267 version 2.7. Variant annotation was performed using 
ANNOVAR289 program with references to GRCh37/hg19, dbSNP version 132, 1000 Genomes 
project (1KGP) (2012 data release)290, 69 Complete Genomics (2012 update) and exome variant 
server (EVS) with approximately 6,500 exomes (NHLBI-ESP project, 2013 update). Finally, 
variant segregation analysis was performed using an in-house segregation program, using more 
than 1,000 exomes of different ethnicities from our lab as controls.  
The sequencing quality were determined by GATK's DepthOfCoverage Walker. QC step 
excluded variants with sequencing depth <10 or with genotype quality <90, and of those presented 
in a selected of frequently mutated genes, pseudo-genes and genes in repetitive regions. After QC, 
preliminary analysis focused on variants that potentially affect protein function (missense, 
splicing, small indels). Variants from all aforementioned databases were removed, to focus on 
French-Canadian specific variants. Polyphen-2296 and GERP++324 were used to predict the 
deleterious level of the functional variants.  
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Subsequently, French-Canadian specific, potential deleterious variants shared by two or 
more affected individuals from each family were prioritized for further analysis, and genes 
harboring two or more of those variants are further selected of interest.  
Variants from 106 French-Canadian exome controls from those genes of interest were 
selected by the same criteria, and gene-based burden test was performed to those genes using 
variable thresholds method325 implemented in Variant Association Tools (VAT)326.  
Validation cohort and target resequencing 
After the prioritization of variants and the selection of the most promising candidate gene, the 
whole coding region of two isoforms of the RNF213 gene (MIM613768) (NM_020954 and 
NM_001256071) were sequenced in a validation cohort of 223 affected individuals and 88 IA 
negative controls. 74 of the subjects were sporadic and rest were with family history. The mean 
age of onset for familial IA were 53.5±12 years compared to sporadic IA which were 55.4±9 years. 
Out of the individuals with detailed clinical information, 37.4% of subjects with family history 
were indicated to have multiple aneurysms, compared to 29% in sporadic cases. On the other hand, 
40.8% of the familial IA subjects were indicated to have hypertension, while among sporadic 
subjects 47.7% were shown with high blood pressure. Other environmental factors also seemed to 
play a larger part in sporadic cases, such as drinking (22.4% familial vs 40% sporadic) and smoking 
(60.5% familial vs 76.9% sporadic) (Table S1).  The targeted resequencing was done using 
Fluidigm Access ArrayTM System. 122 pairs of primers were designed to cover a total of 58 exons 
of RNF213, with each fragment under 300 bp in length (Table S2). 50ng of DNA for each sample 
were used for performing multiplex PCR and products were sequenced paired-end on Illumina 
MiSeq platform. 
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Bioinformatic analysis of the Fluidigm sequencing data was done to first remove bad QC 
reads and adaptor sequences. Subsequently the reads were aligned against GRCh37 using the 
Burrows-Wheeler Aligner (BWA) v0.7.5327 and alignments of each sample were combined. 
UnifiedGenotyper267 implemented in the Genome Analysis Toolkit (GATK) were used to perform 
variant calling in the coding intervals of RNF213. The annotation and segregation steps were made 
in a manner that was similar to what was done for WES. All variants were validated by IGV328 and 
rare (MAF ≤ 0.01) missense variants were further validated by Sanger sequencing. 
Genotyping RNF213 common SNPs  
SNP genotyping data from NeuroX SNP-chip (Illumina Human OmniExpress bead chip as 
backbone) was obtained for 257 IA subjects and 1,988 controls, which contains 719,885 SNPs. 
Principle component analysis (PCA) was performed using smartPCA software (implemented in 
eigensoft)329 to confirm the FC ethnicity of the samples used, and SNPs within the RNF213 gene 
region was extracted from the genome wide data. Additionally, RNF213 common SNPs from 33 
different populations were also obtained from in-house database, Gene Expression Omnibus 
(GEO) database16; 39; 330; 331 and 1000 genome (1KGP) phase 3 data290 (Table S3).  
Statistical and population analysis 
In order to further select the genes that are most likely to be a risk candidate for IA, gene-based 
burden test was performed for genes prioritized in initial cohort using variable thresholds (VT) 
method325 implemented in Variant Association Tools (VAT)326. 
Sequence Kernel Association Test (SKAT)332 was performed to evaluate the effect of 
RNF213 variants with weighted scores; this unified statistical test allows both rare and common 
variants to contribute to the overall statistic by calculating the logistic weights for each variant and 
apply them to the analysis using the following formula: 
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𝑤𝑒𝑖𝑔ℎ𝑡𝑠 =
𝑒(𝑝𝑎𝑟1−𝑀𝐴𝐹)𝑝𝑎𝑟2
1 + 𝑒(𝑝𝑎𝑟1−𝑀𝐴𝐹)𝑝𝑎𝑟2
 
SKAT optimal test (SKAT-O) was then performed to evaluate the statistical significance 
of RNF213 functional variants between affected individuals and controls. 
A Cochran-Armitage trend test was performed using Plink 1.9273  to compare the allele 
distributions of all RNF213 common SNPs in IA cases and controls; an adjustment was made for 
multiple testing.  Pairwise FST were calculated using Arlequin 3.5
333 between different populations 
to measure the population differentiation according to two different sets of their RNF213 
variations: (1) RNF213 common SNPs from FC IA subjects, controls and 33 other populations; 
(2) RNF213 functional variants from FC IA subjects, controls and 25 populations from 1KGP 
phase III data. Variation burden of RNF213 between FC and 1KGP phase III populations were 
also calculated by Variable Thresholds (VT) method325 using Variant Association Tools (VAT)326. 
Expression vector design 
The RNF213 full-length cDNA cloned into pcDNA3.1+ was obtained from a previous study334. 
Two AAA+ module fragments (aa 2,370–2,632 and 2,717–3,004, respectively) were individually 
amplified using Gibson assembly adapted primers, with 1st AAA primer GGT TCC GCG TGG 
ATC CCC GGA ATT Cgt gcc ctt caa tgt cga ctt tga taa ac and GTC AGT CAC GAT GCG GCC 
GCT CGA Ggc gag tcc cgt ttt cat cta gg; and 2nd AAA+ primer GGT TCC GCG TGG ATC CCC 
GGA ATT Cag cag gct gct tct gga tg and GTC AGT CAC GAT GCG GCC GCT CGA Gtc tat ttg 
aag cct ttg ctg cag caa aga cc. The two AAA+ amplified fragments were assembled and cloned 
into EcoRI and XhoI sites of the pGEX-4T1 vector (GE Healthcare) using the Gibson assembly 
method335. All clones were sequence validated. 
Mutagenesis 
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PCR site-directed mutagenesis was performed to introduce two variants p.Arg2438Cys and 
p.Ala2826Thr in the 1st AAA+ and 2nd AAA+ plasmids, respectively. Four additional mutations 
(p. Lys2426Ala, p. Glu2488Ala, p. Lys2775Ala and p. Glu2845Ala) described previously336 which 
known to cause loss of function (LOF) of the AAA+ ATPase were also introduced as controls.  
Protein purification 
Both the wildtypes, variants and LOF controls of the two AAA+ fragments and empty pGEX-4T1 
plasmid were transformed into BL21-CodonPlus cells, the protein was inducted at 16°C for 
overnight and N-terminal glutathione S-transferase (GST)-tagged protein was extracted using 
Glutathione Sepharose 4B beads (GE Healthcare), in PBS buffer contain PMSF protease inhibitor. 
PBS was carefully removed after the protein extraction, GST protein was eluded using buffer 
contains 50 mM Tris-HCl and 10 mM reduced glutathione. Bradford protein assay was used for 
protein quantification. 
ATPase assay 
ATPase assay was performed using BIOMOL Green (Enzo life sciences) for the detection of free 
phosphate. The GST-tagged wildtypes, variants and LOF controls were incubated in a 50 l buffer 
containing 300 mM KCl, 10 mM MgCl2, 50mM HEPES-KOH at PH 7.5 and 5 mM ATP at 37°C 
for 20-40 min. The reaction was terminated by adding 100ul BIOMOL Green reagent, and 
incubated in room temperature for 10 min. OD630nm was measured for the wildtypes, the variants, 
and the LOF controls and standard curve was made using phosphate standard based on the 
manufacturer’s protocol. ATPase activity (Vmax) was measured by PO4 quantity (nmol) per mg 
of protein per minute of reaction. 
 
RESULTS 
 117 
 
Variant Segregation analysis and RNF213 recurrent mutations 
The average base depth of coverage of the 26 IA samples from the discovery cohort was 101-fold 
and 89.5% of the total target region was covered at 20-fold (Table S4). After QC and variant 
prioritization, 79, 109, 103, 15, 99 and 67 FC specific deleterious variants segregated across more 
than two affected individuals of each of the six families (Table VIII, row G). 35 out of these 
variants defined 19 genes which presented variants in more than one family, with 11 out of these 
19 genes contain 25 distinct variants (Table IX). Interestingly, one of the 11 genes, RNF213, 
revealed 5 distinct variants in 4 families (Table IX, Figure 12). These RNF213 
(NM_001256071.2) variants were a nonsense mutation c.11413del; p.Glu3806Argfs*27, an 
exonic splicing mutation c.2017C>T; p.Arg673Trp and 3 missense mutations c.13577T>C; 
p.Ile4526Thr; c.6980A>G; p.Asn2327Ser) and c.3134C>T (NM_020954.3); p.Ser1045Leu 
(NP_066005.2). Only the c.6980A>G and c.3134C>T variants were observed once each in 189 
FC descent control individuals. Variation burden of the 11 genes were displayed in Table X. After 
Bonferroni correction for multiple testing, only RNF213 still differ significantly between subjects 
and controls (p=0.013). 
Target re-sequencing validation 
After Fluidigm capture and sequencing, the average coverage for the RNF213 targeted region of 
each individual was calculated to range between 6,828 and 227,160-fold. Only 4% of individuals 
had ≤ 70% of the total target region covered at less than 100-fold. 
272 exonic variants were first observed across the validation cohort of 311 samples (223 
cases and 88 controls) and after IGV examination, 142 variants were used for the study (the 
remaining variants were deemed to be false positives because they were either located in adaptors 
or PCR duplicates). Non-coding and synonymous variants were further removed from the 142 
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variants and 60 variants were left for the final analysis. Additionally, 44 functional RNF213 
variants were also found in 189 French-Canadian population controls. 
SKAT analysis and RNF213 rare variants in FC 
In total, 72 functional (missense, indel, splicing) RNF213 variants were observed in FC cases and 
controls, which including 233 IA subjects (10 selected from nuclear families of the discovery 
cohort and 223 affected individuals from the validation cohort) and 277 controls (88 from 
validation cohort and 189 from exome population controls) (Table S5). Hardy–Weinberg 
equilibrium (HWE) and missingness test was performed using Plink 1.9, no variant was removed. 
The comparison of RNF213 functional variants using a SKAT-O test with logistic weights 
showed significant different allelic distributions between 233 FC cases and 277 controls 
(P=0.008); the difference was even more significant when only rare functional variants (p=0.006) 
were compared. When the comparison of FC cases was examined using only 88 IA negative 
controls, the difference remained significant (p=0.018); if sex was added as covariate a slight 
increase of difference emerged (p=0.013). 
It is also noteworthy that among the 34 rare functional variants of RNF213 that were 
observed in 233 IA cases, 18 were absent from all controls (Table S5). 13 of which were predicted 
to be probably deleterious (Polyphen2 score > 0.8 or GERP++>2) (Table XI). On the other hand, 
30 rare functional variants were observed in 277 controls, 14 were absent from affected 
individuals, from which only 4 were predicted deleterious (Table S5 and Table XI). Hence there 
is a significant difference between the number of deleterious variants observed in only cases and 
controls (p=0.00006, binomial test). Twenty-five FC IA cases from 249 discovery and validation 
cohorts carry 14 rare deleterious RNF213 variants (13 plus p.Glu3806Argfs*27) that absent in FC 
controls, from which nine individuals had multiple IAs, eight had SAH, eight with hypertensions 
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and three cases with hypercholesterolemia from which two also had myocardial infarctions. Only 
6 individuals had no other recoded clinical histories besides smoking. 
RNF213 common variants in population-based study 
Among 257 IA subjects and 1,988 controls with SNP-chip genotyping data, PCA analysis showed 
that 3 IA cases and 92 controls presented an admixture of East-Asian and African ancestry and 
these samples were excluded from subsequent analysis (Figure S1). We performed gene-wide 
association test on 38 polymorphic SNPs across the RNF213 loci in 254 cases and 1,896 control 
individuals, and the SNP rs6565666 appears to significantly associated with IA cases (p=0.03, 
After Bonferroni Correction, Cochran-Armitage trend test) (Table S6). 
The pairwise FST comparisons of 1KGP phase III populations with FC suggest the common 
SNPs of RNF213 vary between populations. FC individuals have a higher number of distinct 
variations compared with South-Americans, followed by Africans and East-Asians. However, 
East-Asians are sharing less RNF213 functional variations with the FC population than they are 
with the African and Caribbean populations (Figure 13). Overall 8 SNPs of RNF213 appear to be 
outliers in the frequency changes across the worldwide populations and 4 of these SNPs were 
located in the C-terminal domain region, it also appeared that more functional variants of RNF213 
were possibly being affected by genetic drift (Figure S2). 
A burden test comparing the FC population to other populations showed a similar trend as 
East-Asians appear to have the most significant difference of derived RNF213 allele frequencies 
when compared with overall FC, followed by Peruvians, Indians, and Finnish. As expected, FC 
IA cases also have significantly increased burden of RNF213 than control individuals (Table XII). 
Functional characterization of selected RNF213 variants 
 120 
 
Among the 14 RNF213 variants predicted to be deleterious and specific to IA cases only two 
variants, p.Arg2438Cys (c.7312C>T) and p.Ala2826Thr (c.8476G>A), were located in the two 
distinct AAA+ modules of the protein. These two variants were therefore the most suitable for a 
functional test measuring the ATPase activity of RNF213. As previously reported336 this activity 
can be detected using a recombinant fragment containing amino acids from 2,370–2,632 and 
2,717–3,004. 
The baseline of ATP hydrolysis was determined by the GST protein. As a result, the 
average ATPase activity of the 1st AAA+ protein wildtype (A1WT) and the p.Arg2438Cys variant 
(A1M) were estimated to be 72.0 nmol/mg/min and 142.1 nmol/mg/min, respectively; while the 
LOF variant in walker A domain (A1WA) was estimated to be 12.2 nmol/mg/min, with the walker 
B LOF variant (A1WB) 23.1 nmol/mg/min. The average ATPase activity of the 2nd AAA+ protein 
wildtype (A2WT) and the p.Ala2826Thr variant (A2M) were estimated at 127.1 nmol/mg/min and 
242.6 nmol/mg/min, respectively; while the LOF variants of walker A and B domains (A2WA and 
A2WB) were as low as 8.8 nmol/mg/min and 15.5 nmol/mg/min, respectively. There were 
significantly increases of ATPase activities for both variants compared to their respective wildtype 
proteins (Mann-Whitney-Wilcoxon Test, pA1M-A1WT=0.015, pA2M-A2WT=0.0003); the differences 
were also significant compared with the LOF variants (Mann-Whitney-Wilcoxon Test, pA1M-
A1WA=0.002, pA1M-A1WB=0.002; pA2M-A2WA=0.0007; pA2M-A2WB=0.0009) (Figure 14). 
 
DISCUSSION 
A major weakness of using a GWAS approach in IA is that the effect of rare variants and 
population specific variants are not well addressed. Recently two studies using exome sequencing 
on multiple IA families attempted to address the issue. Though no recurrent mutations were found, 
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using different hypotheses and in different populations they respectively reported 68219 and 78 
genes218. Only one gene ITGB6 (MIM147558) was found to be common across the two lists 
established by these two studies; nonetheless both studies did not deem this to be an interesting IA 
candidate gene. We believe genetic heterogeneity is likely at play in the development of IA in 
distinct populations. Therefore, we conducted this research exclusively in FC individuals and 
focused on finding genes that harbor founder mutations/haplotypes in FC as candidates for 
predisposition to IA. Although in the current study, exome sequencing results of the first six FC 
families strongly suggested RNF213 deleterious rare variants predispose to IA in FC individuals, 
there are also some other interesting variants that worth noting - such as ABCA10 (MIM612508) 
that is expressed predominately in intracranial vascular endothelia cells337. 
The functional characterization of RNF213 gene and variants 
Mysterin/RNF213 (ring finger protein 213) has been identified as an important candidate for 
moyamoya disease (MMD) in the Japanese population334; 338. MMD is a rare cerebrovascular 
disorder that is characterized by stenosis of the internal carotid arteries and abnormal angiogenesis. 
It is a population specific condition with an extremely low prevalence in Western populations. A 
founder mutation, c.14429G>A (rs112735431; p.Arg4810Lys, previously annotated as 
XM_005257545.3: c.14576G>A; XP_005257602.2: p.Arg4859Lys338) was found significantly 
and specifically associated with the disease in the East Asian population334. However, in a study 
looking at French MMD subjects there was no evidence linking RNF213 to MMD339, another 
recent study further reported ZXDC and OBSCN with higher variation burden in affected 
individuals of European descent, suggesting the complexities in the MMD genetic etiology340.  
RNF213 encodes an AAA type ATPase with E3 ubiquitin ligase activity and studies 
suggest a role in vascular wall construction334. A functional study focused on RNF213 
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p.Arg4810Lys suggested that the founder mutation is a MMD risk factor through reduced 
angiogenic activity341; 342 and induced mitotic abnormalities343. When exploring the functions of 
RNF213, studies have found the gene to be linked with a variety of artery wall developments. 
Several studies were conducted on Rnf213 KO mice, showing thinning of the intima and media 
layer after CCA ligation344, thinning in vascular walls and increased Mmp9 expression345 or 
enhanced post-ischemic angiogenesis346; a recent report also showed that RNF213 was associated 
with inflammatory responses and angiogenesis342; 347; all these results suggest that RNF213 is 
involved in vascular remodeling processes. A recent study even showed that RNF213 is associated 
with aneurysm formation post anastomotic surgery348. 
In addition to MMD, RNF213 has also been associated with other vascular disorders349 
such as fibromuscular dysplasia (MIM135580)350, high blood pressure351, intracranial major artery 
stenosis352; 353, and heterogeneous intracerebral vasculopathy354. The p.Arg4810Lys RNF213 
mutation is suggested to be a risk factor for MMD by causing stenosis353; 355, other mutations, 
however, may have different effects on the artery. Some studies suggested other RNF213 
mutations were associated with different types of MMD, i.e., a rare variant p.Ala4399Thr with 
intermediate frequency in East Asians was associated with hemorrhage type of MMD356 affected 
individuals356, in contrast to that p.Arg4810Lys which was associated with the ischemia type.  
Rare variants in RNF213 were found in MMD cases who were not have the p.Arg4810Lys 
mutation and who were of Japanese 357, Taiwanese358 and non-Asians349 ethnicities. Of the 30 rare 
functional variants found in 649 MMD case-controls in Japan, 16 of these were only observed in 
affected individuals; additionally, 3 novel variants were found in 31 Taiwanese MMD subjects 
and 7 rare variants were found in 24 individuals with diverse ethnicity, respectively. Compared to 
the Japanese case-control study357, our result has a significantly larger proportion of RNF213 
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mutations in affected individuals compared to controls (Cochran-Mantel-Haenszel Test, 
p<0.0001) (Figure 15). 
AAA+ ATP domain variants and the risk of IA 
One of the very important functions of RNF213 is likely mediated by the two AAA+ regions 
located in exon 29, which exhibit ATPase activity336. In our study focused in IA, several 
deleterious mutations in the AAA+ domains were found, whereas other studies focused on MMD 
affected individuals did not (Figure 16)349; 359. We may assume that variants in different locations 
of the RNF213 gene are risk factors for different cerebrovascular disorders by affecting the gene 
function differently. Cecchi et al.349 suggested the C-terminal domain of RNF213 to be the main 
risk region for MMD, we believed that exon 29 which contains AAA+ domains may be the risk 
region for IA. 
In our study, we found that a gain of ATPase activity may lead to increased risk of IA. A 
recent study suggested that the p.Glu2488Gln variant in the 1st AAA+ domain and the 
p.Arg4810Lys variant reduced protein ATPase activity in the MMD model342, inhibiting 
angiogenesis, opposite to our observation. The discordance may lay with the pathological 
differences between MMD and IA, although both have disrupted vascular walls, the main 
characteristic of MMD is progressive stenosis accompanied by aberrant angiogenesis of collateral 
vasculature 360, while  IA lesions are characterized by vascular wall weakness and dilatation, 
accompanied by vascular remodeling and inflammatory response. Actually, the increased 
angiogenic activity may be a characteristic of the formation of aneurysm lesion361, and there were 
studies suggesting high expression of angiogenic factors in IA tissues362; 363. Another paper also 
stated that the ATP concentration is lower in the aneurysm walls than in normal artery tissue364. 
We hypothesize that increased ATPase activity of RNF213 may lead to increased or unbalanced 
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level of angiogenesis, therefore associate with the formation of aneurysmal lesion. Although the 
Rnf213 KO models inflict different angiogenesis alternations under different circumstances342; 346, 
we imply that RNF213 is critical in vascular wall remodeling which can explain the pathogeneses 
of both MMD and IA.  Additionally, the increased ATP hydrolysis may also affect the oxidative 
phosphorylation process365, which plays an important role in cases including hypertension366 and 
heart failure. Both IA individuals carrying AAA+ domain mutations shown signs of hypertension, 
one of them were recorded to also suffer multiple cardiovascular problems, including 
hypercholesterolemia, myocardial infarction and arrhythmia. 
RNF213 variants in general populations  
We found that an RNF213 SNP rs6565666 was associated with IA in FCs. Interestingly, when 
compared to other populations, we found a gradual decrease in the non-ancestral allele (A) 
frequency, which matches the out-of-Africa migration pattern (Figure S3), and may be the result 
of genetic drift, as this non-ancestral allele also might be a risk allele of IA (dominant model for 
allele A, P=0.007, corrected). The Finnish have a relatively high frequency of allele A 
(MAF.FIN=0.26) compared to other European populations (MAF.CEU=0.18); which correlate 
with their high incidence of IA89; 213. 
When further exploring the RNF213 variant distributions across populations, we noted that 
groups of Native American population (Inuit, Argentinian and Peruvian) diverged the most from 
other populations, which fit the migration patterns. However, if focused on potential functional 
variants of RNF213, East-Asians (Chinese, Japanese and Vietnamese) seem to have the highest 
diversity (Figure 13) beside Native American peoples. The results seem in accord with the fact 
that RNF213 East-Asian specific variants are risk factors for MMD, which is also an East-Asian 
high prevalence disease. The significant difference in RNF213 burden between FC and East Asians 
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further suggested the variations in this gene lead to different risk among those two populations. 
The potential genetic drift of RNF213 variations may explain the difference between MMD 
prevalence and RNF213 founder variants in only East Asians but not in other populations. The 
exploration of population difference of RNF213 variants also provided additional evidence that 
the risk gene of IA may be ethnically different89. Additionally, as there have been studies 
suggesting Inuit have a high prevalence of IA, it would be interesting to see if other Native 
Americans also have this predisposition. Nevertheless, we can also assume that RNF213 may not 
be a risk factor for IA among those populations based on our observations. 
We could not determine any founder mutation that presented in high frequency in FCs that 
was significantly associated with IA due to the limiting number of our subjects. The population 
control used in this study were mostly unscreened for IA, which may also lead to an underlying 
bias to our results. Only 10% of the affected individuals carry rare, deleterious variants in RNF213, 
suggesting the gene is only a risk factor to some of the cases and that the pathogenesis of IA is 
very complex and heterogeneous. Additionally, since RNF213 mutations have not been reported 
in IA cases of other ethnicities, and that the risk genes of MMD also differs population-wide, 
suggesting RNF213 variations may associate with different vascular disorders in different 
populations. We further assume that different genes are likely to contribute to IA in other 
populations. 
In conclusion, our study supports a role for RNF213 as a risk factor for IA, possibly via 
variants affecting different portions of the protein and lead to increased ATPase activity.  
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Figures 
 
Figure 12. Six IA pedigrees with 26 affected individuals from the initial cohort 
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Figure 13. Matrix of pairwise FST of RNF213 between world-wide populations 
FST was calculated by RNF213 common variants (A) from Omni chip and functional variants (B) from exome sequencing between each 
two populations. FC_CTRL and FC_IA are French-Canadian control cohort and IA cohort, other populations indicated by three letter 
codes are in accord with 1KGP. The allele distributions of RNF213 common SNPs varies among populations, suggesting the existence 
of genetic drift. Among others, there is a big difference in the allelic distributions of RNF213 functional variants between Asians and 
FC populations. 
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Figure 14. ATPase activity of the wildtypes, variants and LOF controls of the two AAA+ domains of RNF213 
Box-and-whisker plot showing ATPase activity measured as nmol of free-phosphate release per mg protein per minute. 
A1WTand A2WT are the wild-types of the first and second AAA+ modules, respectively; A1M and A2M are the p.Arg2438Cys and 
p.Ala2826Thr variants, respectively. A1WA, A1WB, A2WA, and A2WB are four LOF controls (p. Lys2426Ala, p. Glu2488Ala, 
p.Lys2775Ala, and p. Glu2845Ala, respectively) located in the walker A and B domains of the first and second AAA+ modules. The 
results were generated by eight ATPase assays from two independent cell cultures; each sample is measured in duplicate. Boxes show 
the interquartile range, and whiskers show maximum and minimum measurements. 
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Figure 15. Meta-analysis of two RNF213 studies in different populations 
Forest plot of Moteki, Y et al. 357 and the current study. Result shown significantly more RNF213 mutations in FC IA affected 
individuals (Cochran-Mantel-Haenszel Test, p<0.0001). 
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Figure 16. RNF213 missense patient-only variants in IA and MMD 
Figure reconstructed based on Cecchi et al. (2014)349 and Koizumi at al. (2016)359. 14 variants found in the current study are marked in 
red, variants reported in Moteki et al study are marked in blue, other MMD variants reported in Cecchi et al study are marked in black 
and the greys are the MMD variants found in other studies. The result showed FC IA affected individuals harbor more deleterious 
mutations in the AAA+ domains compared to other populations.
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Tables 
 
Table VIII.  Exome variant filtration steps and results of initial cohort 
Coding and splicing variants after QC Family 
60 
Family 
89 
Family 
10 
Family 
09 
Family 
28 
Family 
94 
A:Variants in 1+ family affected  33,061 38,609 37,706 31,975 33,090 32,727 
B:functional variants 18,455 21,857 21,255 17,602 18,417 18,118 
C:French-Canadian specific variants 1,489 2,041 1,797 825 1,089 882 
D:exclude most variable exonic genes 999 1,388 1,157 595 670 627 
E:inhouse database <5 403 581 509 309 360 294 
F:Variants in 2+ family affected 178 258 226 50 236 201 
G:deleterious(PP2>0.8 or GERP>2, and 
frameshift) 
79 109 103 15 99 67 
Number of genes 78 108 102 15 90 64 
Gene with cross-family recurrent 
variants (variants) 
6 (6) 7 (7) 6 (6) 2 (2) 8 (9) 11 (13) 
Genes with cross-family recurrent 
variants (variants) 
19 (35) 
Gene with different variants 11  
Gene with 2+ different variants 1 (RNF213)a 
a. p=0.01, VT test, bonferroni correction, 5000 permutations. 
 
  Table IX.  Prioritized genes with French-Canadian specific deleterious variants  
Gene Chr Position Annotation Family 
ID 
PP2 GERP++ 
ABCA10 
  
17 67215903 NM_080282:c.313A>G;NP_525021:p.Asn105Asp 60 0.995 1.83 
17 67221498 NM_080282:c.2T>C; NP_525021:p.Met1Thr 94 0.998 3.6 
AIM1 
  
6 107008779 NM_001624:c.4733G>T; 
NP_001615:p.Gly1578Val 
89 1 3.4 
6 106968391 NM_001624:c.2084C>A; 
NP_001615:p.Ser695Tyr 
94 0.966 5.62 
CDAN1 
  
15 43028521 NM_138477:c.548C>T; 
NP_612486:p.Ser183Leu 
89 0.127 3.91 
15 43023250 NM_138477:c.1880C>T; 28 0.007 5.49 
 133 
 
NP_612486:p.Ala627Val 
GPATCH8 
  
17 42477055 NM_001002909:c.2390G>A; 
NP_001002909:p.Arg797Gln 
28 0.658 2.67 
17 42475271 NM_001002909:c.4174G>A; 
NP_001002909:p.Gly1392Ser 
10 0.98 4.57 
HELZ2 
  
20 62196325 NM_033405:c.2143C>T; 
NP_208384:p.Arg715Trp 
28 0.858 4.11 
20 62195122 NM_033405:c.3346C>T; 
NP_208384:p.Arg1116Trp 
60 1 -0.842 
RNF213 
  
  
  
  
17 78272125 NM_001256071:c.2017C>T; 
NP_001243000:p.Arg673Trp 
28 0.997 0.06 
17 78319115 NM_001256071:c.6980A>G; 
NP_001243000:p.Asn2327Ser 
60 0.006 2.19 
17 78293222 NM_020954.3:c.3134C>T; 
NP_066005.2:p.Ser1045Leu 
10 0.496 2.628 
17 78353451 NM_001256071:c.13577T>C; 
NP_001243000:p.Ile4526Thr 
94 0.291 2.81 
17 78336958 NM_001256071:c.11413del; 
NP_001243000: p.Glu3806Argfs*27 
60     
OR11H1 
  
22 16449405 NM_001005239:c.400G>A; 
NP_001005239:p.Ala134Thr 
89 0.852 0.664 
22 16449399 NM_001005239:c.406G>A; 
NP_001005239:p.Asp136Asn 
10 0.988 1.84 
PLEC 
  
8 144998555 NM_201384:c.5542C>T; 
NP_958786:p.Leu1848Phe 
60 0.726 4.06 
8 144996050 NM_201384:c.7939G>T; 
NP_958786:p.Asp2647Tyr 
89 0.992 0.966 
RTTN 
  
18 67806837 NM_173630:c.2786G>A; 
NP_775901:p.Arg929Lys 
94 0.985 4.96 
18 67742698 NM_173630:c.4454A>G; 
NP_775901:p.His1485Arg 
89 0.043 2.92 
SF3A2 
  
19 2248232 NM_007165:c.1082C>G; 
NP_009096:p.Ala361Gly 
28 0.474 2.57 
19 2245459 NM_007165:c.260C>T; 
NP_009096:p.Ala87Val 
94 0.024 4.54 
ZNF335 20 44577719 NM_022095:c.3902C>T; 60 0.201 4.91 
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  NP_071378:p.Ala1301Val 
20 44596594 NM_022095:c.593A>G; 
 NP_071378:p.Asp198Gly 
10 0.977 3.92 
 
 
Table X.  Mutation burden of 11 prioritized genes between FC IA patients and controls 
Gene Risk/total allelea 
in affected 
individuals 
risk/total allele 
in controls 
VT 
statistic 
p (unadj) std error permutations 
ABCA10             2/36 2/212 0.709677 0.0775845 0.347336 5,000 
AIM1               2/36 3/212 0.569837 0.126873 0.339132 1,000 
CDAN1              2/36 2/212 0.709677 0.0771846 0.346911 5,000 
GPATCH8            2/36 1/212 0.903274 0.0259948 0.345287 5,000 
HELZ2              2/36 4/212 0.569837 0.135864 0.340307 1,000 
OR11H1             2/36 3/212 1.20892 0.0195961 0.398189 5,000 
PLEC               2/36 15/212 0.121577 0.532468 0.376399 1,000 
RNF213             5/36 4/212 1.50576 0.00119976b 0.354706 5,000 
RTTN               2/36 5/212 0.371868 0.260739 0.344665 1,000 
SF3A2              2/36 2/212 0.903274 0.0313937 0.325226 5,000 
ZNF335             2/36 1/212 0.903274 0.0269946 0.378224 5,000 
a. Risk alleles were alleles harboring FC specific deleterious variants, total alleles were calculated by the 
founder alleles of 6 IA families.  
b. Corrected p=0.013.   
 
Table XI.  Patient-only and control-only RNF213 variants which predicted deleterious  
Position Annotations affected 
individuals 
(233) 
Control 
individuals 
(277) 
PP2 GERP++ Freq in 
EVS 
78264463 c.1208_1210del:p.403_404del 1 0 1 0 0.001917 
78268746 c.1699A>G:p.Met567Val 1 0 0.999 2.72 0 
78272125 c.2017C>T:p.Arg673Trp 3 0 0.997 0.06 0 
78305962 c.3674A>G:p.Asp1225Gly 1 0 0.919 0 0 
78319447 c.7312C>T:p.Arg2438Cys 1 0 0.655 2.35 0.000077 
78320611 c.8476G>A:p.Ala2826Thr 1 0 1 5.59 0 
78321697 c.9562G>A:p.Val3188Met 1 0 0.96 5.36 0 
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78321844 c.9709C>A:p.Gln3237Lys 3 0 0.264 2.61 0 
78345744 c.12496G>A:p.Asp4166Asn 1 0 1 5.02 0.000923 
78346877 c.12854G>A:p.Ser4285Asn 1 0 0.024 2.7 0.000077 
78348389 c.13074G>A:p.Lys4358Lys 1 0 1 0 0 
78353451 c.13577T>C:p.Ile4526Thr 3 0 0.290848 2.81 0 
78363707 c.15275G>A:p.Arg5092Gln 1 0 0.998 3.14 0.000077 
78321941 c.9806G>A:p.Arg3269Gln 0 2 1 3.02 0.000077 
78328364 c.10850C>T:p.Ala3617Val 0 1 0.555 4.79 0 
78291060 c.2884G>A:p.Glu962Lys 0 1 0.068 3.66 0 
78321560 c.9425T>C:p.Val3142Ala 0 1 0.998 5.09 0 
 
 
Table XII.  RNF213 variable thresholds of world-wide populations compared to French-
Canadians 
 
sample # variants Total mac statistic p-value SE permutations 
CHB 380 55 2,333 3.95287 0.00019996 0.364289 5,000 
JPT 381 54 2,453 1.79685 0.00119976 0.346035 5,000 
CDX 370 54 2,306 3.21125 0.00019996 0.343601 5,000 
KHV 376 51 2,322 3.61053 0.00019996 0.355326 5,000 
CEU 376 54 2,187 0.955313 0.113629 0.346662 3,000 
TSI 384 54 2,151 1.23624 0.0319936 0.364394 5,000 
GBR 368 52 2,108 1.0242 0.0657868 0.349268 5,000 
FIN 376 51 2,104 1.48321 0.00679864 0.358871 5,000 
IBS 384 57 2,250 1.01387 0.124875 0.388177 1,000 
YRI 385 83 2,666 0.741073 0.361638 0.421002 1,000 
LWK 376 80 2,545 -0.0442278 0.936064 0.415337 1,000 
GWD 390 81 2,763 -0.0641889 0.924076 0.433297 1,000 
MSL 362 82 2440 -0.177864 0.973027 0.401114 1,000 
ESN 376 84 2,598 -0.6186 0.998002 0.436067 1,000 
ASW 338 82 2,173 -1.80752 1 0.39357 1,000 
ACB 373 82 2,552 -0.38227 0.99001 0.43374 1,000 
MXL 341 55 2,060 0.660489 0.275724 0.302976 1,000 
PUR 381 66 2,335 -0.359017 0.995005 0.379015 1,000 
CLM 371 69 2,293 -0.673233 1 0.420994 1,000 
PEL 362 58 2,313 1.48289 0.0039992 0.350589 5,000 
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GIH 380 53 2,312 1.47606 0.00559888 0.355099 5,000 
PJL 373 56 2,169 1.07995 0.0631874 0.351286 5,000 
BEB 363 58 2,212 0.293378 0.743257 0.33014 1,000 
STU 379 56 2,278 0.959633 0.135864 0.362751 1,000 
ITU 379 57 2,271 0.434712 0.601399 0.349177 1,000 
FC_IA 513 72 2,938 1.69234 0.0125975 0.454633 5,000 
Abbreviations are as follows: MAC, minor allele count; CHB, Han Chinese in Beijing, China; JPT, Japanese 
in Tokyo, Japan; CDX, Chinese Dai in Xishuangbanna China; KHV, Kinh in Ho Chi Minh City, Vietnam; CEU, Utah 
residents with northern and western European ancestry from the CEPH collection; TSI, Toscani in Italia; GBR, British 
in England and Scotland; FIN, Finnish in Finland; IBS, Iberian population in Spain; YRI, Yoruba in Ibadan, Nigeria; 
LWK, Luhya in Webuye, Kenya; GWD, Gambian in western divisions in the Gambia; MSL, Mende in Sierra Leon; 
ESN, Esan in Nigeria; ASW, Americans of African ancestry in southwest USA; ACB, African Caribbeans in 
Barbados; MXL, Mexican ancestry from Los Angeles, USA; PUR, Puerto Ricans from Puerto Rico; CLM, 
Colombians from Medellin, Colombia; PEL, Peruvians from Lima, Peru; GIH, Gujarati Indian from Houston, Texas; 
PJL, Punjabi from Lahore, Pakistan; BEB, Bengali from Bangladesh; STU, Sri Lankan Tamil from the UK; ITU, 
Indian Telugu from the UK; and FC_IA, French-Canadian individuals with intracranial aneurysms. 
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3.3: GENOME-WIDE ASSOCIATION ANALYSIS IDENTIFIES 
NEW CANDIDATE RISK LOCI FOR FAMILIAL 
INTRACRANIAL ANEURYSM IN FRENCH-CANADIANS 
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ABSTRACT 
Intracranial Aneurysm (IA) is a common disease with a worldwide prevalence of 1-3%. In French-
Canadian (FC) population, where there is an important founder effect, the incidence of IA is higher 
and is frequently seen in families. In this study, we genotyped a cohort of 257 FC familial IA 
patients and 1,992 FC controls using the Illumnia NeuroX SNP-chip. The most strongly associated 
loci were tested in 34 Inuit IA families and in 32 FC IA patients and 106 FC controls that had been 
exome sequenced. After imputation, one locus at 3p14.2 (FHIT, rs1554600, p=4.66×10-9) reached 
a genome-wide significant level of association and a subsequent validation in Nunavik Inuit cohort 
further confirmed the significance of the FHIT variant association (rs780365, FBAT-O, 
p=0.002839). Additionally, among the other 28 promising loci (p<5×10-6), the one at 3q13.2 
(rs78125721, p=4.77×10-7), which encompasses CCDC80, also showed an increased mutation 
burden in the WES data (CCDC80, SKAT-O, p=0.0005). The product of CCDC80 has been 
reported to have an important function in angiogenesis. In this study, we identified two new 
potential IA loci in the FC population: FHIT, which is significantly associated with hypertensive 
IA, and CCDC80, which has potential genetic and functional relevance to IA pathogenesis. Our 
results also suggest that the genetic background of familial IA might be different from the risk loci 
revealed by previous IA GWA studies and that population-wide genetic heterogeneity may also be 
an important variable for IA. 
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INTRODUCTION 
Intracranial Aneurysm (IA) has a prevalence of 1-3% in the general population102; 312. The rupture 
of an IA can lead to subarachnoid hemorrhages (SAH), which has devastating consequences. 
Environmental and genetic factors, such as hypertension and smoking109, family history and 
ethnicity all contribute to the risk of IA. Because of the complexity of IA, genome-wide association 
studies (GWAS) have become the predominant strategy lately used to look for genetic factors 
associated with IA. These studies used several large cohorts with IA patients, mainly of Finnish, 
Japanese or European descent. Several risk loci were discovered in these GWA studies: 8q11.23 
(SOX17), 9p21.3-23.1 (CDKN2A-CDKN2BAS)207; 214 and 2q33.1 from the European and Japanese 
cohorts; 18q11.2 (RBBP8), 13q13.1 (STARD13-KL) and 10q24.32208 from the Finnish and 
Japanese cohorts; 1q23.1, 3p25.2, 7p21.2, 9q31.3208 and 4q31.22 (EDNRA)211 from two Japanese 
cohorts, and 7p21.1 (HDAC9)215 from a cohort with European ancestry. A more recent Finnish IA 
study revealed additional GWAS risk loci, including 2q23.3, 5q31.3 and 6q24.2, represented by 
low-frequency SNPs89. Multiple GWAS signals suggest that the genetic etiology of IA may be 
complex and population specific.  The risk loci found in each GWA study was estimated to only 
account for 4.1%-6.1% of the heritability in the respective cohort89. 
It has been reported that French-Canadian (FC) population has higher IA/SAH incidence 
and that patients usually aggregate in large pedigrees321, with 30% of IA patients having a family 
history (fIA)322. Similarly, to the Finnish people, French-Canadians are also descended from a 
relatively small founder population and have population specific variants due to the population 
bottleneck and genetic drift. Therefore, we hypothesized that population specific and median/low 
frequency variants may play an important part in the disease risk in FC fIA. 
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RESULTS 
GWAS discovery phase 
After data QC and sample pruning, 621,983 SNPs with 173 FC IA cases and 1,772 FC controls 
remained in the analysis. The genome-wide threshold for significance after Bonferroni correction 
was set to 5×10-8. Marker-wise P values of Cochran–Armitage trend test were performed using 
PLINK 1.9273 for genotyped variants. Genomic inflation factor λ = 1.02 indicated that there was 
little inflation of excessive significant markers, as shown in quantile-quantile (QQ) plot (Figure 
S1). 
The result of the initial trend test showed 3q13.2 as the most significant locus: rs2705520 
(p=6.93×10-8), an intronic SNP in ATG3 (autophagy 3), followed by rs1877362 (p=1.16×10-7) in 
CCDC80 (coiled-coil domain containing 80) and rs1472107 (p=1.18×10-7) in SLC35A5 (Solute 
Carrier Family 35 member A5) (Figure S2). 
After imputation using the Haplotype Reference Consortium (HRC) and the exclusion of 
low quality and low MAF variants, 7,614,484 remaining variants were included in the test of 
associations using SNPtest367. The results were shown in the Manhattan plot (Figure 17). One 
locus reached genome-wide significant level after imputation: 3p14.2 (rs1554600, OR 0.26, 
p=4.66×10-9) located in gene FHIT. TaqMan validation of rs1554600 on IA cases and controls 
suggested the imputation was accurate (MAF.case=0.0838 and MAF.control=0.026).  28 most 
significant SNPs, representing distinct loci that each reached promising level (p<5×10-6), were 
prioritized for further validation (Table XIII).  
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Using imputed SNPs, the two loci 3p14.2 and 3q13.2 were estimated by GCTA-
GREML368-370 (Genome-wide Complex Trait Analysis) to account for approximately 3% of the 
heritability in the FC cohort (standard error (SE) =0.026).  
Replication in exome data and Inuit cohort 
We looked into the exome sequencing data of the aforementioned 28 genes containing the top 
GWAS SNPs in our FC WES cohort; of the 25 genes that had exonic variants, a total of 186 exonic 
and splicing variants were found in 138 FC cases and controls. Sequence Kernel Association Test 
(SKAT)371 results showed excessive exonic variation burden in IA cases in four genes SLC35F3 
(p=0.002), DTNB (p=0.003), CCDC80 (p=0.0005) and PABPC3 (p=0.0001) (Table XIV). 
However, the first two genes were less convincing with the limited number of variants in the testing 
(two variants for each). PABPC3 was unlikely to be a risk gene for IA due to its human testis-
specific expression. Thresholds Test (VT)325 focused on the selected genes revealed that only 
CCDC80 (p=0.01) in 3q13.2 reached the statistical significance after accounting for multiple 
testing.  
In the Nunavik Inuit IA cohort, of the 207 SNPs within the 28 aforementioned genes and 
neighboring regions which were found to have p<0.05 in Family Based Association Test 
(FBAT)372, 50 SNPs located in the FHIT gene region showed significant associations (top SNP 
rs780365, p=0.002839) (Table S1). Although the associations were no longer significant after 
corrections of multiple testing, the similar results established in two distinct populations still 
suggested that intronic variants in FHIT may likely be associated with IA.  
Replication of previous GWAS risk loci 
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A regional Manhattan plot covering the 13 previously identified GWAS risk loci across our FC IA 
cohort is shown in Figure S3, where the top association signal was located in the 4q region near 
EDNRA (endothelin receptor type A) (rs114324350, p=4.8×10-5). The two IA risk loci 9p 
(CDKN2BAS) and 8q (SOX17), which were discovered and replicated at least once in previous 
GWAS 207; 214, showed significant associations but did not reach genome-wide significant levels 
(top signal: rs575427, CDKN2BAS, p=1.2×10-3 and rs4738913, SOX17, p=2.3×10-3; previous 
SNP: rs1333040, p=0.008565 and rs10958409, p=0.006042). 
Overall these 13 previously defined loci encompassed 68 genes for which our FC IA 
exomes revealed 497 exonic variants (Table S2). Among those genes only STARD13 (star-related 
lipid transfer (START) domain containing 13) showed a significant variation burden in cases 
compared to control individuals (VT test, P = 0.0476, adjusted). While STARD13 was previously 
associated with IA208, it was not replicated in our GWAS data (top signal: rs9536854, P = 1.6 x 
10-3). 
 
DISCUSSION 
In this study, we discovered a new IA associated region on 3p14.2 which encompasses gene FHIT 
in the French-Canadians (Figure 18), intronic variants in FHIT also showed significant association 
with IA in the Nunavik Inuit population. Additionally, we found evidence suggesting exonic 
variants in CCDC80 within the 3q13.2 locus to be associated with the French-Canadian IA cases. 
Collectively, SNPs in FHIT and CCDC80 could explain approximately 3% of the heritability of 
IA in French-Canadians, higher than that was reported in the Finnish study (2.1%)89 and in the 
GWAS replication (2.5%)208. The underlying reason for this might be that French-Canadians are 
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a more homogenous population and this study has mainly included familial cases. On the other 
hand, two of the previously identified GWAS loci, encompassing the genes CDKN2BAS and 
SOX17, showed only a moderate association in the French-Canadian founder population.  
Although the number of cases in this study was limited, we tried improving the power by 
doing the following: 1) targeting IA patients with family history, 2) focusing on individuals only 
with the French-Canadian ethnicity, and 3) validating the findings in exome sequencing results 
and in another founder population. Because French-Canadian originated from a small founder 
population, we also included intermediate variants after the imputation. The top SNPs that we 
discovered in FHIT and CCDC80 had rare or intermediate frequency (2-4%). rs1554600 in FHIT 
has a slightly higher frequency in French-Canadians (3.3%) compared to 1KGP CEU population 
(1.9%), which suggest a bottleneck drift may be the reason for the accumulation of low-frequency 
variants that potentially associated with the risk of IA in the French-Canadians.  
FHIT (fragile histidine triad) is a tumor suppressor gene that regulates DNA replication 
and signals stress responses373, and encompasses the most active of the common human 
chromosomal fragile regions (FRA3B); and its expression has an important role in response to 
oxidative damage374. On the other hand, oxidative stress is known to be a key contributor to IA 
formation and rupture375. Interestingly, a study highlighted that the SNPs in FHIT have been 
associated with hypertensive traits in populations from Saguenay-Lac-St-Jean region, mainly 
French-Canadians376. As over 40% of our French-Canadian IA cases are also affected with 
hypertension (Table XVI), we considered that rs1554600 in FHIT is more likely to be a risk for 
hypertensive IA in French-Canadians. Further test of FHIT SNPs between IA patients with and 
without hypertension revealed several SNPs in LD to be significantly associated with this trait 
(rs73098963, p=0.002611, GWAS p value=2.42×10-8).  
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The 3q13.2 locus is a gene-rich region with many function in inflammatory responses. 
BTLA (B- and T-lymphocyte attenuator) is involved in inflammatory responses377 and homeostasis 
of the immune system378. A previous study showed BTLA expression to be up-regulated in organs 
after a hemorrhagic shock379. The 3q13.2 locus also comprises ATG3, which encodes a protein 
known to induce apoptosis380 and also to act as a regulator of oxidant and inflammatory balance 
that regulates endothelial cell stress response381. The top SNP rs2705520 in ATG3 was also 
reported in a GWAS to be associated with asthma382, suggesting its role in inflammatory diseases. 
The most interesting gene in the 3q13.2 locus is CCDC80, also known as SSG1 (steroid-
sensitive gene 1), which is a cGMP signalling effector and was reported to be widely express in 
vascular smooth muscle cells383. A previous study also showed that it has a role as a modulator of 
glucose and energy homeostasis384. Another study highlighted that the product of fibroblast growth 
factor (FGF) regulates the expression of CCDC80385, which is in turn also involved in cell 
adhesion during differentiation of fibroblast386. CCDC80 was reported as a tumor suppressor as 
well387. These evidences suggest the critical function of CCDC80 in vascular formation.  
Although no variant from these four regions has shown effects of genetic drift or selection, 
CCDC80 does harbor a large number of rare variants in the French-Canadians (Table XV); the 
gene also has significant difference in the variation burden in cases and controls. The 3q13.2 region 
contains dosage sensitive genes, among which are ATG3 and CCDC80388; 389, therefore the 
potential different expression levels of those genes may affect the risk of IA.  Interestingly, these 
two genes were the only ones that have been validated in our Nunavik Inuit cohort, which has a 
completely different genetic background compared to the French-Canadians. 
We have also found evidence of associations in two of the seven genes reported in the 
previous GWA studies, STARD13 and EDNRA. These genes showed strongest association in an 
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earlier Finnish study208; 210. Previous GWAS risk loci on 9p21 and 8q11 showed weak associations 
in our cohort. The result is expected as familial IA may have different underlying genetic 
background then sporadic IA, which were the main recruits of the previous GWAS. In the GWAS 
conducted by Foroud et al.214, the discovery cohort comprised of familial IA and also suggested 
different risk loci on 2q32 (PDE1A, p=6.66×10−7) and 10q26 (BTBD16, p=6.69×10−6).  
In conclusion, we have provided evidence for four new loci associated with IA in French-
Canadian IA cohort recruited from Montréal and Québec city, which could explain 3% of the 
disease heritability. Based on the findings of this study and the functions of their encoded products, 
two genes (FHIT and CCDC80) are potentially relevant to IA with strong aggregation of familial 
IA cases with high blood pressure in the French-Canadian population. FHIT is more particularly 
associated with hypertensive IA cases and this may be the consequence of a bottleneck drift that 
affected the French-Canadian founder population. CCDC80 was shown to have a large number of 
rare variations in the French-Canadian cohort and with significantly different variation burdens 
between IA cases and controls. The lack of association of SNPs in FHIT and CCDC80 in previous 
GWAS studies suggested a genetic heterogeneity in IA, and thus additional studies targeting other 
high-risk populations are needed. However, the limited number of cases available in our study 
warrants a validation study that will have access to a larger cohort from the same founder 
population, thus to increase the power of detection.  
 
MATERIALS AND METHODS 
Discovery cohort 
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The discovery cohort included 257 French-Canadian IA patients with family history and recruited 
in Montréal and Québec City, Canada. The diagnoses were confirmed either by magnetic 
resonance angiography (MRA), or by surgical confirmation (clipped or coiled). An additional 
1,992 FCs, comprised of unrelated individuals without cerebrovascular diseases were included as 
population controls. Their demographic information is listed in Table XVI.  Written consent was 
obtained from all individuals and this study was approved by appropriate institutional ethics 
committees (Québec, Canada). 
Genotyping and quality control 
All patients and controls were genotyped using the Illumnia NeuroX SNP-chip, which contains 
719,885 markers and is comprised of the backbone of Illumnia HumanOmniExpress-v24 
BeadChip. Raw data was processed by Illumnia GenomeStudio software before the genotypes 
were generated. Both markers and samples were passed through a series of quality control (QC) 
steps. Samples were first removed if duplicated or if they had one of the following issues: 1) sex 
discrepancies; 2) exceeded a missing rate of 0.02; 3) ethnical admixture determined by PCA; or 4) 
with cryptic relateness determined by PLINK. Markers were removed if they meet one of the 
following criteria: 1) exceeding a missing rate of 0.02; 2) having a minor allele frequency (MAF) 
lower than 0.01; 3) deviating from Hardy Weinberg Equilibrium (p<0.0001). 
Principal Component Analysis (PCA) impelemented in the package EIGENSOFT 6.0329 
was performed to assess the ethnicity of the samples. Three distinct populations CEU, CHB and 
YRI from 1000 Genome (1KGP) Phase III were used for clustering and CEU outliners were 
removed from further analysis. The remaining homogeneous population was also adjusted for the 
principal components in the subsequent tests for associations.  
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Imputation 
Imputation was done by the Sanger Imputation Server (https://imputation.sanger.ac.uk/) using 
Haplotype Reference Consortium r1.1390, and were pre-phased using SHAPEIT2391. Imputed 
variants were included in the further analyses only with MAF > 0.01 and with imputation quality 
score > 0.3.  
Association analysis 
Frequentist additive association implemented in SNPtest367 was used to test for association of the 
imputed dataset, between FC IA cases and controls. Five major principal components were used 
as covariates for ancestry adjustment along with the sex of samples. Only autosomal SNPs were 
analyzed. 
Regional association of suggestive loci were plotted using LocusZoom392 with LD data 
from 1KGP CEU population.  
Heritability estimation 
We estimated the heritability from the original and imputed variants within the most promising 
loci, using methods of Estimation of Variance explained by SNPs (GREML)368 and GREML-
LDMS370 programs implemented in the package of the Genome-wide Complex Trait Analysis 
(GCTA)369. 
FC and Inuit IA WES data  
We examined the loci from the GWAS signals that have reached suggestive significance (p<5×10-
6) in the exome sequencing results of 32 selected FC IA cases and 106 FC controls. Variable 
Thresholds Test (VT)325 implemented in Variant Tools (Vtools)393 and Sequence Kernel 
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Association Test (SKAT)371 were performed to test the exonic variation burden in the genes 
located in the GWAS significant regions. 
Thirty-four Nunavik Inuit (Québec, Canada) families comprised of 49 IA patients and 124 
family controls were also used to follow up the regions of significance. The samples was genotyped 
on Illumina HumanOmniExpress-v24 Beadchip which contains 730,525 SNPs. We looked into all 
the suggestive loci of the FC IA discovery cohort, and performed family-based association analysis 
(fbat) implemented in FBAT package372 in the Inuit SNP-chip data to test the case-control 
association in related individuals.  
Replication of previous IA GWAS loci 
At this point 13 loci from previous GWA studies (Table S2) were selected to examine if they could 
be replicated in our study. A 2Mb (1Mb each upstream/downstream) region was selected for each 
previous associated SNP in the data of both FC discovery cohort and FC exome replication cohort. 
PLINK and Genome Analysis Toolkit (GATK)267 were used to extract the variants in the two 
respective datasets. 
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Figures 
 
Figure 17. Manhattan plot of FC IA case-control association analysis using imputed data. 
Red line indicates the level of genome-wide significant association (p=5×10-8); blue line indicates the level of suggestive association 
(p=5×10-6).  Green dots indicate FHIT SNPs.
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Figure 18. Regional association signals of 3p14.2 locus  
4Mb region around the most significant association, rs1554600 in 3p14.2 locus is displayed using 
imputed data. Purple line indicates the genetic recombination rate (cM/Mb). Variants in linkage 
disequilibrium is shown in color gradient indicating r2 levels (hg19, 1KGP, Nov 2014, EUR). 
Variant with the most significant association (rs1554600) is indicated in purple diamond. 
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Tables 
 
Table XIII.  28 genes with top SNPs reached promising level of association 
loci top SNP Position 
(hg19) 
Gene (or 
nearby) 
Frequenc
y in cases 
Frequency 
in controls 
OR P-value INFO 
3p14.2 rs1554600 61157774 FHIT 0.080925 0.022291 0.258936 4.66E-09 0.94 
7p22.2 rs12535623 2951412 CARD11 0.260116 0.154345 0.519156 1.15E-07 0.95 
4p15.32 rs116130729 16012786 PROM1 0.072254 0.023138 0.304125 1.8E-07 0.86 
3q13.2 rs78125721 1.12E+08 CCDC80 0.043353 0.009029 0.201063 4.77E-07 0.97 
21q22.13 rs111610752 38151254 HLCS 0.052023 0.016366 0.303181 5.39E-07 0.68 
8p23.1 rs117537300 10743939 XKR6 0.118497 0.052765 0.414387 6.64E-07 0.88 
13q12.13 rs7989887 25681112 PABPC3 0.16185 0.087472 0.4964 6.93E-07 0.99 
13q14.3 rs114375292 54413853 LINC00558 0.080925 0.030756 0.360387 7.25E-07 0.89 
1q42.2 rs150148362 2.34E+08 SLC35F3 0.040462 0.008183 0.195651 8.16E-07 0.74 
16p13.2 rs138031402 8960325 CARHSP1 0.043353 0.01044 0.232811 8.87E-07 0.77 
7p13 rs146929064 44346336 CAMK2B 0.060694 0.020598 0.325486 1.32E-06 0.85 
1q41 rs12058987 2.17E+08 ESRRG 0.083815 0.035553 0.402958 1.33E-06 0.98 
8q24.21 rs7011138 1.28E+08 PCAT1 0.092486 0.19526 2.38087 1.35E-06 0.99 
9p23 rs2039332 9138642 PTPRD 0.049133 0.011005 0.215339 1.48E-06 0.79 
16p13.2 rs982855 8297685 RBFOX1 
/TMEM114 
0.572254 0.437641 0.581703 1.78E-06 0.99 
6p21.1 rs6911069 43617687 RSPH9 0.069364 0.025113 0.34561 1.92E-06 0.99 
20p13 rs56040592 1611918 SIRPG 0.104046 0.051072 0.463459 1.98E-06 0.98 
3p24.1 rs142836448 29398714 RBMS3 0.063584 0.153217 2.66475 2.26E-06 0.95 
2p23.3 rs77639126 25598423 DTNB 0.072254 0.023984 0.315525 2.35E-06 0.91 
2p23.2 rs13028204 28853137 PLB1 0.086705 0.041479 0.455814 2.39E-06 0.98 
3q22.1 rs114999403 1.32E+08 CPNE4 0.049133 0.014955 0.293814 2.67E-06 0.97 
20p13 rs77402555 876841 ANGPT4 0.046243 0.012415 0.259286 2.69E-06 0.89 
5p13.3 rs72753560 31626036 PDZD2 0.086705 0.178612 2.29048 2.75E-06 0.97 
22q12.3 rs150551568 33136068 SYN3 0.046243 0.011851 0.247359 3.12E-06 0.95 
14q24.2 rs117272176 72902205 RGS6 0.046243 0.014108 0.295149 3.23E-06 0.77 
2p33.3 rs1207426 2.06E+08 PARD3B 0.16763 0.096501 0.530358 4.1E-06 0.99 
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15q25.1 rs8032417 78569930 DNAJA4 0.393064 0.275959 0.588522 4.82E-06 1.0 
10p14 rs7084131 8399121 GATA3 0.011561 0.068002 6.23842 4.83E-06 0.99 
 
Table XIV. Exonic and splicing variants of 23 GWAS suggestive genes in 138 FC cases and 
controls from WES 
Gene Loci Number of tested variants P-value (SKAT) 
ESRRG 1q41 2 0.7073712 
SLC35F3 1q42.2 1 0.002189217 
DTNB 2p23.3 2 0.002747022 
PLB1 2p23.2 20 0.1122009 
PARD3B 2p33.3 13 0.9205563 
RBMS3 3p24.1 1 0.354907 
CCDC80 3q13.2 8 0.0005070405 
CPNE4 3q22.1 1 0.7073712 
PROM1 4p15.32 12 0.05065522 
PDZD2 5p13.3 19 0.7212919 
RSPH9 6p21.1 2 0.8510591 
CARD11 7p22.2 4 0.8172528 
CAMK2B 7p13 3 0.09754801 
PTPRD 9p23 7 0.2814774 
PABPC3 13q12.13 54 0.0001097577 
RGS6 14q24.2 1 0.7073712 
DNAJA4 15q25.1 2 0.5637608 
RBFOX1 16p13.2 5 1 
CARHSP1 16p13.2 2 0.3250554 
ANGPT4 20p13 4 0.09886071 
SIRPG 20p13 5 0.7073707 
HLCS 21q22.13 6 0.6115834 
SYN3 22q12.3 3 0.5083075 
 
 
 
Table XV.  CCDC80 exonic and splicing variants in FC IA cases and controls 
Position Annotation MAF 
(CEU) 
SNP MAC in 
case 
MAC in control 
3:112324305 c.T2812C:p.Y938H 0.01 rs114697626 0 4 
3:112328856 c.C2394G:p.L798L 0.002 rs61732242 0 2 
3:112357336 c.C1417T:p.H473Y 0.009 rs116307644 4 1 
3:112357537 c.A1216G:p.R406G 0  0 1 
3:112357730 c.G1023T:p.L341F 0.01 rs115738438 5 2 
3:112357878 c.C875A:p.A292E 0  0 1 
3:112358168 c.G585C:p.E195D 0 rs370290734 0 1 
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3:112358171 c.T582A:p.G194G 0.01 rs116819563 5 2 
3:112358658 c.G95A:p.S32N 0.001 rs75074453 0 1 
3:112358761 UTR5 c.-9G>T 0  0 1 
 
Table XVI.  FC sample demographics and the clinical information of IA cases 
Sample demographic of cases and controls 
 Cases Controls 
Number 257 1192 
Mean age of recruit (SD) 53.9 (11.2) 54.4 (16.8) 
% Male 31.5% 60.6% 
Clinical information of cases (212) 
 With family history Sporadic 
With clinical information 147 65 
Multiple lesions (%) 55 (37.4) 19 (29.2) 
SAH (%) 51 (34.7) 25 (38.5) 
Hypertension (%) 60 (40.8) 31 (47.7) 
Drinking (%) 33 (22.4) 26 (40.0) 
Smoking (%) 89 (60.5) 50 (76.9) 
Hypercholesterolemia (%) 29 (19.7) 24 (36.9) 
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CHAPTER 4: DISCUSSION 
4.1: POPULATION GENETICS: STUDY OF NUNAVIK INUIT 
Genetic studies of complex diseases sometimes neglect to characterize the studied population first 
before launch into their genetic risk. This can be critical as some populations are admixed while 
others are much more homogeneous, and every population can be very different from the others. 
Until recently, most genetic studies of complex traits have been conducted using samples of 
European ancestry and this is now limiting our efforts to validate if the detected risk variants from 
the general human genome are functional variants or not in other distinct and isolated populations, 
and vice versa. Experimental designs can thus be biased – especially before the era of 1KGP. 
Consequently, when a non-European ancestry population is examined to identify the genetic 
factors underlying a complex disease, it is important to have a thoroughly characterized genomic 
profile of the targeted population, before attempting to establish if variants are associated with a 
particular trait or disease.  
The work presented in the first part of this thesis was focused on uncovering the unique 
genetic landscape of an arctic indigenous population. Nunavik Inuit represent an important human 
population that has adapted to an extremely harsh environment since the Siberian Neolithic, 
possibly more than 5,000 years ago. Until very recently, Nunavik Inuit have been subjected to a 
high level of genetic isolation; and has made this population a powerful model to discover certain 
disease genes. Unfortunately, currently available commercial SNP genotyping arrays are designed 
to only suit major present-day populations, especially European descendants. We therefore 
resorted to use a WES approach – which is not commonly used in the field of population genetics. 
The approach has provided us with critical information regarding rare variants across genes under 
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selective sweeps, which would have been neglected if only a more conventional genotyping 
approach of common variants had been used.  
Our first objective was to get a comprehension of the genetic structures of Nunavik Inuit. 
In comparison to similar Arctic indigenous populations, such as Northeastern Siberians39 and 
Greenlandic Inuit14, the genomes of Nunavik Inuit contain much higher levels of Inuit ancestry 
due to limited admixture with the Europeans, i.e., 87.6% of the Nunavik Inuit have >99% Inuit 
ancestry, by comparison, only 12% of Greenlandic Inuit have >95% Inuit ancestry and ~60% Inuit 
ancestry in overall Northeastern Siberians. Taking into account evidences such as the high LD of 
Inuit (Figure 4) and the higher mutation load reported for dispersed Out-of-Africa populations14; 
394, we assumed the genomic landscape of Inuit completely differs from the major worldwide 
populations and deemed that disease gene discovery approaches needed to be adjusted so that they 
would be best suited to the Inuit population. 
Following an overview of the current knowledge regarding the demography of Nunavik 
Inuit, the first chapter presented analyses aimed at revealing genetic signatures that underlie their 
adaptation. Although Fumagalli et al. reported in the Greenlandic Inuit study that the FADS gene 
family is accounted to be the most significant signals as the result of positive selection29, the fact 
that this family of genes is critical in dietary fat metabolism had been previously discovered as 
under adaptive evolution in many other populations46; 271. The Metabochip used in the Fumagalli 
et al. study was custom-designed to capture loci associated with metabolic traits; and again it was 
designed using variants that were essentially identified in individuals of European ancestry. Thus 
their findings failed to include critical information regarding the Inuit genome; one of the most 
important Inuit variant CPT1A p.P479L, which follows strong selective sweep, was noticeably not 
reported in their results.  
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Our study avoided such potential bias by making a repertoire of all coding variants across 
the Inuit genome. Though high-throughput sequencing generates variant call data with less 
accuracy compared to SNP genotyping array, it captures population specific variants that can be 
critical for the identification of loci under positive selection, as well as disease predisposition. In 
order to minimize the false positive call rate and bias caused by inconsistent wildtype/homozygous 
calls, we have developed a pipeline that: 1) calculates the high-confidence regions of our Inuit 
samples according to the initial set of variants’ calls, and 2) only performs variant calling within 
the high-confidence regions of Inuit and 1KGP as reference data.   
We used FST-based population branch statistic (PBS) to identify targets of recent and 
localized adaptation of Nunavik Inuit genome236. This method measures the variant frequency 
changes that are fitting with recent selection events since the Inuit’s genome has started to diverge 
from the Han Chinese at approximately 23 kya BP29. We have also identified even more recent 
selection events that took place following the divergence of Nunavik Inuit and Northeastern 
Siberians, possibly at 4-8 kya BP according to the age of the CPT1A p.P479L variant, which was 
successfully replicated using PBS method.  
The CPT1A p.P479L variant represents a very particular genetic signature of Inuit and 
Northeastern Siberians as these are the only two existing populations that commonly carry this 
loss of function variant. Chapter 2.3 is largely dedicated to the study of CPT1A variants, as well 
as other variants in the genes encode carnitine acyltransferase (CPT) family (CPT1A, CPT1B, 
CPT1C, CPT2 and CART). Because of their importance in the fatty acid synthesis, Inuit may carry 
rare and damaging variants in these genes, such as CPT1A p.P479L variant, with a derived allele 
frequency of 95% among Nunavik Inuit while all homozygous in ancestral allele in non-Arctic 
indigenous populations. The CPT1A p.P479L variant can probably serve as an indicator of the 
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percentage of Inuit ancestry in an indigenous population. Because of their low-carbohydrate and 
high-fat diet of Arctic indigenous populations, these individuals may be in a permanent metabolic 
state of ketosis-like; the p.P479L variant is estimated to lead to a decreased activity of CPT1A and 
become a positive selective pressure to these people. Three other missense variants, CPT1C 
p.T265M, CPT2 p.R477W and CRAT p.S78F were also found unique to Nunavik Inuit and were 
significantly more deleterious than the missense variants of those genes found in concurrent Asian 
populations. The FST score of these CPT genes also suggested significant population separations 
between Nunavik Inuit and Asians. This study was just a preliminary exploration of genes involved 
in Inuit metabolic genes related to diet, thus we had also presented an in-depth analysis in Chapter 
2.2, where we looked for genome-wide signatures in Nunavik Inuit that would be linked to their 
adaptation to their diet and the arctic climate.  
The genome-wide PBS analysis revealed 30 new genes (Table I) to be under selective 
sweep in Nunavik Inuit with CPNE7 (PBS=1.74) and ICAM5 (PBS=1.16) as the most interesting 
ones. The latter being the outcome of more recent selection events, as supported by high PBS score 
between Nunavik Inuit and Northeastern Siberians (PBS=1.04). The function of the CPNE7 
product is not very well established, while one group reported its association with odontoblast 
differentiation395, others also pointed out its role in inflammatory response and oncogenesis396. 
The product of ICAM5 is an intercellular adhesion molecule protein that is expressed in the 
vascular endothelium and it has been associated with hematological disorders397. It is noteworthy 
that both CPNE7 and ICAM5 are involved in vascular cell adhesion processes and this suggests 
that lipid metabolism genes are not the only ones involved in the adaptation of Inuit population.  
To further the examination of the genes revealed by the PBS analyses under selective 
sweep, we used qRT-PCR to measure their levels of expression in both Nunavik Inuit and French-
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Canadians, the latter representing a control population living in a similar geographical area. The 
French-Canadian colonization took place much later than Nunavik Inuit and the adaptation of this 
population has not yet been as fully established as the one of Inuit. Both CPNE7 and ICAM5 
showed significant difference in expression levels between Inuit and French-Canadian LCL, 
similar trend also appeared in the previously-identified gene FADS1. The functional validation 
presented in our study, at our best knowledge, was the first of its kind to have used in any 
population-based genetic study, which has provided direct biological proof of the adaption signals. 
However, a major pitfall of this validation is that most of the coding variants do not affect gene 
expression levels. Moreover, several functionally interesting genes which also have high PBS 
scores, such as CYP11B1 and CYP11B2 family on chr8 and IMPDH1 on chr7, failed to have 
detectable RNA expressions in LCL cells, which, unfortunately, were the only Inuit cells available 
to conduct our expression measures currently. Because LCL are not an ideal cellular model to 
explore the biological functions of these targeted genes, we cannot determine whether the genes 
that failed to show differential expressions between Nunavik Inuit and French-Canadians are 
involved in the adaptation of Inuit.  
We further hypothesized that in an isolated founder population, genetic loci containing 
selection signals may also harbor genes predisposing this population to certain complex diseases, 
which may be related to the recent changes of their living environment. As a result, we discovered 
a splicing variant rs2289367 in CCM2 (MAF=0.2) that is associated with the risk of IA. This 
variant is observed at a much higher frequency in Nunavik Inuit (MAF=0.82, PBS=0.82), thus 
suggesting that this approach could be a successful example as another way of identifying disease 
risk genes in small, isolated population. CCM2 is a candidate for familial cerebral cavernous 
malformations (CCM), which is another cerebrovascular disorder that may have etiological 
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continuity with IA. Unlike IA, CCM mostly follows autosomal-dominant inheritance and only 5–
15% of familial cases cannot be explained by the three known CCM genes (CCM1-3). The genetics 
of CCM largely relies on ethnic differences. A study discovered that mutations in CCM2 accounted 
the majority of Japanese CCM cases398, which is different from what was observed in Caucasian 
cases. It is not surprising that the rs2289367 variant in CCM2, which appears to be under selection 
or genetic drift, may be associated with another cerebrovascular disorder (IA) in another distinctive 
population. Additional correlations between genes under selection in Nunavik Inuit (revealed in 
iHS test) and the risk of IA may also be speculated. Among the other genes for which we observed 
an association, SERPING1 presents a reduced expression in Nunavik Inuit LCL (Appendix 1). In 
past studies multiple members of the SERPIN family179; 199 were reported to contribute to the 
development of IA.  
Interestingly a scenario similar to the one described above was also observed in the second 
part of our study focused on the genetic susceptibility of IA in French-Canadians (Chapter 3.2); 
when we discovered that RNF213, a gene supposed to be also under genetic drift (Figure 13), 
appeared to be associated with IA in the French-Canadian population. RNF213 was identified as a 
causative gene for Japanese moyamoya disease (MMD), which suggested these two 
cerebrovascular disorders share some genetic similarities. Furthermore, the population background 
seems to additionally contribute to the risk of MMD, as 95% and 79% of familial and sporadic 
MMD in Japanese are respectively explained by RNF213 variants. Japanese is one of the East 
Asian populations for which a founder effect is observed. While Caucasian MMD cases were not 
found to be associated with RNF213399. Evidence from two of our studies suggest a new 
hypothetical approach for the study of cerebrovascular diseases, one that considers how different 
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functional disruptions (different variants) of the same gene may lead to the different phenotypes 
(outcomes) across the same body system, depending on the ancestry of the populations studied.     
There are other examples suggesting genes (variants) under weak selection or genetic drift 
in Nunavik Inuit might also to be associated with highly prevalent disease in this population. As 
reported in one of our studies, a nonsense variant (rs61736969) in TBC1D4400, which is well 
studied in the Inuit population because of its association with elevated postprandial glucose and 
T2D, we validated the findings first reported by Moltke et al.30. TBC1D4 rs61736969 is another 
Inuit specific variant with MAF varies between Inuit populations (13.2% in Alaskan Inuit, 16.3% 
in Nunavik Inuit and 38.9% in un-admixed Greenlandic Inuit). Unlike the CPT1A p.P479L variant, 
the TBC1D4 rs61736969 does not present in Northeastern Siberian populations, instead having a 
very low frequency in Native Americans (0.6%). We took a step further and looked into ancient 
American genome data237, one of which traces back to an individual (6,260-5,890 cal BP, mtDNA 
haplogroup D4h3a7) from today’s British Colombia. This individual has been described to have 
had a diet rich in marine protein, and also carried the alternative allele of TBC1D4 rs61736969, 
indicating the variant may have occurred in the New World of Pleistocene America.  
Several hypotheses can be proposed to explain how disease risk alleles happened to be 
located in the evolutionary adaptive signals. Williamson et al. mentioned that selective sweeps 
may “carry tightly linked, initially rare, deleterious, and potentially disease-causing variation to 
relatively high frequencies” (adaptive hitchhiking)401. Alternatively according to Dudley et al., 
“high-frequency disease-associated variants can be the result of past adaptive events that now have 
detrimental consequences in our present contexts” (thrifty gene hypothesis and hygiene 
hypothesis)402. The functional relevance of the genes we observed to be within the Nunavik Inuit 
adaptation signals is likely due to the original adaptive events, especially in the cases of metabolic 
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adaptations, and this probably is one of the reasons behind the differences of CVD and IA 
prevalence among today’s world populations. However, the thrifty gene hypothesis has its 
limitations, some of the signals we discovered using the PBS model thus may not only reflect the 
result of a positive selection, but instead have a neutral origin which has accumulated to high 
frequency through bottleneck effect (genetic drift). This scenario could have very well been at play 
for Nunavik Inuit and the recent changes of their lifestyle disrupted the neutrality of those variants 
and lead to their increased risk of developing CVD and IA. Nevertheless, because the adaptive 
variants have a higher probability of becoming pathogenic in altered environments (by comparison 
to previously neutral alleles), additional studies will be necessary to accurately interpret the 
enrichment of CVD and IA functional relevant genes in Nunavik Inuit selection signals. 
Several weaknesses of this study still remain to be addressed. First, there may be some 
ascertainment bias due to the way of sampling – Inuit individuals were largely recruited as families 
and this may have led to an inflation when some of them are more related. However, the fact that 
any two individuals have at least one IBD>222 cM, even when they were recruited in different 
villages, indicates that such inflation is negligible in a population with strong founder effect. 
Nevertheless, the increased relativeness may have led to a certain bias in some analysis (e.g. 
ancestry estimation). Therefore, further tests and additional samples are needed to validate whether 
there is indeed an admixture of Native American ancestry in Nunavik Inuit as indicated in our 
study (Figure 2). While the increased relativeness of our cohort might not have influenced the 
adaptation signals we identified, additional numbers of Nunavik Inuit (especially in villages that 
we have not sampled from) could greatly strengthen the power to identify variants related to certain 
disease risk based on our PBS-based method. Also obtaining WES/whole genome sequencing 
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(WGS) data of other Canadian and Greenlandic Inuit could help in determine the population split 
time and to map a clearer migration routes.  
The combination of SNP-chip genotyping and WES is probably the most efficient way by 
far to gather critical genetic information. However, some statistical tests (e.g. demographic 
inference and estimation of the selection starting time) perform better when using WGS data. A 
new human genome reference panel focused on Arctic indigenous population could also become 
available as more Inuit WGS is carried out, this would greatly enhance the imputation accuracy of 
genetic studies conducted for indigenous populations. Moreover, there may be other selective 
sweeps happening in the non-coding regulatory regions, which may be of equal importance 
towards the human evolution and adaptation as the coding variants, and we would not be able to 
detect these unbiasedly with the data currently available to us.  
WGS is also ideal for the detection of copy number variation (CNV), and these have been 
shown to be associated with many complex diseases, and also to be subjected to natural selection 
during human evolution. A recent study describing the general spectrum of CNVs among global 
populations indicated that CNVs behave differently than SNV403. CNVs change more drastically 
over short period of time and consequently their differences across populations are much larger. 
Moreover, duplications and deletions also exhibit different functions in human genome adaptations 
as the number of duplications are much more than deletions, being the target for adaptive selection. 
Sudmant et al. also reported population stratification in a duplication in CLPS, a colipase functions 
in dietary metabolism of fatty acids403, which happens to be one of the genes under selection in 
Nunavik Inuit discovered in our study (Appendix 1). The most interesting result of CNV studies 
is that they may explain part of the missing heritability of complex diseases, including cancer and 
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psychiatric diseases. Therefore, it would be complementary to our previous focus of SNV in order 
to explore the genetics of disease risks in Nunavik Inuit.  
Another potential contribution to the population genetic study of Nunavik Inuit is 
examination of their mtDNA. Not only is it interesting to establish the mtDNA haplogroup of 
today’s Nunavik Inuit, it is also important considering that in our study of Inuit adaptation to cold 
and diet. It has been observed that genes acting in energy generation pathways (mitochondrial 
coupling, ATP production and oxidative phosphorylation) have highly distinctive genetic profiles 
(Appendix 1). Mitochondria are structures within cells that convert the energy from food into ATP 
and it would not be surprising that a selection of mtDNA variants exist in Nunavik Inuit. Moreover, 
some of these variants could be deleterious and linked to some of the increased disease risks 
observed in this population. A recent study that examined the entire mtDNA genome of 
Greenlandic Inuit404 revealed that Greenland Inuit are mostly descendent from three main 
haplogroups: A2a, A2b1 (16,200 years BP), and D4b1a2a1 (11,000 years BP). This confirmed the 
previous findings regarding sex biased Inuit-European admixture and it showed there was also 
lack of genetic continuity between Palo-Eskimos (D2a1) and Greenland Inuit. Our results which 
focused on autosomal DNA indicate that mtDNA findings may not likely to be the same in 
Nunavik Inuit, an examination of their mtDNA would thus complete the genetic picture of their 
adaptation. Some connections may exist between Nunavik mtDNA haplogroups, CNV and Inuit 
specific variants in the regulatory regions, and the genes we have thus far observed to be under 
selection signals. Overall it could be their collective contribution that affects the intricate energy 
generation mechanism as it has underlined the evolution and adaptations, and even the disease 
predispositions of Nunavik Inuit.  
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4.2: NEW RISK GENES FOR INTRACRANIAL ANEURYSM IN 
FRENCH-CANADIANS 
IA is a very common but complex disorder that threatens the general population and more 
especially the elderly. It is estimated that as much as 10% of the population may harbor 
asymptomatic IA, depending on age, gender, as well as ethnicity96; though most of them remain 
unruptured and undetected. There are several risks factors and both the environment and genetic 
component are deemed to play a significant role. Nevertheless, it has been proven in the past that 
identifying the genetic risk factors of IA is a challenging task.  
As IA is such a common disorder, GWAS seems to be the optimal approach – and several 
multi-ethnical GWAS have indeed discovered six major candidate regions including 9p21.3 
(CDKN2BAS), 8q11.23-12.1 (SOX17)207, 10q24.32 (CNNM2), 13q13.1 (STARD13), 18q11.2 
(RBBP8)320 and 4q31.22 (EDNRA)210. While the power of detection behind those loci was high 
enough for them to have been replicated in the follow-up studies, together they only explain 4.1-
6.1% of the IA heritability89.   
It is possible that the genetic risk for IA differs across populations with different ancestries. 
It could be the consequence of an accumulation of low-frequency founder variants, some of which 
would contribute to an increased burden of variants in IA-susceptibility genes in a population 
predisposed to this condition. If such a scenario proves to be true it would explain the missing 
heritability of GWAS loci. In support of this a GWAS study that focused only on a cohort of 
Finnish IA case reported completely different risk loci (2q23.3, 5q31.3 and 6q24.2)89. However 
even with the increased power of imputation, GWAS, which are based on SNP genotyping 
platforms, are not an ideal approach to identify population specific variants, especially if those 
happen to be under a recent selective sweep in a high-risk population.  
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We decided to use WES in familial IA cases to capture population specific coding variants, 
even though usually high-throughput sequencing technologies are not best suited for the gene 
discovery of a complex disease, especially when heavily affected by genetic heterogeneity and 
incomplete penetrance. In order to minimize the false negative rate in risk variant discovery, we 
lowered the stringency in the variant prioritization step to allow the presence of low penetrance 
variants. We hypothesized that it would not be the increased frequency of common variants that 
would account the genetic heritability of IA in French-Canadians, thus our focus was on the rare 
variants specific to this population. We discovered that there seems to be a genetic continuity 
among cerebrovascular diseases as we identified French-Canadian IA variants in RNF213, a gene 
previously established to be a susceptibility factor for a rare type of cerebrovascular malformations, 
MMD, which was predominately observed in East Asians. Our study showed that variants located 
in different functional regions of RNF213 can in fact be associated with different types of 
cerebrovascular diseases in different populations as they affect the function of RNF213 in a distinct 
manner. Indeed we observed an increased activity in an ATPase assay where recombinant AAA+ 
domains of RNF213, carrying two variants (p.Arg2438Cys and p.Ala2826Thr) that were observed 
exclusively in French-Canadian IA case. By opposition, the Japanese founder mutation 
(p.Arg4810Lys) predisposing to MMD leads to a reduced ATPase activity334. Such divergent 
ATPase activities could be at the base of two distinct pathogenic mechanisms where the 
cerebrovascular walls would be affected differently in MMD and IA.     
Our findings suggest that approximately 10% of French-Canadian familial IA cases might 
be explained by rare functional variants in RNF213, and that still leaves significant portion of the 
IA heritability to be discovered. At this point we only investigated RNF213 in the French-Canadian 
cases and it remains to be established whether RNF213 can be extended to IA cases from other 
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populations, something which at the very least should be done in population of European descents 
that are ethnically closest to French-Canadians. RNF213 is a large gene, for which many private 
variants are listed in the NHLBI Grand Opportunity Exome Sequencing Project (GO-ESP) 
database. It is however important to consider that the ESP project is known heavily aggregated 
with cardiovascular and atherosclerosis patients, whom are supposed to have increased risk of IA 
as well. Moreover, the prevalence of unruptured IA can be 5-10% in general population, thus some 
private variants in GO-ESP database might be associated with increased IA risk as well. Further 
studies are necessary to determine whether RNF213 is also an IA risk gene in non-Asian 
populations. This study, on the other hand, demonstrated that a WES approach can also be useful 
for studying common diseases under a right hypothesis.  
To further our investigation of IA in the French-Canadians, we also performed a GWAS in 
an attempt to detect potential risk loci that were not discovered by WES. We used a large cohort 
(1,992) of control individuals to compensate the limited power of our relatively small IA cases 
(257) forming the discovery cohort. We identified a genome-wide significant loci at 3p14.2 
(p=4.66×10-9) after imputation, which is located in the intronic region of an established tumor 
suppressor gene FHIT374. However, none of the loci previously reported in large and IA GWAS 
cohorts with multiple ethnicity had even reached the promising level of association (5×10-6) 
observed in our study. Further analyses revealed another gene, CCDC80, which is located in a 
promising locus at 3q13.2 (p=1.16×10-7). CCDC80 appears to present an increased mutation 
burden in IA patients when all the rare variants from the French-Canadian WES cohort are 
collapsed together (SKAT, p=0.0005), thus making it an additional interesting candidate.  
Similar to the previous Finnish-only study89, the replication rate of previous GWAS loci 
was also poor in our study. Only two SNPs, the well-established rs1333040 located in 9p21 
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(p=0.008565, no adjustment) and rs10958409 in 8q11 (p=0.006042, no adjust) showed significant 
association, however far from reaching genome-wide significant level. Apart from these two SNPs, 
none of the top SNP identified across other IA GWAS loci (4q31, 7p21, 10q24, 13q13 and 18q11), 
which were previously replicated at least twice, were found to show any significant association in 
our study. A region in 4q31 showed significant association (p=4.8×10-5), however this region is 
440 kb upstream to the top SNP of EDNRA found in other studies211.  
The low replication rate of IA loci in our French-Canadian GWAS could be due to our 
limited number of cases. It is also possible that the previously conducted larger GWAS only 
revealed association signals, which are shared between populations, thus loci that would be more 
strongly associated with a higher IA risk in specific populations remain to be found, especially in 
populations that are not of Japanese or Finnish origin. The two largest IA GWAS were conducted 
in earlier days of the genome-wide research (2008207 and 2010320). One may speculate if their 
results would have to be different, had population stratification been included as a covariate in the 
discovery stage of these studies. Nonetheless, previously established GWAS loci collectively 
explain only a very small portion of the IA heritability. Even in an independent follow-up Finnish 
study, only 2.5% of the heritability was explained, lower than the 6.1% indicated in the Finnish 
GWAS discovery study89.  
The criteria behind the selection of IA cases in our French-Canadian GWAS included a 
large number of cases with familial aggregation and this might also explain our identification of 
novel loci. An investigation of the genetic risk score for previous identified GWAS loci failed to 
discover significant associations when examining familial IA cases213, suggesting additional 
potential risk loci of familial IA remain to be discovered.  
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Our GWAS identified two genes (FHIT and CCDC80) that may provide additional 
evidence to the genetic risk of familial IA in French-Canadians. FHIT has been associated with 
stress response and hemodynamic traits in populations from the Saguenay-Lac-St-Jean region, in 
which the residents are predominantly French-Canadian376. CCDC80 is a cGMP signalling effector 
and affects the growth of vascular smooth muscle cells, and it is also associated with pulmonary 
arterial hypertension through its modulating effect on the expression of endothelin-1 and COL1A1, 
two genes known to be critical in endothelial cells formation405. Low frequency SNPs were 
identified as top association signals in both FHIT and CCDC80, and these SNPs were identified 
through imputation based on the Haplotype Reference Consortium (HRC) dataset, which regroups 
39 million SNPs to impute the haloptypes390. Low frequency variants have been shown to be 
informative in GWAS that were examining founder populations, as some of these were found 
representing high risk loci in Finnish IA cohort89.  
While it does not explain all heritability of IA in the French-Canadian population, RNF213, 
FHIT and CCDC80 may collectively contributing to a fair share of the genetic etiology underlying 
IA in the French-Canadians. The studies of common diseases in founder populations offer an 
avenue that can be particularly useful and a number of simulations have shown that complex 
diseases are influenced by rare susceptibility alleles at many loci, as opposed to the GWAS-derived 
common disease/common variant (CD/CV) hypothesis. The CD/CV hypothesis cannot explain 
most of the complex diseases, as susceptibility alleles of complex diseases may have appeared 
more recently, and some of the more recent variants also came to be geographically restricted 
because of genetic drift and selective pressure. Therefore, the two studies we presented in the 
second part of this thesis highlight the importance of an approach to identify associations between 
low frequency variants specific to population and a complex disease, such as IA.  
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We also concluded from our studies that it may be beneficial to apply population 
stratification as covariates in large scale whole genome disease studies (e.g. GWAS). Such 
stratification should also be applied in higher resolution, which could be done using variant Site 
Frequency Spectrum (SFS) instead of PCA to avoid not only inflations but also potential false 
negatives brought by non-informative genotype data. New algorithms that introduce population 
specific data in the disease gene discovery may help to answer questions brought up by population 
heterogeneity and stratification.  
Finally, towards the end of this thesis, we explored some new territories to relate the genetic 
susceptibility of IA and other complex traits with the course of human evolution. The risk of 
complex diseases owes to the human genetic diversity, particularly in metabolic (coronary artery 
disease, T2D, Stroke), immunological (TB, malaria, IBD) and neuropsychiatric phenotypes, which 
could be brought by either natural selection, genetic drift or admixture. As discussed above, past 
selective pressures might trigger local adaptations, which in turn might change the functional 
pathways and somehow lead to altered risk predisposition to certain diseases406. Admixture events 
might also be playing a role - a recent study discussed the presence of Neanderthal alleles in the 
contemporary human population and it appears that even small, archaic admixture can influence 
the risk to some diseases (immunology, metabolism, depression and addiction) in modern 
humans407.  
Natural selection signatures have been reported to overlap with many complex diseases 
(e.g. hypertension). Lipid metabolism is also one of the two key pathways that is subjected to 
human evolution, the other being inflammatory response408. Hypertension and inflammatory 
response have been known to affect the vascular wall remodelling of IA, and through evidence of 
atherosclerotic plaque formation in the affected vascular walls recent studies have also highlighted 
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the role of lipid metabolism in the pathogenesis of IA256. There are strong evidences of IA 
coexisting with many types of cardiovascular disorders, which therefore might also subject to 
human adaptive evolution. Thus, it is likely that we may also find new IA susceptible genes in the 
selection signatures of high risk populations, such as Japanese, Finnish, French-Canadians and 
Nunavik Inuit. 
In the future, another important focus of IA genetic study is likely to concern the detection 
of somatic mutations. In one of our early IA experiment, we hypothesized that the pathogenesis of 
IA might be explained by the two-hit hypothesis. However, the analysis of this experiment was 
hindered by technical difficulties, the primary reason being that WES was unfit for detecting 
variants at very low mutation frequency, which we could not distinguish from sequencing artifacts 
at an average coverage of 100X. Some tissues affected by somatic mutations are easier to isolate 
from normal tissue (e.g. carcinoma cells), however the procedure is more difficult with aneurysmal 
lesions. Moreover, there are lack of potential candidate genes to be examined for the presence of 
somatic mutation, without which the current detection level of bioinformatic pipeline cannot 
accurately handle low frequency somatic mutations. 
Considering that localized weakness is a key to aneurysmal formation, it is likely that 
somatic mutations could very well be involved in the pathogenesis of IA. A number of other 
cerebrovascular malformations are caused by the second somatic hit in their risk genes, for instance 
cerebral cavernous malformations (CCM1-3)409, hemangioma and capillary malformations 
(GNAQ)410, venous malformations (PIK3CA)411 and arteriovenous malformations (RASA1)412. 
However, by opposition to those largely congenital cerebrovascular malformations, the 
development of IA can be affected by multiple factors and further investigations are warranted to 
establish whether or not IA is also associated with somatic mutations. Nevertheless, the discovery 
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of new candidate genes (e.g. RNF213) opens avenues for the testing of a somatic mechanism of 
the genes at play in IA.  
Epigenetic modifications might also be another underlying cause leading to the 
development of IA. Studies have shown that in hypertension subjects DNA methylation affects 
genes involved in smooth muscle cell functions and in aortic aneurysm methylation affects genes 
encoding product involved in inflammatory response413. It was also reported that an enrichment of 
methylation profile variabilities is found across genomic signatures of natural selection and 
sometimes such methylation variabilities are linked to nearby genetic variants414. Thus it would be 
interesting to test if epigenetic profiles that are associated with adaptive selections are also at play 
for some of the increased predisposition to complex diseases like IA.  
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4.3: PERSPECTIVES: HUMAN EVOLUTION AND COMPLEX 
DISEASES 
This thesis brought up three major hypothetical theories in addition to the findings described in 
each chapters. With the first hypothesis, we discovered that there seems to be certain genetic and 
phenotypic continuities in the disease phenotypes affecting the same system, in which the 
pathogenicity of variants within the same risk gene may vary according to the population 
background. Other genetic, environmental or epigenetic factors may also be the forces that trigger 
the direction of the mutational effect, thus leading to different outcomes of the diseases or traits. 
That is to say, if population stratifying is not applicable in the genetic study of a complex disease, 
then pooling together similar, overlapping phenotypes of multiple diseases may actually increase 
the power of detection in certain circumstances. Furthermore, mapping interactions involving risk 
genes, population genetic background and environmental factors would represent an important 
step to follow up the gene discovery and it could greatly impact the area of complex diseases 
studies. As more supporting evidence will be gathered regarding the ethnic background of patients 
and their susceptibility to a particular disease, it will provide important guideline for treatment, 
one can envision to achieve a better medical outcome. 
 The following hypothesis highlights the importance of integrating population genetic data 
into the statistical analysis of complex disease. Although currently there is a lack for algorithms 
that taking this into account, we have observed significant accumulation of population specific, 
low frequency variants using WES and SNP-chip datasets and some of these are contributing to 
the IA genetic etiology. Taking advantages of the fast progression of HTS technology and the 
exponentially increasing amount of human genome data, many groups are beginning to report new 
methods to help with the prioritization of mutation intolerant genes and to characterize 
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populations’ variant landscapes. Undoubtedly, such algorithms will represent great additions to 
current bioinformatics pipeline as these will help complex disease studies by highlighting and 
incorporating population specific variants and genes in the progress of disease gene discovery.  
The last hypothesis concerned past adaptive events that might be the roots of many complex 
diseases today. Selection on SNV, CNV or mtDNA represent driving forces that have affected the 
evolution of complex diseases and have led to the increased prevalence of some of these diseases 
in distinct populations by making its individuals more susceptible to them; although changes of 
CNV and mtDNA are thought to be much more drastic and assumed to be under less selective 
stress. Complex diseases to which humans are particularity susceptible (e.g. psychiatric disorders) 
have been suggested to also arise from certain ancient evolutionary events415. Past GWAS 
successfully testified the validity of the CD/CV hypothesis by discovering multiple risk loci based 
on large, multi-ancestry populations. But perhaps a new strategy could be developed in order to 
incorporate population genetic covariates (e.g. selection signals) in association studies, and this 
could fill the gaps left by GWAS and help to discover the missing heritability of some complex 
diseases. Just as admixture mapping has solved many problems in hunting for disease risk genes 
that were brought by the diverse ancestries in an admixed population, we believe a similar model 
that take into account the signals of natural selection could also yield significant results, especially 
in founder populations.   
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CONCLUSION 
This thesis first described the genetic history and adaptive signatures of Nunavik Inuit, it also 
presented studies regarding the genetic susceptibility of IA in Nunavik Inuit and French-Canadian 
founder populations, which stressed the implication of their particular genetic backgrounds. Two 
major genes, RNF213 and CCM2 were discovered to be associated with IA in French-Canadians 
and Inuit, respectively, while both being risk genes for other cerebrovascular malformations in 
distinct populations. These new IA risk genes were revealed using population-based burden test 
that took into account the natural selection of population specific variants in the studied population, 
thus suggesting a new approach for the genetic investigation of complex diseases risk in isolated 
populations. Independently, additional discoveries were made in regard to the Nunavik Inuit 
population, including confirming the isolation and genetic homogeneity of this particular 
indigenous group and the identification of cardiovascular related genes located within the genetic 
signatures linked to their adaptations. This research further showcased the benefits from 
implementing (and sometime integrating) the datasets from HTS and high-density SNP array, this 
approach led to the identification of strong links between population specific variants and disease 
risks.   
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Abstract 
Nunavik Inuit have been challenged by the harsh conditions of the Arctic environment throughout 
their history. Due to the extremely cold weather, the traditional Inuit diet is unusually low in 
carbohydrates and high in animal protein and fat. Identifying the adaptive genetic factors 
associated with this population may provide insight into the health risks they are currently facing. 
In this study, we analyzed genome-wide SNP genotype data of 126 Inuit from the Nunavik region 
(northern Québec, Canada). Results from population structure analyses showed that Nunavik Inuit 
were genetically closest to Siberians living in the far northeastern Siberia, with shared genetic 
components from 42% to 65%. They also shared 25% genetic components with Na-Dene-speaking 
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Chipewyans residing in the northwestern and central Canada.  Selective sweep analyses using iHS 
(integrated haplotype score) and XP-EHH (cross-population extended haplotype homozygosity) 
revealed that genes involved in protein metabolism (SERPING1), lipid metabolism (APOBEC1 
and CLPS) and body temperature regulation (ADRA2A and ESRRG) were located in the strongest 
selected regions. Compared to French Canadians, who live south to the Nunavik Inuit, the 
expression level of SERPING1 in cells from Inuit was significantly reduced. Collectively, our 
study identified the genetic relationship of the Inuit and Siberians, and the genetic factors 
underlying the adaptation of the Inuit to their environment.  
 
Introduction 
Recent studies have found that a minimum of three gene flow events have happened from Siberia 
to the Americas through Bering Strait 1. The first event happened at least 15,000 years ago. After 
they arrived, the majority travelled to the south. The second and third events happened about 4,500 
and 1,000 years ago. They represent the settlement of the Native Americans in the North American 
Arctic. Paleo-Eskimos, who migrated to America during the second event, are genetically close to 
Na-Dene groups currently residing in the northwestern and central Canada1; 25. Paleo-Eskimos are 
not the direct ancestors of the modern Canadian Inuit. Modern Canadian Inuit are likely to be the 
descendants of the Thule people from Neo-Eskimo lineage, who came during the third migration 
event and replaced Paleo-Eskimos 700 years ago9. 
Currently, the Inuit represent approximately 89% of the inhabitants of the Nunavik region. 
Throughout their history, Nunavik Inuit have been challenged by the harsh conditions of the Arctic 
environment. Based on the data from Environment Canada (1981 to 2010)416, in January and 
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February, the average daily mean temperature of Kuujjuaq, the administrative centre of Nunavik, 
was -25 °C, with wind chill commonly below -40 °C at night. As the extremely cold weather makes 
it impossible to cultivate plants, Nunavik Inuit are skilled fishermen and hunters of caribou and 
large marine mammals including seals and walrus. The traditional Inuit diet is unusually low in 
carbohydrates and high in animal protein and fat417. Nonetheless, several studies conducted in 
Greenland and Canada have reported that the age-adjusted mortality due to cardiovascular diseases 
of the Inuit was lower than that of the non-Inuit populations418; 419, although the results were not 
replicated by other studies420; 421. Recently, the lifestyle of the Inuit has substantially changed with 
a decrease of physical activity and an increased consumption of Western food, which results in a 
dramatic increase in the prevalence of obesity, type 2 diabetes, and cardiovascular diseases2.  
How the Inuit genetically adapt to the cold environment and high protein and lipid diet 
remains largely unknown. A nonsynonymous variant in CPT1A (rs80356779) was previously 
suggested to be the target of a strong selective sweep in the Northeast Siberian populations40. 
CPT1A encodes a key enzyme in the carnitine-dependent transport across the mitochondrial inner 
membrane during long-chain fatty acids metabolism. We have also observed that the derived allele 
frequency of rs80356779 was very high in Nunavik Inuit (96%)49. It is possible that this allele is 
strongly selected in the Arctic populations, in part because of its association with increased serum 
high-density lipoprotein and thus protective effect of cardiovascular diseases304; 305. Recently, 
Fumagalli et al. identified a cluster of three fatty acid desaturase genes (FADS1, FADS2 and 
FADS3) to be strongly selected in Greenlandic Inuit29. The FADS gene cluster may have effects 
on metabolic phenotypes, as well as height and weight.  
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In this study, we analyzed genome-wide SNP genotype data of 126 Inuit from Nunavik, 
Québec. For the 112 Inuit without evidence of mixed ethnicity, we performed population structure 
analyses and compared them with Native American and Siberian populations from Reich et al.1. 
Selection analyses identified that genes involved in protein metabolism (SERPING1), lipid 
metabolism (APOBEC1 and CLPS) and body temperature regulation (ADRA2A and ESRRG) were 
located in the strongest selected regions. While the expression of these genes is regulated by 
physiological conditions and cell types, we found that the expression of SERPING1 in cells from 
the Inuit was half of what is observed in the French Canadian population.  
Results 
Population structure analyses 
In this study, we genotyped DNA samples of 126 Nunavik Inuit using Illumina 
HumanOmniExpress-12v1 platform containing 730,525 SNPs. After quality control steps, 112 
Inuit without evidence of mixed ethnicity were left for further analyses. We first performed 
principle component analysis (PCA) of the 112 Nunavik Inuit, and Native Americans and 
Siberians without evidence of recent admixture of other ethnicities from the study of Reich et al.1. 
Unrelated individuals of CEU (Utah Residents with Northern and Western European Ancestry) 
and CHB (Han Chinese in Beijing, China) from HapMap phase 3 were used as reference 
populations. The first principal component (PC1) explained 33% of the variance in the data, 
separating Native American (including Nunavik Inuit) and Siberian populations from CEU and 
CHB. PC2 explained 20% of the variance, separating Nunavik Inuit from the other Native 
American and Siberian populations. Nunavik Inuit were genetically closest to Siberians, and they 
were quite distinct from the other Native American populations (Fig. 1A).  
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Admixture analysis was used to further explore the genetic relationships between Nunavik 
Inuit and indigenous peoples of the Americas and Siberia. At K=5 (Fig. 1B), Nunavik Inuit shares 
65% genetic components with Eskimo-Aleut-speaking Naukans, as well as 42% genetic 
components with Chukchi-Kamchatkan-speaking Chukchi and Koryaks. All three populations are 
indigenous inhabitants of the far northeastern Siberia. We also observed that Nunavik Inuit share 
25% genetic components with the Na-Dene-speaking Chipewyans residing in the northwestern 
and central Canada. Nunavik Inuit shared very few (< 8%) genetic components with the other 
Native American populations. 
Selection analysis 
To identify genomic regions under positive selection, we performed iHS (integrated haplotype 
score) and XP-EHH (cross-population extended haplotype homozygosity) analyses of genome-
wide SNP genotype data of 39 unrelated Nunavik Inuit. A total of 12,649 and 12,773 windows, 
each with 200 kb region, were in the iHS and XP-EHH analysis, respectively. iHS analysis is most 
powerful to detect selective sweeps with moderate frequency, while XP-EHH has maximum power 
to detect close to fixed selective sweeps422.  
Gene ontology (GO) enrichment analysis of the 208 genes located in the top 1% iHS 
windows revealed significant enrichment of GO term “cellular senescence” (P=0.0076). Six of the 
208 genes are known to encode proteins regulating cell cycle and/or apoptosis under cellular stress 
(OPA1, SRF, MAPK14, ID2, ARNTL, and SMC6). For the 268 genes located in the top 1% XP-
EHH windows, GO enrichment analysis revealed significant enrichment of GO terms related to 
sensory perception of smell due to overrepresentation of olfactory receptor genes (P=9.2 × 10−6). 
Olfactory receptor gene family contains more than 400 genes with a large number of genetic 
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polymorphisms423; 424. The significant GO term may reflect high genetic diversity and positive 
selection of certain olfactory receptor genes in Nunavik Inuit. 
To focus on the most strongly selected genes, we further examined the genes located in the 
top 10 ranking 200-kb-windows in the iHS and XP-EHH analyses (Table 1). Forty-nine genes 
mapped to these windows. We extensively explored the functions of these genes in the published 
literatures. Because of the unique living environment and diet habit of Nunavik Inuit, we focused 
on genes involved in lipid and protein metabolisms, as well as body temperature regulation.  
Two genes involved in lipid metabolism were strongly selected. APOBEC1 was very close 
to (2.0 kb downstream) the 1st ranking iHS window chr12:7.6-7.8 Mb, and it was fully covered by 
the positively selected haplotype. The protein product of APOBEC1 is a catalytic subunit of an 
apolipoprotein B (apoB) mRNA editing enzyme complex. In human small intestine cells, apoB 
mRNA editing enzyme converts mRNA of apoB-100 into apoB-48 by introducing a stop codon425. 
Intestinal apoB-48 is crucial in chylomicron assembly during fat absorption426. The second gene 
involved in lipid metabolism was CLPS. Although it was 34.9 kb upstream of the 8th ranking iHS 
window (chr6:35.8-36.0 Mb), CLPS was completely covered by the positively selected long-range 
haplotype in this region. CLPS is a small gene encoding pancreatic colipase preproprotein in 
exocrine pancreatic cells. In small intestine, trypsin splits colipase preproprotein into enterostatin 
and colipase. Enterostatin reduces the serum cholesterol level in mice on a high cholesterol diet427. 
Colipase is a cofactor of pancreatic lipase. It increases the efficiency of lipid hydrolysis by 
stabilizing the active conformation of lipase428.  
One gene involved in protein metabolism, SERPING1, was located in the 7th ranking iHS 
window (chr11:57.2-57.4 Mb). SERPING1 encodes C1 serine protease inhibitor which inactivates 
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C1r, C1s, kallikrein, and factor XII in the complement system and blood coagulation cascade429. 
It also inhibits chymotrypsin430, which catalyzes the hydrolysis of proteins in human small 
intestine.  
Two genes regulating body temperature, namely ADRA2A and ESRRG were located in the 
4th ranking XP-EHH window (chr10:112.8-113.0 Mb) and the 9th ranking iHS window 
(chr1:216.8-217.0 Mb), respectively. ADRA2A encodes the α2-adrenergic receptor, which 
regulates brown adipose tissue thermogenesis431. Its agonists, such as clonidine and xylazine, lead 
to dose-dependent hypothermia432. In human subcutaneous white adipose tissue, sympathetic 
nervous system activation inhibits lipolysis through α2-adrenergic receptor signalling pathway to 
maintain fat pads433; 434, which is important in cold exposure435. ESRRG encodes the orphan nuclear 
receptor estrogen-related receptor γ (ERRγ). Overexpression of ERRγ stimulates nonshivering 
thermogenesis in brown adipocytes through upregulating uncoupling protein 1 (UCP1) and 
oxidative genes expression levels436; 437. 
Gene expression analyses of genes mapping in the top 10 iHS and XP-EHH windows 
We investigated the expression levels of 29 of the 49 genes located in the top 10 iHS and XP-EHH 
windows, as well as APOBEC1 and CLPS in 14 unrelated Nunavik Inuit and 15 unrelated French 
Canadians using RT-qPCR of EBV-transformed lymphoblastoid cell lines. In windows with more 
than one gene, those covered by the strongest selection signals were tested. Eighteen of the 31 
genes were found to yield high quality RT-qPCR results (Table 2). Most genes encoding products 
involved in metabolism and body temperature regulation, including APOBEC1, ADRA2A, and 
ESRRG, are not expressed in lymphocytes438, and thus their expression levels could not be 
evaluated. Compared to French Canadians, SERPING1 was found to have significantly reduced 
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expression in Inuit. The expression ratio (Nunavik Inuit / French Canadians) of SERPING1 was 
0.57 (P=0.05, Fig. 2).  
Identification of coding variants in the top 10 iHS and XP-EHH windows 
Among the 112 Inuit without evidence of mixed ethnicity or poor DNA quality, we performed 
exome sequencing in 104 of them. To identify functional variants that were likely to be the targets 
of selection sweeps, we searched for variants located in the exons and the splicing sites (≤ 6 bp 
away from an exon) of the 49 genes mapping to the top 10 iHS and XP-EHH windows in 104 
Nunavik Inuit. We also searched for variants in APOBEC1 and CLPS. A total of 39 qualified 
variants were identified in the top 10 iHS windows, and another 45 variants in the top 10 XP-EHH 
windows. Three of the 84 variants had allele frequencies ≥ 30% in Nunavik Inuit, and ≤ 10% in 
ExAC database (Table 3). However, only one of them was nonsynonymous (rs41265137). This 
variant is located in SCN3A which encodes a subunit of voltage-gated sodium channels. The minor 
allele frequency of rs41265137 was 42% in Inuit and 1.9% in ExAC database (P < 0.0001, Chi-
square test).  
Strong selection sweeps in chromosome 11q 
Recently, Cardona et al. investigated genome-wide SNP genotype data of northeast Siberian 
populations and observed positive selection signals in chr11:66-69 Mb, which contains 79 protein-
coding genes39. Further analysis of the sequence data of this region suggested that the 
nonsynonymous variant rs80356779 located in CPT1A may be the target for this strong selective 
sweep40. We have previously reported that the derived allele frequency of rs80356779 was 96% in 
our Inuit subjects49, which is higher than that observed in northeast Siberian population (68%)40. 
However, in this study, our analyses based on extended haplotype homozygosity failed to identify 
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any positive selections in or around CPT1A, which is located in window chr11:68.4-68.6 Mb. In 
XP-EHH analysis, we observed selective signals in chr11:67.4-67.8 Mb, which ranked 16th 
genome-wide. This same region was the 1st ranking window in XP-EHH analysis in northeast 
Siberian populations in the study of Cardona et al.39. In our study, the genes with the strongest 
selection signal in chr11:67.4-67.8 Mb were ALDH3B1 and ALDH3B2, both of which encode 
aldehyde dehydrogenase. Aldehyde dehydrogenase protects the cells from the lipid peroxidation-
derived aldehydes including trans-2-octenal, 4-Hydroxynonenal, hexanal, H2O2 and menadione
439. 
In addition, we found two nonsynonymous variants in ALDH3B2 that were enriched in the Inuit 
(chr11:67431974_C>T and chr11:67432821_C>T). They had extremely low minor allele 
frequencies in ExAC database (0.9% and 0.008%), while their frequencies in the Inuit were both 
33% (P < 0.0001 for both variants, Chi-square test). 
 
Discussion 
In this study, we investigated genome-wide SNP genotype data of 112 Nunavik Inuit without 
evidence of mixed ethnicity. Population structure analyses showed that Nunavik Inuit shared 42-
65% genetic components with the indigenous peoples living in the far northeastern Siberia. They 
also shared 25% genetic components with the Na-Dene-speaking Chipewyans residing in the 
northwestern and central Canada, which may reflect a genetic admixture between Paleo-
Eskimos/Na-Dene and Neo-Eskimos. Nunavik Inuit shared very few genetic components (< 8%) 
with the other Native American populations living in the United States and South America, which 
was consistent with previous studies1; 9; 25.  
Selection tests in Nunavik Inuit identified that genes involved in protein metabolism 
(SERPING1), lipid metabolism (APOBEC1 and CLPS) and body temperature regulation (ADRA2A 
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and ESRRG) were located in the top 10 most selected 200-kb-windows in the iHS and XP-EHH 
analyses. C1 serine protease inhibitor encoded by SERPING1 inhibits chymotrypsin. The reduced 
level of SERPING1 observed in Inuit cell lines, if it also occurs in the duodenum, would allow 
more activated chymotrypsin for protein hydrolysis during a high-protein traditional Inuit diet. In 
terms of fat digestion, both genes have well established roles in lipid metabolism. The product of 
APOBEC1 truncates apoB-100 to form apoB-48 in small intestine cells. ApoB-48 assembles 
chylomicrons, which transport fat from the intestine to liver during fat absorption. Apobec1–/– mice 
had defective transport of triacylglycerol from intestinal mucosa to lymph after a high-fat diet440. 
CLPS encodes two proteins, enterostatin and colipase. Enterostatin induces early satiety to prevent 
overconsumption of fat441 and reduces serum cholesterol level427. Colipase increases the efficiency 
of lipid hydrolysis. Compared to wild type mice, Clps–/– mice had deceased body fat, impaired fat 
absorption, elevated cholesterol and reduced triglycerides442. The two genes regulating 
thermogenesis, ADRA2A and ESRRG, play important roles in preventing hypothermia. Both of 
them have been shown to regulate nonshivering thermogenesis in brown adipocytes431; 436; 437. In 
human subcutaneous adipocytes, when sympathetic nervous system is activated by cold exposure, 
subcutaneous fat pads can be maintained through α2- adrenergic receptor signalling pathway433-
435. Increased nonshivering thermogenesis and preservation of the subcutaneous fat would give the 
Inuit survival advantages to live in the artic environment. 
Gene expression analysis of EBV-transformed Inuit and French Canadians lymphoblastoid 
cell lines found that the expression of SERPING1 was reduced by almost 50% in Nunavik Inuit. 
For CLPS, based on the results from the genotype-tissue expression (GTEx) project, the expression 
level of CLPS was 2.5 × 104 times higher in pancreas than in EBV-transformed lymphoblastoid 
cell line438. Therefore, although the expression patterns in cell lines were similar between Inuit and 
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French Canadians, a small change in gene expression in cell lines might reflect a large difference 
in the exocrine pancreatic cells. Only by examining pancreas tissues would we be able to 
confidently compare the expression pattern of CLPS between the Inuit and non-Inuit populations. 
According to the GTEx Consortium database438, APOBEC1 is only expressed in small intestine 
(terminal ileum), ADRA2A is largely expressed in adipose tissues, and ESRRG is expressed in 
multiple tissues including brain and heart. However, none of them are expressed in EBV-
transformed lymphoblastoid cell lines, so we were unable to measure their expression levels in the 
Inuit.  
Recently, Fumagalli et al.29 studied Greenlandic Inuit and identified strong positive 
selection signals in a cluster of three fatty acid desaturase genes (FADS1, FADS2 and FADS3) 
located in chr11:61.4-61.6 Mb. We did not observe any selective signals in or around this region 
in Nunavik Inuit. It is important to point out that the methodology of our study and Fumagalli et 
al.29 were different. We used unbiased genome-wide SNP genotype data (730,525 SNPs) and 
selection analyses based on extended haplotype homozygosity. In Fumagalli et al.29, genotype data 
was generated using Illumina MetaboChip, which contains 196,725 SNPs from GWAS studies 
associated with atherosclerotic and cardiovascular disease traits. In addition, their selective sweep 
results were from population branch statistics (PBS), a test based on SNP frequency differences 
rather than haplotype homozygosity. Therefore, our results are not comparable with those from 
Fumagalli et al.29. 
We searched for functional variants that were likely to be the targets of selection sweeps 
in the top 10 iHS and XP-EHH windows. By examining the exons and the splicing sites of genes 
located in the windows, we only observed one nonsynonymous variant (rs41265137) in SCN3A 
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that had allele frequencies ≥ 30% in Nunavik Inuit and ≤ 10% in ExAC database. Due to the 
moderate allele frequency, we could not conclude that rs41265137 was the target of the selective 
sweep in this region. Because this study only investigated SNP genotype data, an important 
direction for future work will be to analyze exome sequencing or even genome sequencing data to 
identify variants that are strongly selected in the Inuit.   
 
Materials and Methods 
Subjects 
We recruited 126 Inuit from thirteen villages of Nunavik, Québec, Canada. All participants were 
self-reported as Inuit. Written informed consent was obtained from all participants. The study was 
approved by University Ethics Committee and the Nunavik Nutrition and Health Committee. 
SNP genotyping and quality control 
DNA was extracted from whole blood samples and genotyped on two 96-well plates of Illumina 
HumanOmniExpress-12v1 platform containing 730,525 SNPs at the McGill University and 
Génome Québec Innovation Centre. SNP genotypes were called using the genotyping module in 
the GenomeStudio software (Illumina). Quality control steps were performed using PLINK293. We 
filtered out SNPs a) located on non-autosomes, b) having call rate < 96%, c) having plate bias P < 
10-5, c) lacking ancestral allele information in the dbSNP database. In the end, a total of 697,804 
SNPs were kept for analysis.  
For the quality control steps, we first used PLINK to identify and remove five samples with 
ambiguous sex. To identify Inuit of mixed ethnicity, we merged genotype data of Nunavik Inuit 
and unrelated individuals of CEU, JPT-CHB and YRI from HapMap phase 3. SNPs with one allele 
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of A and the other allele of T, and SNPs with one allele of C and the other allele of G were removed 
before merging, because it was impossible to know whether the two sets of SNPs were concordant 
in terms of positive or negative strand, as they were genotyped on different chips. Then we pruned 
a set of 50,848 unrelated SNPs with r2 < 0.1 within a 50-SNP sliding window, and performed 
multidimensional scaling (MDS) analysis using PLINK293. Ten individuals (one was also 
identified to have ambiguous sex) had mixed ethnicity of Caucasians and Inuit. ADMIXTURE 
analysis231 using the same data confirmed the results. After deleting DNA samples with ambiguous 
sex and mixed ethnicity, 112 Nunavik Inuit were left, all of whom had < 4.5% mixture from other 
ethnicity (0.7% on average). All samples had call rate > 99%.  
Next we calculated genome-wide alleles shared identical-by-descent (IBD) and PI_HAT 
by PLINK to exclude Nunavik Inuit who were closely related. We randomly removed one member 
of a pair of Inuit if the PI_HAT value was greater than 0.18, which is between the second 
(PI_HAT=0.25) and the third degree relative (PI_HAT=0.125). After the above quality control 
steps, 39 unrelated Inuit were left for selection analyses. 
Population structure analyses 
We requested access to the genome-wide genotype data of 52 Native American and 17 Siberian 
groups from the study of Reich et al.1. Two hundred and ten Native Americans and Siberians with 
no evidence of recent admixture with other ethnicities were included in the population structure 
analyses with the data of 112 Nunavik Inuit who had no evidence of mixed ethnicity. Due to the 
limited number of individuals in each Native American and Siberian population from Reich et al.1, 
we grouped them into nine linguistic families based on the original study using Greenberg’s 
classification1, namely, Andean (n=6), Central-Amerind (n=21), Chibchan-Paezan (n=47), 
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Chukchi-Kamchatkan (n=31), Equatorial-Tucanoan (n=66), Eskimo-Aleut (n=19), Ge-Pano-Carib 
(n=7), Na-Dene (n=2), and Northern-Amerind (n=11). Among the 50,848 unrelated SNPs from 
the above MDS analysis, 32,204 of them were also genotyped by Reich et al.1 which were 
extracted for principal component analysis (PCA). PCA was conducted using the Eigensoft 
package274; 329 to identify population structure of Nunavik Inuit, Native Americans, and Siberian 
populations. Unrelated individuals of CEU (n=106) and CHB (n=80) from HapMap phase 3 were 
used as reference populations. The same set of SNPs were also analyzed using ADMIXTURE231 
to estimate genome-wide admixture pattern of Nunavik Inuit compared to the nine linguistic 
families of Native Americans and Siberians.  
Selective sweep analyses 
We phased the 697,804 SNPs of the 39 unrelated Inuit using Beagle 4.0275, where phased 1000 
Genomes Project phase 3 data was used as the reference panel. The ancestral state of each SNP 
was retrieved from dbSNP human Build 142. The iHS (integrated haplotype score)443 was 
calculated using an R package rehh444. iHS scores were normalized based on allele frequencies 
using the same R package. The iHS test result was ranked by the fraction of SNPs in each 200 kb 
window with the absolute value of iHS > 2. After excluding windows with less than five SNPs, a 
total of 12,649 windows were kept in the results of the iHS analysis.  
For the XP-EHH (cross-population extended haplotype homozygosity) analysis445, we used 
85 unrelated CHB individuals from 1000 Genomes Project phase 3 as the reference population. 
XP-EHH analysis was done using the same method described in Pickrell et al.422 
(http://hgdp.uchicago.edu/Software/). XP-EHH scores were normalized with mean of 0 and 
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standard deviation of 1. A total of 12,773 windows each with 200 kb region were in the analysis. 
Results were ranked by the highest normalized XP-EHH score in each 200 kb region.  
Genes located in top 1% iHS and XP-EHH windows were retrieved based on consensus 
coding sequence (CCDS) release 19. Gene ontology (GO) enrichment analysis was performed 
using the tool provided by Gene Ontology Consortium (http://geneontology.org/). 
Gene expression analysis by real-time quantitative reverse transcription-PCR (RT-qPCR) 
We tested the expression levels of 31 genes located in the top 10 iHS and XP-EHH windows in 
EBV-transformed lymphoblastoid cell lines of 14 unrelated Nunavik Inuit and 15 unrelated French 
Canadians. In windows with more than one genes, those with the highest selection signals were 
tested. cDNA was generated from RNA extractions prepared from lymphoblastoid cell lines using 
the SuperScript VILO cDNA Synthesis Kit (Invitrogen). RT-qPCR was performed using the 
TaqMan Gene Expression Assay on QuantStudio 7 Flex Real-Time PCR System (Applied 
Biosystems). Three independent RNA extractions and RT-qPCR experiments were done for all 29 
lymphoblastoid cell lines. In every RT-qPCR experiment, the same cDNA sample was tested in 
triplicate.  
Next, gene expression levels were normalized to the RNA polymerase II polypeptide A 
gene (POLR2A). For each gene, ∆Ct values of 14 Nunavik Inuit were compared with those of 15 
French Canadians by Bayesian analysis with Markov Chain Monte Carlo (MCMC) using R 
package rjags (http://www-ice.iarc.fr/~martyn/software/jags/). MCMC simulation allows the data 
and its variability to generate sampling distributions of the maximum likelihood estimator without 
strong prior or test assumptions. P values were calculated from 100,000 comparisons of this 
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estimator between Nunavik Inuit and French Canadians. Expression ratio of each gene was 
calculated using the Livak method (ΔΔCt)276. 
Exome sequencing and identification of selected variants in the top 10 iHS and XP-EHH windows 
Among the 112 Inuit who had no evidence of mixed ethnicity or poor DNA quality, we performed 
exome sequencing for 104 of them. The detailed methods have been described before49. In short, 
all DNA samples were captured by Agilent SureSelect 50 Mb (V4) chip and sequenced on the 
Illumina Hiseq 2000. Three samples were barcoded to be sequenced in one lane to ensure an 
average coverage depth of 100 fold. Raw sequence reads were aligned to GRCh37 using Burrow-
Wheeler Aligner288 and variants were called by Genome Analysis Toolkit using standard 
methods267. ANNOVAR289 was used to perform variant annotation.  
We searched for variants located in the exons and the splicing sites (≤ 6 bp away from an 
exon) of genes covered by the top 10 iHS and XP-EHH windows. Quality filters were set at 
sequencing depth ≥ 20x and variant frequency ≥ 25%, with genotype quality ≥ 10. Allele 
frequencies of the variants observed in the 104 Inuit subjects were compared with those found in 
~60,000 individuals of Exome Aggregation Consortium (ExAC, release 0.2). To identify coding 
variants that were positively selected in the Inuit, we focused on variants with allele frequencies ≥ 
30% in Nunavik Inuit subjects, and ≤ 10% in ExAC database. All qualified variants were manual 
inspected using the Integrative Genomics Viewer (IGV)292.   
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Fig. 1: Principal component analysis (A) and Admixture analysis (K=5, B) of 112 Nunavik Inuit 
who had no evidence of admixture, and 210 Native Americans and Siberians with no evidence of 
recent admixture with other ethnicities from the study of Reich et al. Native Americans and 
Siberians were grouped into nine linguistic families based on Reich et al. using Greenberg’s 
classification. (Andean: Aymara, Quechua and Yaghan; Central-Amerind: Pima, Tepehuano and 
Zapotec; CEU: Utah residents with Northern and Western European ancestry; CHB: Han Chinese 
in Beijing; Chibchan-Paezan: Bribri, Cabecar, Embera, Guaymi, Maleku, Teribe and Waunana; 
Chukchi-Kamchatkan: Chukchi and Koryak; Equatorial-Tucanoan: Chane, Guahibo, Guarani, 
Jamamadi, Karitiana, Palikur, Parakana, Piapoco, Surui, Ticuna and Wayuu; Eskimo-Aleut: 
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Naukan; Ge-Pano-Carib: Arara, Toba and Wichi; Na-Dene: Chipewyan; Northern-Amerind: 
Kaqchikel, Maya and Mixe.) 
 
 
Fig. 2: RT-qPCR experiments identified that the expression ratio (Nunavik Inuit / French 
Canadians) of SERPING1 was 0.57 (P=0.05). Three independent RNA extractions of EBV-
transformed lymphoblastoid cell lines (14 unrelated Nunavik Inuit and 15 unrelated French 
Canadians) and RT-qPCR experiments were performed. 
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Table 1: Top 10 iHS and XP-EHH windows in Nunavik Inuit, and protein-coding genes that map 
in the respective window. 
Rank  Window (hg 19), Mb Genes 
iHS 
1 chr2:24.4-24.6 FAM228A, ITSN2 
1 chr2:72.4-72.6 EXOC6B 
1 chr4:47.8-48.0 CORIN, NFXL1, CNGA1 
1 chr5:42.0-42.2 
 
1 chr10:94.6-94.8 EXOC6 
1 chr12:7.6-7.8 CD163 
7 chr11:57.2-57.4 RTN4RL2, SLC43A1, TIMM10, UBE2L6, SERPING1 
8 chr6:35.8-36.0 SRPK1, SLC26A8, MAPK14 
9 chr1:216.8-217.0 ESRRG 
10 chr14:60.8-61.0 C14orf39, SIX6 
XP-EHH 
1 chr12:56.2-56.4 ORMDL2, DNAJC14, MMP19, WIBG, DGKA, PMEL, CDK2, RAB5B, 
SUOX 
2 chr12:56.0-56.2 OR10P1, METTL7B, ITGA7, BLOC1S1, RDH5, CD63, GDF11, SARNP 
3 chr4:18.6-18.8 
 
4 chr10:112.8-113 ADRA2A 
5 chr13:53.2-53.4 HNRNPA1L2, SUGT1, LECT1 
6 chr2:166.0-166.2 SCN3A, SCN2A 
7 chr15:58.0-58.2 GCOM1, POLR2M 
8 chr20:21.0-21.2 
 
9 chr11:14.2-14.4 SPON1, RRAS2 
10 chr19:54.2-54.4 NLRP12, MYADM, PRKCG 
 
  
 194 
 
Table 2: RT-qPCR results of 29 out of 49 genes mapping in the top 10 iHS and XP-EHH windows, 
as well as APOBEC1 and CLPS. In windows with more than one genes, those with the highest 
selection signals were tested. Three independent RNA extractions and RT-qPCR experiments were 
done for EBV-transformed lymphoblastoid cell lines of 14 unrelated Nunavik Inuit and 15 
unrelated French Canadians. Eighteen of the 31 genes had high quality RT-qPCR results. 
Expression ratio (RQ) with P < 0.05 were highlighted in bold.   
Gene Position (hg19) Rank of 
genomic 
window 
RQ_1 RQ_2 RQ_3 RQ 
mean 
FAM228A chr2:24397972-24414567 iHS_1 NA NA NA NA 
ITSN2 chr2:24425735-24583397 iHS_1 0.84 0.8 0.95 0.86 
EXOC6B chr2:72406444-73053177 iHS_1 0.8 0.67 0.83 0.77 
CORIN chr4:47596018-47840059 iHS_1 NA NA NA NA 
NFXL1 chr4:47849258-47916633 iHS_1 0.98 1.02 0.8 0.93 
EXOC6 chr10:94608225-94819251 iHS_1 0.8 0.92 0.87 0.86 
CD163 chr12:7623412-7656414 iHS_1 NA NA NA NA 
APOBEC1 chr12:7801996-7818502 iHS_1 NA NA NA NA 
RTN4RL2 chr11:57228339-57244384 iHS_7 NA NA NA NA 
SLC43A1 chr11:57252004-57282358 iHS_7 1.18 0.95 1.21 1.11 
TIMM10 chr11:57295936-57298232 iHS_7 1.17 0.95 1.02 1.05 
UBE2L6 chr11:57319128-57335180 iHS_7 0.96 0.78 1.11 0.95 
SERPING1 chr11:57365027-57382326 iHS_7 0.53 0.62 0.55 0.57 
CLPS chr6:35762759-35765121 iHS_8 0.88 0.66 0.74 0.76 
SRPK1 chr6:35800811-35888957 iHS_8 1.1 0.89 1.11 1.03 
SLC26A8 chr6:35911291-35992305 iHS_8 NA NA NA NA 
MAPK14 chr6:35995454-36079013 iHS_8 1.05 0.77 1.04 0.95 
ESRRG chr1:216676588-216896814 iHS_9 NA NA NA NA 
C14orf39 chr14:60902674-60952764 iHS_10 NA NA NA NA 
SIX6 chr14:60975938-60978525 iHS_10 NA NA NA NA 
ORMDL2 chr12:56211806-56214959 XP-EHH_1 1.55 0.95 1.1 1.2 
DNAJC14 chr12:56214744-56223420 XP-EHH_1 0.97 0.87 0.94 0.93 
MMP19 chr12:56229214-56236767 XP-EHH_1 0.92 0.94 0.71 0.86 
SARNP chr12:56146247-56211540 XP-EHH_2 1.07 0.93 1.13 1.04 
 195 
 
ADRA2A chr10:112836790-112840662 XP-EHH_4 NA NA NA NA 
LECT1 chr13:53277400-53313947 XP-EHH_5 NA NA NA NA 
SCN3A chr2:165944030-166060577 XP-EHH_6 1.59 1.5 1.44 1.51 
POLR2M chr15:57998901-58001556 XP-EHH_7 1.14 0.85 0.99 0.99 
SPON1 chr11:13984184-14289679 XP-EHH_9 NA NA NA NA 
RRAS2 chr11:14299466-14380730 XP-EHH_9 1.11 0.65 0.83 0.86 
NLRP12 chr19:54296855-54327657 XP-EHH_10 NA NA NA NA 
 
 
 
Table 3: Coding variants of 49 genes located in the top 10 iHS and XP-EHH windows, as well as 
those in APOBEC1 and CLPS were investigated in 104 Nunavik Inuit using exome sequencing 
method. Three variants were found to have allele frequencies ≥ 30% in Nunavik Inuit, and ≤ 10% 
in Exome Aggregation Consortium (ExAC, release 0.2) database. 
Position (hg19) Variant dbSNP Gene Variant Function Inuit  Allele 
Frequency 
ExAC 
Frequency 
chr11:57268808 G>T rs150660444 SLC43A1 intronic_splicing 0.67 0.012 
chr2:165947079 C>A rs41265137 SCN3A nonsynonymous 0.42 0.019 
chr19:54403925 T>C rs2242244 PRKCG synonymous 0.38 0 
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Appendix 2: Supplemental material for Chapter 2.2 
Supplemental Figures 
Figure S1: PCA result showing all populations included in the structural analysis. 
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Figure S2: Genome-wide local ancestry of Arctic indigenous populations (blue: Inuit ancestry; 
red: European ancestry; green: Native American ancestry). 
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Figure S3: Nunavik Villages and sample recruitment (figure adapted from 
http://www.inuitfirstcanadians.com/)  
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Supplementary tables 
 
Table S1: Study populations and controls 
 
Array based 
(no.populations) 
WGS / WES (no.populations) 
[Ancient name] 
Nunavik Inuit (current study) 170 (10) 114 (10) 
Siberians (Cardona, 2014; 
Clemente, 2014) 
218 (10)  25 (3) 
Native Americans / Siberians 
(Reich, 2012) 
2351 (66) NA 
Sakha-Siberians (Fedorova, 
2013) 
40 (9) NA 
Caucasus (Yunusbayev, 2012) 204 (13) NA 
Turkic (Yunusbayev, 2015) 322 (32) NA 
Siberia-New World (Rasmussen, 
2010) 
188 (14) 1 [Saqqaq] 
Altai regions (Raghavan, 2014) 85 (9) 1 [Mal’ta] 
Siberians (Raghavan, 2015) 20 (5) 9 current + 23 ancient 
1000 Genome phase III NA 2504 (26) 
Ancient America (Rasmussen, 
2014) 
NA 1 [Clovis] 
Ancient New World Arctic 
(Raghavan, 2014) 
NA 34 (5) 
Ancient Altai (Allentoft, 2015) NA 5 
Ancient America (Rasmussen, 
2015) 
NA 1 [Kennewick] 
TOTAL 5422 (197) 
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Table S2: 132 variants from PBS analysis met the empirical threshold of 99.9th. 
chrom pos rs MAF.Inuit MAF.CEU MAF.CHB PBS gene function 
11 68548130 rs80356779 0.956731 0.000505 0.000485 3.111911 CPT1A missense 
15 48426484 rs1426654 0.000481 1 0.029126 2.062288 SLC24A5 missense 
3 12574298 rs735640 0.830097 0.000505 0.00049 1.756087 TSEN2 3-prime-
UTR 
16 89661807 rs12445560 0.947115 0.09596 0.126214 1.744347 CPNE7 synonymous 
7 1.28E+08 rs72624969 0.975962 0.070707 0.286408 1.650973 IMPDH1 intron 
7 1.28E+08 rs4731447 0.975962 0.076531 0.276699 1.648679 IMPDH1 intron 
16 89662837 rs12447806 0.985149 0.111111 0.252427 1.634635 CPNE7 intron 
16 89656162 rs139901937 0.802885 0.000505 0.000485 1.606432 CPNE7 intron 
7 1.28E+08 rs2288553 0.966346 0.075758 0.281553 1.564838 IMPDH1 intron 
12 56743044 rs2066815 0.793269 0.000505 0.009709 1.525998 STAT2 missense-
near-splice 
20 13550127 rs11697393 0.830097 0.020202 0.048544 1.524275 TASP1 intron 
8 1.44E+08 rs5280 0.961538 0.015152 0.441748 1.521063 none upstream-
gene 
16 89971316 rs140032244 0.802885 0.000505 0.024272 1.519637 TCF25 intron 
8 1.44E+08 rs4534 0.961538 0.015152 0.446602 1.511838 CYP11B1 missense 
16 90130139 rs4264393 0.805825 0.000602 0.007143 1.504595 PRDM7 missense 
20 13514603 rs6033751 0.831731 0.020202 0.058252 1.499884 TASP1 intron 
20 13463855 rs2273479 0.831731 0.015152 0.063107 1.498412 TASP1 intron 
22 42276742 rs2228314 0.995192 0.252525 0.194175 1.48112 SREBF2 missense 
19 55418054 rs2278428 0.956731 0.065657 0.320388 1.45223 NCR1 missense 
15 78191608 rs58169519 0.870192 0.030303 0.135922 1.451833 none intergenic 
4 47578971 rs16851681 0.980769 0.232323 0.194175 1.433606 ATP10D missense 
16 89760474 rs12595968 0.947115 0.065657 0.31068 1.405871 CDK10 intron 
16 89702620 rs2070992 0.947115 0.107143 0.257282 1.393311 DPEP1 intron 
19 55417731 rs2278427 0.956731 0.080808 0.325243 1.391171 NCR1 intron 
3 12858557 rs180768267 0.788462 0.000556 0.021739 1.389524 CAND2 missense 
16 88909095 rs35137494 0.879808 0.156566 0.058252 1.379805 GALNS intron 
4 47548431 rs12498466 0.960784 0.206522 0.195 1.377129 ATP10D intron 
4 48566843 rs79352370 0.911458 0.084337 0.209677 1.377057 FRYL intron 
2 1.1E+08 rs3827760 0.004808 1 0.067961 1.348744 EDAR missense 
3 12641425 rs5746223 0.826733 0.09596 0.033981 1.344314 RAF1 intron 
16 89294595 rs74466939 0.908654 0.050505 0.252427 1.338114 ZNF778 synonymous 
16 89663072 rs659974 0.004808 0.858586 0.592233 1.315908 CPNE7 3-prime-
UTR 
13 53049267 rs34494025 0.740385 0.010101 0.000485 1.30311 CKAP2 synonymous 
 201 
 
2 1.34E+08 rs55724759 0.028846 0.903409 0.570423 1.292132 NCKAP5 intron 
13 53286822 rs62637607 0.735577 0.010101 0.000485 1.28517 LECT1 intron 
1 1.59E+08 rs2276405 0.75 0.000505 0.029126 1.279471 AIM2 missense 
13 53238148 rs112815564 0.73301 0.010101 0.000485 1.278989 SUGT1 intron 
3 1.26E+08 rs4679121 0.826923 0.074713 0.067164 1.274227 ZXDC intron-near-
splice 
8 1.44E+08 rs6432 0.95098 0.015152 0.519608 1.26684 CYP11B2 intron 
22 40803112 rs55844816 0.879808 0.09596 0.169903 1.25915 SGSM3 intron 
12 1.31E+08 rs1212936 0.966346 0.328283 0.160194 1.240326 GPR133 intron 
8 1.44E+08 rs3764795 0.038835 0.954545 0.504854 1.237918 GML missense 
1 2.13E+08 rs3738800 0.024038 0.838384 0.631068 1.2193 NSL1 intron 
16 89757132 rs12598665 0.947115 0.141414 0.305825 1.219236 CDK10 intron 
16 89986154 rs885479 0.014423 0.921348 0.436782 1.199063 MC1R missense 
4 48610961 rs776604 0.081731 0.823171 0.76 1.196354 FRYL intron 
2 2.41E+08 rs77816205 0.754808 0.066327 0.000485 1.194793 NDUFA10 intron 
13 52598189 rs17480245 0.705882 0.010101 0.000485 1.187379 ALG11 missense 
13 76445155 rs9544057 0.052885 0.78 0.648649 1.185765 none upstream-
gene 
5 54398339 rs3136555 0.798077 0.06701 0.082524 1.177476 none upstream-
gene 
22 40800518 rs760701 0.879808 0.136364 0.169903 1.1761 SGSM3 intron 
22 40800544 rs2235318 0.879808 0.136364 0.169903 1.1761 SGSM3 intron 
6 49755030 rs28372930 0.932692 0.116162 0.320388 1.173198 PGK2 5-prime-
UTR 
13 52678741 rs34326189 0.711538 0.020202 0.000485 1.170403 NEK5 intron 
11 61580635 rs174556 0.004808 0.689655 0.664706 1.169148 FADS1 intron 
2 1.34E+08 rs76742066 0.028846 0.89375 0.5 1.166751 NCKAP5 intron 
19 10402938 rs1056538 0.019231 0.616162 0.81068 1.163544 ICAM5 missense 
19 10403368 rs2228615 0.019231 0.616162 0.81068 1.163544 ICAM5 missense 
13 52513266 rs7334118 0.706731 0.005495 0.000588 1.152985 ATP7B missense 
16 27246617 rs17856580 0.009615 0.773684 0.604167 1.147446 NSMCE1 missense 
19 10370542 rs11115 0.004808 0.656566 0.718447 1.147055 MRPL4 3-prime-
UTR 
19 10403947 rs2569702 0.019231 0.611111 0.805825 1.146108 ICAM5 intron 
15 44198288 rs76332091 0.68932 0.000505 0.004902 1.143801 FRMD5 intron 
11 61624414 rs174602 0.932692 0.191919 0.257282 1.140539 FADS2 intron 
1 2.13E+08 rs2291772 0.024038 0.838384 0.57767 1.128437 FLVCR1 intron 
1 2.13E+08 rs17019870 0.024038 0.838384 0.57767 1.128437 FLVCR1 intron 
1 2.13E+08 rs3768548 0.033654 0.858586 0.57767 1.117401 FLVCR1 intron 
19 55420924 rs3765014 0.043269 0.836735 0.627451 1.110749 NCR1 intron 
8 1.44E+08 rs2294008 0.033654 0.594118 0.786885 1.105699 PSCA 5-prime-
UTR 
1 1.52E+08 rs4845606 0.802885 0.085859 0.106796 1.105564 RORC intron 
1 2.13E+08 rs17019873 0.029126 0.838384 0.57767 1.098868 FLVCR1 intron 
16 89212200 rs4302032 0.9375 0.136364 0.354369 1.096629 ACSF3 intron 
 202 
 
11 61569830 rs174546 0.004808 0.639535 0.648649 1.096416 FADS1 3-prime-
UTR 
13 52715168 rs55969405 0.706731 0.005814 0.000833 1.096289 NEK3 intron 
19 746206 rs2384776 0.932692 0.252525 0.223301 1.094707 PALM intron 
19 16630224 rs12460141 0.692308 0.005495 0.005952 1.093478 CHERP intron 
11 57268808 rs150660444 0.668269 0.000505 0.000485 1.088858 SLC43A1 intron-near-
splice 
4 47560386 rs4298115 0.019231 0.570707 0.81068 1.088358 ATP10D intron 
22 40801312 rs12483888 0.879808 0.106061 0.247573 1.086952 SGSM3 intron 
13 52544577 rs151202111 0.695 0.010989 0.000704 1.085456 ATP7B intron 
11 61551927 rs174536 0.009615 0.676768 0.674757 1.085322 MYRF intron 
1 2.13E+08 rs41300993 0.04902 0.861446 0.589109 1.079095 FLVCR1 intron 
7 66281040 rs1984651 0.884615 0.121212 0.247573 1.078964 GTF2IRD1P1 intron 
1 2.13E+08 rs2291771 0.033654 0.833333 0.582524 1.076281 FLVCR1 intron 
11 47311905 rs147735512 0.663462 0.000505 0.000485 1.074561 MADD intron 
6 7574536 rs7741957 0.854369 0.000505 0.315534 1.074353 DSP intron 
1 2.13E+08 rs1890932 0.033981 0.838384 0.57767 1.073821 FLVCR1 intron 
8 1.44E+08 rs2978982 0.033654 0.593023 0.769841 1.071862 PSCA synonymous 
4 47561179 rs11730590 0.019231 0.575758 0.796117 1.071372 ATP10D intron 
11 61570783 rs174547 0.004808 0.639175 0.673684 1.069415 FADS1 intron 
16 49823239 rs2271063 0.859223 0.107143 0.212766 1.066081 ZNF423 intron 
11 57080882 rs145672238 0.663462 0.000505 0.004854 1.063441 TNKS1BP1 missense 
15 1.01E+08 rs76411473 0.826923 0.036082 0.218447 1.06048 ADAMTS17 intron 
1 2.04E+08 rs3737975 0.052885 0.942105 0.485294 1.060047 LAX1 intron 
13 42335222 rs9566844 0.941748 0.328283 0.194175 1.056225 VWA8 intron 
5 6605271 rs506416 0.014851 0.70202 0.650485 1.054262 NSUN2 intron 
5 54319997 rs3822315 0.043269 0.811828 0.613861 1.051998 none upstream-
gene 
17 47123824 rs4265867 0.663462 0.005102 0.004854 1.051564 IGF2BP1 intron 
11 61560081 rs174538 0.004808 0.661616 0.650485 1.051003 TMEM258 5-prime-
UTR 
19 16639121 rs12459056 0.745192 0.076923 0.025974 1.050362 CHERP intron 
12 52369300 rs2242106 0.932692 0.20202 0.300971 1.050174 ACVR1B intron 
19 44351694 rs2195980 0.038462 0.813131 0.601942 1.048763 ZNF283 missense 
2 1.15E+08 rs13418557 0.870192 0.050505 0.305825 1.047977 ACTR3 intron 
4 47561141 rs13106043 0.019231 0.565657 0.791262 1.04723 ATP10D intron 
11 47304564 rs143653424 0.653846 0.000505 0.000485 1.04657 MADD intron 
3 12628920 rs2290159 0.821053 0.222222 0.038835 1.040277 RAF1 intron 
12 96180692 rs59294014 0.908654 0.015152 0.470874 1.040168 NTN4 intron 
3 12861600 rs181307051 0.663462 0.000538 0.000568 1.03994 CAND2 missense 
12 53344318 rs2070875 0.067308 0.994949 0.412621 1.036721 KRT18 intron 
3 12633083 rs2290160 0.822115 0.227273 0.033981 1.0341 RAF1 intron 
7 44612229 rs2289057 0.841346 0.020202 0.281553 1.032202 DDX56 synonymous 
1 2.13E+08 rs10864004 0.024038 0.806122 0.553398 1.031811 C1orf227 missense 
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11 61557826 rs102274 0.004808 0.637755 0.656863 1.02932 TMEM258 intron 
11 68678962 rs560096 0.048077 0.883838 0.538835 1.028293 IGHMBP2 missense 
13 28239940 rs11029 0.942308 0.353535 0.18932 1.02751 POLR1D synonymous 
11 61547237 rs108499 0.004808 0.641414 0.650485 1.022169 MYRF intron 
12 1.31E+08 rs1195923 0.028846 0.571429 0.796117 1.018131 GPR133 intron 
6 7580958 rs2076299 0.855769 0.035354 0.305825 1.01754 DSP intron 
19 16666347 rs73514949 0.692308 0.010204 0.048544 1.017043 SLC35E1 intron 
11 61549025 rs174533 0.004808 0.636364 0.650485 1.015209 MYRF intron 
19 16617486 rs74418457 0.692308 0.005051 0.053398 1.013774 C19orf44 intron 
5 6620459 rs2288446 0.033654 0.712121 0.665049 1.012473 NSUN2 intron 
7 44609752 rs2304373 0.836538 0.020202 0.281553 1.012413 DDX56 intron 
7 44611009 rs3793250 0.836538 0.020202 0.281553 1.012413 DDX56 intron 
12 8808222 rs79153086 0.745192 0.055556 0.087379 1.011511 MFAP5 intron 
11 61551356 rs174535 0.004808 0.636364 0.645631 1.008394 MYRF synonymous 
3 12618269 rs2442805 0.826923 0.232323 0.053398 1.007626 MKRN2 intron 
5 6604970 rs6888601 0.019231 0.680412 0.643564 1.006427 NSUN2 intron 
5 76734260 rs33205 0.759615 0.050505 0.116505 1.005718 WDR41 intron 
5 6602544 rs2303711 0.033654 0.712121 0.660194 1.005363 NSUN2 intron 
3 1.08E+08 rs3957558 0.868932 0.109756 0.28 1.000842 MYH15 intron 
19 10395683 rs5498 0.019231 0.585859 0.737864 0.997435 ICAM1 missense 
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Table S3: Variants under different selection strength between Nunavik Inuit with Europeans and Nunavik Inuit with Northeast 
Siberians. 
 
chrom pos rs PBS (NUI-
CHB-CEU) 
gene function AF 
(GI) 
PBS 
(GI) 
PBS (NUI-
NES-CHB) 
MAF.NES CADD 
1 1.59E+08 rs2276405 1.279471376 AIM2 missense 0.8611 2.536098 0.634696 0.28 16.34 
3 12858557 rs180768267 1.389523908 CAND2 missense #N/A #N/A 1.094545 0.12 16.91 
3 12861600 rs181307051 1.039940373 CAND2 missense 0.3889 1.067382 0.625435 0.14 25.7 
4 47578971 rs16851681 1.433606237 ATP10D missense #N/A #N/A 1.073339 0.46 0.09 
8 1.44E+08 rs3764795 1.237917802 GML missense #N/A #N/A 0.368187 0.28 15.17 
8 1.44E+08 rs4534 1.511837689 CYP11B1 missense #N/A #N/A 0.495403 0.32 0.009 
11 61551356 rs174535 1.008393664 MYRF synonymous 1 0.76399 0.284129 0.08 0.924 
11 68548130 rs80356779 3.111911226 CPT1A missense #N/A #N/A 0.839809 0.32 18.21 
11 68678962 rs560096 1.028292975 IGHMBP2 missense 0 0.954138 0.15293 0.12 1.24 
12 56743044 rs2066815 1.5259979 STAT2 missense-
near-splice 
#N/A #N/A 0.839179 0.24 25 
13 52513266 rs7334118 1.152985299 ATP7B missense 0.4722 1.25654 0.613102 0.2 11.53 
13 52598189 rs17480245 1.187378938 ALG11 missense 0.4722 1.212806 0.532059 0.22 0.017 
13 52715168 rs55969405 1.096288839 NEK3 intron 0.4722 1.212806 0.571077 0.22 #N/A 
13 53049267 rs34494025 1.303110102 CKAP2 synonymous #N/A #N/A 0.502239 0.3 4.588 
16 89661807 rs12445560 1.744346679 CPNE7 synonymous #N/A #N/A 0.48916 0.74 9.53 
16 89986154 rs885479 1.199063038 MC1R missense 0.8889 0.57 0.375297 0.18 9.495 
16 90130139 rs4264393 1.504595068 PRDM7 missense #N/A #N/A 0.039348 0.62 8.187 
19 10395683 rs5498 0.997435183 ICAM1 missense 0.8056 0.424054 0.881544 0.4 0.754 
19 10402938 rs1056538 1.163543685 ICAM5 missense #N/A #N/A 1.038068 0.44 16.96 
19 10403368 rs2228615 1.163543685 ICAM5 missense 0.8056 0.5465 1.038068 0.44 12.92 
19 55418054 rs2278428 1.452229608 NCR1 missense #N/A #N/A 0.510609 0.3 5.939 
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Table S4: Result of GO analysis of 1,596 genes with one or more coding variants with weak 
signals of selection (PBS>0.3) 
 
 
 
 
 
GO biological process 
(PANTHER 
Overrepresentation Test) 
Total 
(20814) 
observed expected fold 
Enrichment 
P-value 
cell adhesion (GO:0007155) 1039 124 78.87 1.57 6.52E-03 
biological adhesion 
(GO:0022610) 
1044 124 79.25 1.56 8.25E-03 
localization (GO:0051179) 4838 452 367.25 1.23 3.79E-03 
cellular response to stimulus 
(GO:0051716) 
6061 560 460.09 1.22 2.60E-04 
signaling (GO:0023052) 5052 461 383.5 1.2 3.78E-02 
single organism signaling 
(GO:0044700) 
5049 460 383.27 1.2 4.61E-02 
response to stimulus 
(GO:0050896) 
7482 677 567.96 1.19 7.46E-05 
single-organism cellular 
process (GO:0044763) 
11573 1021 878.51 1.16 1.57E-09 
single-organism process 
(GO:0044699) 
12867 1107 976.74 1.13 3.41E-08 
cellular process 
(GO:0009987) 
14439 1211 1096.07 1.1 6.16E-07 
biological regulation 
(GO:0065007) 
11293 946 857.26 1.1 3.08E-02 
biological_process 
(GO:0008150) 
16739 1368 1270.66 1.08 5.53E-07 
Unclassified 
(UNCLASSIFIED) 
4075 213 309.34 0.69 0.00E+00 
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Table S5: Association tests of 49 SNVs with PBS>0.8 between IA cases and controls in Nunavik Inuit 
CHR SNP BP F_A F_U P OR GENE FUNC FCEU FCHB FGI PBS 
1 rs2276405 1.59E+08 0.2976 0.2177 0.1918 1.522 AIM2 missense 0.000505 0.029126 0.8611 1.279471 
1 rs2070150 1.62E+08 0.1548 0.2097 0.3194 0.6901 ATF6 missense 0.045455 0.300971 #N/A 0.846154 
1 rs1135983 1.62E+08 0.1548 0.2097 0.3194 0.6901 ATF6 missense 0.045455 0.291262 0.8889 0.862562 
1 rs800292 1.97E+08 0.1071 0.05645 0.1782 2.006 CFH missense 0.782828 0.635922 #N/A 0.891947 
1 rs10864004 2.13E+08 0.02381 0.02419 0.9858 0.9837 C1orf227 missense 0.806122 0.553398 0.1944 1.031811 
2 rs3827760 1.1E+08 0 0.008065 0.4093 0 EDAR missense 1 0.067961 0.97222 1.348744 
2 rs16866391 1.79E+08 0.1786 0.1129 0.1797 1.708 TTN,TTN-
AS1 
missense 0.000556 0.037313 #N/A 1.72467 
3 rs180768267 12858557 0.1786 0.2339 0.338 0.7121 CAND2 missense 0.000556 0.021739 #N/A 1.389524 
3 rs181307051 12861600 0.2619 0.3871 0.06081 0.5618 CAND2 missense 0.000538 0.000568 0.3889 1.03994 
3 rs148960024 20189472 0.4643 0.3548 0.1137 1.576 KAT2B missense 0.000505 0.009709 #N/A 0.882443 
3 rs7614116 1.3E+08 0 0.01613 0.2422 0 COL6A6 missense 0.784884 0.439655 #N/A 0.98193 
4 rs16851681 47578971 0.02381 0.01613 0.6923 1.488 ATP10D missense 0.232323 0.194175 #N/A 1.433606 
5 rs61739424 1.78E+08 0.3571 0.2984 0.3736 1.306 COL23A1 missense 0.042169 0.085714 #N/A 0.805394 
5 rs634501 1.8E+08 0.04762 0.05645 0.78 0.8357 MGAT1 missense 0.787879 0.514563 #N/A 0.81513 
6 rs1864312 49701439 0.02381 0.04032 0.517 0.5805 CRISP3 missense 0.60101 0.650485 #N/A 0.843453 
7 rs2289367 45113170 0.07143 0.25 0.000952 0.2308 CCM2 synonymous-
splicing 
0.20202 0.194175 0.8889 0.820568 
7 rs2304693 45148667 0.131 0.25 0.03585 0.4521 TBRG4 missense 0.171717 0.174757 0.8056 0.822423 
7 rs2304694 45148773 0.131 0.25 0.03585 0.4521 TBRG4 missense 0.171717 0.174757 0.8056 0.822423 
8 rs2741098 6690276 0.04762 0.02419 0.358 2.017 XKR5 missense 0.62069 0.572289 #N/A 0.811216 
8 rs3764795 1.44E+08 0.03571 0.04098 0.8475 0.8667 GML missense 0.954545 0.504854 #N/A 1.237918 
8 rs4534 1.44E+08 0.03571 0.04032 0.8653 0.8815 CYP11B1 missense 0.015152 0.446602 #N/A 1.511838 
9 rs78341003 1.07E+08 0.3286 0.4865 0.05412 0.5165 OR13C5 missense 0.000521 0.000617 #N/A 0.951218 
10 rs117193245 38404188 0.3333 0.3629 0.6611 0.8778 ZNF37A missense 0.005051 0.082524 0.5833 0.827687 
10 rs3998860 70405855 0.08333 0.1774 0.05459 0.4215 TET1 missense 0.207071 0.165049 #N/A 0.984147 
11 rs145672238 57080882 0.3452 0.3306 0.827 1.067 TNKS1BP1 missense 0.000505 0.004854 0.2222 1.063441 
11 rs17152659 58170780 0.3571 0.2823 0.2529 1.413 OR5B3 missense 0.000505 0.082524 0.1389 0.936222 
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11 rs80356779 68548130 0.03571 0.04839 0.6594 0.7284 CPT1A missense 0.000505 0.000485 #N/A 3.111911 
11 rs560096 68678962 0.04762 0.04839 0.9797 0.9833 IGHMBP2 missense 0.883838 0.538835 0 1.028293 
12 rs61729512 7637769 0.3333 0.3226 0.8711 1.05 CD163 missense 0.116162 0.014563 0.3889 0.812778 
12 rs2066815 56743044 0.25 0.1774 0.2047 1.545 STAT2 missense-near-
splice 
0.000505 0.009709 #N/A 1.525998 
13 rs7334118 52513266 0.3095 0.2823 0.6717 1.14 ATP7B missense 0.005495 0.000588 0.4722 1.152985 
13 rs17480245 52598189 0.3214 0.275 0.4738 1.249 ALG11 missense 0.010101 0.000485 0.4722 1.187379 
13 rs7986131 76423248 0.04762 0.05645 0.78 0.8357 LMO7 missense 0.787879 0.548544 0.05556 0.865208 
16 rs17856580 27246617 0.0119 0.008065 0.7806 1.482 NSMCE1 missense 0.773684 0.604167 0.8889 1.147446 
16 rs1126464 89704365 0.08333 0.03226 0.1063 2.727 DPEP1 missense 0.70202 0.669903 0.75 0.924261 
16 rs885479 89986154 0 0.02419 0.151 0 MC1R missense 0.921348 0.436782 0.8889 1.199063 
16 rs4264393 90130139 0.2262 0.1721 0.3351 1.406 PRDM7 missense 0.000602 0.007143 #N/A 1.504595 
18 rs3744900 33779705 0.369 0.2823 0.187 1.487 MOCOS missense 0.045455 0.053398 0.3889 0.916642 
18 rs623053 33779855 0.369 0.2823 0.187 1.487 MOCOS missense 0.045455 0.063107 0.6111 0.89798 
18 rs678560 33785093 0.369 0.2661 0.1146 1.613 MOCOS missense 0.045455 0.063107 0.6111 0.924335 
18 rs2278154 72103782 0.119 0.06452 0.1699 1.959 FAM69C missense 0.678571 0.8 0.8056 0.977466 
19 rs5498 10395683 0.0119 0.02419 0.5266 0.4859 ICAM1 missense 0.585859 0.737864 0.8056 0.997435 
19 rs1056538 10402938 0.0119 0.02419 0.5266 0.4859 ICAM5 missense 0.616162 0.81068 #N/A 1.163544 
19 rs2228615 10403368 0.0119 0.02419 0.5266 0.4859 ICAM5 missense 0.616162 0.81068 0.8056 1.163544 
19 rs1982074 10668673 0.1667 0.2177 0.3636 0.7185 KRI1 missense 0.151515 0.18932 #N/A 0.845432 
19 rs2195980 44351694 0.02381 0.04839 0.3658 0.4797 ZNF283 missense 0.813131 0.601942 #N/A 1.048763 
19 rs3764609 46823702 0.02381 0.04032 0.517 0.5805 HIF3A missense 0.818182 0.538835 0.5278 0.979903 
19 rs2278428 55418054 0.04762 0.04032 0.7997 1.19 NCR1 missense 0.065657 0.320388 #N/A 1.45223 
22 rs2228314 42276742 0 0.008065 0.4093 0 SREBF2 missense 0.252525 0.194175 0.97222 1.48112 
 208 
 
Appendix 3: Supplemental material for Chapter 2.3 
 
Supplementary figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1: Average coverage for each exon of gene CPT1A, CPT1B, CPT1C, CPT2, CRAT and 
CROT from 113 Inuit exomes. 
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Figure S2(A-C): Chromatograms of Sanger sequencing validation of four rare missense variants 
and three rare silent variants found in Nunavik Inuit (CPT1A P479L from selected samples) 
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Figure S3: Rare variants of Nunavik Inuit and 1KGBP Asian and there gradation profile of 
Polyphen-2 scores. 
 
 
 
 
 
 
 
 
Figure S4: The CPT1A P479L variant frequency in different Inuit settlements in Canada and the 
migration patterns of Inuit. 
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Supplementary tables 
 
Table S1: Variant concordance of CPT1A, CPT1B, CPT1C, CPT2 and CRAT SNPs by genotyping 
and exome sequencing 
Variant location Gene Success rate of 
genotyping (%) 
Success rate of exome 
sequencing (%) 
Variant 
concordance (%) 
rs3019598 Intronic CPT1A 100 100 100 
rs7112615 Intronic CPT1A 100 100 100 
rs2305508 Intronic CPT1A 100 99 91 
rs2924674 Intronic CPT1A 100 93 100 
rs7238 UTR-3 CPT1B 100 82 79 
rs5770911 Intronic CPT1B 100 100 100 
rs12627787 Intronic CPT1B 99 98 100 
rs1557502 Intronic CPT1B 100 43 65 
rs3213445 Exonic CPT1B 100 100 100 
rs10407097 Intronic CPT1C 100 35 80 
rs3766759 Intronic CPT2 100 15 40 
rs12737375 Intronic CPT2 100 80 86 
rs1799821 Exonic CPT2 100 100 100 
rs1799822 Exonic CPT2 100 100 100 
rs3118635 Exonic CRAT 100 100 100 
rs10988209 Intronic CRAT 100 45 73 
 Mean Mean Mean 
Exonic variant 100 100 100 
Intronic variant 99.9 73.3 77 
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Table S2: All exonic variants of CPT1A, CPT1B, CPT1C, CPT2 and CART in 100 Nunavik Inuit 
gene  variant 
position (hg19) 
variant 
function 
nucleotide change amino acid 
change 
SNP 1KGP 
frequency 
Nunavik Inuit 
frequency  
Genoty
ped 
CPT1A chr11:68530122 Silent c.G1848A p.V616V GCGACTTCGT[G/A]CGGGCCATGG 0 0.04 
 
CPT1A chr11:68548130 Missense c.C1436T p.P479L GCAGATGCGC[C/T]GATCGTGGCC 0 0.955 
 
CPT1A chr11:68549340 Silent c.T1251C p.F417F rs2228502 0.91 1 
 
CPT1B chr22:51009953 Missense c.G1591A 
(NM_152246) 
p.E531K  rs470117 0.38 0.32 
 
CPT1B chr22:51011348 Splicing c.C1308T 
(NM_152246) 
p.L436L  rs34744246 0.02 0 
 
CPT1B chr22:51011376 Missense c.C1280G 
(NM_152246) 
p.S427C rs8142477 0.36 0.66 
 
CPT1B chr22:51015838 Missense c.A196G 
(NM_152246) 
p.I66V  rs3213445 0.17 0.185 yes 
CPT1C chr19:50208286 Missense c.C794T p.T265M GTCACACCCA[C/T]GCCTCTGCAG 0 0.005 
 
CPT2 chr1:53676401 Missense c.T1055G p.F352C rs2229291 0.06 0.275 
 
CPT2 chr1:53676448 Missense c.G1102A p.V368I rs1799821 0.5 0.535 yes 
CPT2 chr1:53676775 Missense c.C1429T p.R477W GGCCTTCCTG[C/T]GGCAGTACGG 0 0.03 
 
CPT2 chr1:53679229 Missense c.A1939G p.M647V rs1799822 0.13 0 yes 
CRAT chr9:131857687 Missense c.G1807C 
(NM_000755) 
p.A603P rs17459086 0.04 0.1 yes 
CRAT chr9:131857769 Silent c.G1725A 
(NM_000755) 
p.A575A  ACAGCTGCGC[G/A]GAGACCAAC
G 
0 0.02 
 
CRAT chr9:131860901 Missense c.C1051A 
(NM_000755) 
p.L351M rs3118635 1 1 yes 
CRAT chr9:131866581 Splicing c.C233T 
(NM_000755) 
p.S78F TCCCAGCTGT[C/T]TGAGTGGTGG 0 0.02 
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Appendix 4: Supplemental material for Chapter 3.2 
 
Supplementary figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1: PCA analysis of FC patients and controls 
PCA analysis done using smartPCA and graph constructed by R. (A) PCA plot of the FC NeuroX 
cohort (B) Samples involved in this study after the removal of 95 admixed individuals. YRI, 
CHB/JPT and CEU populations from 1KG phase III were used for clustering and outliers with less 
than 90% of European ancestry are removed. 
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Figure S2: FST of RNF213 common variations between worldwide populations 
FST of RNF213 common variants (A) and (B) functional variants, SNPs in red indicate they are outliers of 50% quantile. 
 215 
 
 
 
 
 
Figure S3: MAF of RNF213 SNP rs6565666 distribution in world-wide populations 
The frequency of rs6565666 non-ancestral allele decreased from Africans (0.26-0.35) to 
Europeans (0.16-0.18) and Asians (0.17-0.1) to the lowest in arctic populations (0.04-0.003). This 
non-ancestral allele seems also to be the risk allele for IA (dominant model for minor allele, 
p=0.0001739), which seems to correlate with the Out-of-Africa migration patterns and risk allele 
being purged in the evolution. 
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Supplementary tables 
Table S1. Clinical descriptions of the IA discovery cohort and replication cohort.  
 
Number of 
individuals in 
discovery cohort 
Number of individuals 
in replication cohort 
(familial) 
Number of individuals in 
replication cohort 
(sporadic) 
With clinical file 26 147 65 
Multiple aneurysms 12 55 19 
SAH 5 51 25 
Hypertension 4 60 31 
Drinking 12 33 26 
Smoking 24 89 50 
Hypercholesterolemia 3 29 24 
Hypothyroidism 0 17 14 
Had heart diseases and 
other vascular diseases 
0 13 3 
 
 
Table S3: Population data retrieved for this study 
Region Populations No. Samples Data access Data source  SNPs in RNF213 
Argentina Argentina 50 GEO Omni 40 
Siberia Chukotka 48 GEO Omni 48 
Siberia East-Siberia 85 GEO Omni 48 
Kamchatka Krai Kamchatka Krai 67 GEO Omni 48 
Sakha Republic Sakha Republic 46 GEO Omni 48 
West-Siberia West-Siberia 103 GEO Omni 48 
Africa Madagascar 69 GEO Omni 39 
East_Asia Han Chinese 203 1000 Genome Omni & Exome 1835 
East_Asia JPT 104 1000 Genome Omni & Exome 1835 
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East_Asia CDX 93 1000 Genome Omni & Exome 1835 
East_Asia Vietnamese 117 1000 Genome & 
GEO 
Omni & Exome 1835 
Europe CEU 99 1000 Genome Omni & Exome 1835 
Europe TSI 107 1000 Genome Omni & Exome 1835 
Europe GBR 91 1000 Genome Omni & Exome 1835 
Europe FIN 99 1000 Genome Omni & Exome 1835 
Europe IBS 107 1000 Genome Omni & Exome 1835 
Africa YRI 108 1000 Genome Omni & Exome 1835 
Africa LWK 99 1000 Genome Omni & Exome 1835 
Africa GWD 113 1000 Genome Omni & Exome 1835 
Africa MSL 85 1000 Genome Omni & Exome 1835 
Africa ESN 99 1000 Genome Omni & Exome 1835 
Native-America ASW 61 1000 Genome Omni & Exome 1835 
Native-America ACB 96 1000 Genome Omni & Exome 1835 
Native-America MXL 64 1000 Genome Omni & Exome 1835 
Native-America PUR 104 1000 Genome Omni & Exome 1835 
Native-America CLM 94 1000 Genome Omni & Exome 1835 
Native-America PEL 85 1000 Genome Omni & Exome 1835 
South_Asia GIH 103 1000 Genome Omni & Exome 1835 
South_Asia PJL 96 1000 Genome Omni & Exome 1835 
South_Asia BEB 86 1000 Genome Omni & Exome 1835 
South_Asia STU 102 1000 Genome Omni & Exome 1835 
South_Asia ITU 102 1000 Genome Omni & Exome 1835 
Inuit Inuit 185 In house & GEO Omni 39 
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Table S4: Exome sequencing coverage of 26 IA patients from the initial cohort 
Indiv Raw reads % Coverage (10X) 20X 30X 50X 75X 100X Average base depth 
09-1 7.90E+07 97.1 90.7 81.2 59.8 35.5 18.5 66.07 
09-2 8.80E+07 97.8 93.6 86.5 68.4 46.1 28.1 78.44 
28-1 1.40E+08 98.4 97 94.7 87.5 75.8 63.4 144.4 
28-2 1.40E+08 98.7 97.1 94.3 85.8 72.8 59.5 133.63 
28-3 1.04E+08 98.2 95.6 90.9 77.7 59.5 42.6 99.55 
28-4 9.10E+07 98.2 95 89.5 75 55.8 38.7 93.58 
94-1 1.10E+08 98.5 96.7 93.3 82.4 65.7 49.7 111.25 
94-2 1.10E+08 98.3 95.7 91.2 79.6 63.3 47.4 108.05 
94-3 1.30E+08 98.8 97.3 94.9 87 74.3 61 137.29 
94-4 1.10E+08 98.5 96.7 93.4 82.5 65.9 50 112.03 
60-1 2.60E+09 90.9 85.5 79.3 62.6 40.9 25.8 78.36 
60-2 3.10E+09 91.9 87.4 82.6 69.2 49.6 33.7 92.27 
60-3 2.70E+09 91.5 86.6 80.9 64.9 43.2 27.7 81.79 
60-4 3.40E+09 91.8 87.6 83.3 72.6 55.5 39.6 102.47 
60-5 2.70E+09 90.6 85.3 79.2 63.4 42.5 27.4 80.68 
10-1 3.10E+09 91.5 86.8 81.9 68.9 49.4 33.4 91.2 
10-2 3.20E+09 91.7 87.2 82.7 70.9 52.8 36.7 97 
10-3 3.80E+09 92.8 89.1 85.3 75.5 59.7 44.5 113.59 
10-4 3.60E+09 92.5 87 81.2 69.4 54.7 41.3 108.23 
10-5 3.10E+10 91.4 86.9 82 68.8 49.1 33.2 91.07 
89-1 6.00E+09 93.6 90.6 88 83.2 75.9 67.1 177.72 
89-2 1.20E+09 82.6 65.5 47 22.3 9.5 4.5 35.36 
89-3 2.60E+09 90.2 84.2 77.7 61 39.7 25.1 76.43 
89-4 2.60E+09 90.2 84.4 78 61.9 41.1 26.2 78.39 
89-5 3.40E+09 91.5 87.1 82.7 71.7 55 39.6 102.88 
89-6 4.20E+09 93 89.3 86.1 78.6 66 51.7 126.19 
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Table S5: 72 RNF213 functional variants in FC IA patients and controls 
Position function Exon Annotation dbSNP v132 1000 
Genome  
NHLBI-ESP PolyPhen2 Case 
maf(233) 
Control 
maf(277) 
78247087 missense 3 c.A145G:p.M49V rs114493717 0.01 0.005152 0.400054 0.002146 0 
78261704 missense 4 c.T352C:p.C118R NA 0.0005 0.000154 0.266834 0.008584 0.001805 
78261961 missense 4 c.G609C:p.E203D rs74003706 0.02 0.019453 0.118686 0.002146 0 
78262538 missense 5 c.T917C:p.F306S NA 0.0014 0.000461 0 0 0.001805 
78263486 missense 6 c.T962C:p.M321T rs17853989 0.2 0.259111 0.006 0.173809 0.1498 
78264463 nonframeshift_
deletion 
7 c.1208_1210del:p.403_40
4del 
NA 0.0023 0.001917 1 0.002146 0 
78265614 missense 8 c.C1459A:p.L487M NA 0 0 0.387 0.002146 0.001805 
78268746 missense 9 c.A1699G:p.M567V NA 0 0 0.999 0.002146 0 
78272125 splicing 11 c.C2017T:p.R673W NA 0 0 0.997 0.006438 0 
78272230 missense 11 c.C2122G:p.H708D rs72849837 0.01 0.012917 0.181 0.012874 0.01264 
78272294 missense 11 c.C2186T:p.P729L rs72849841 0.11 0.145241 0.026 0.145955 0.1296 
78291060 missense 16 c.G2884A:p.E962K NA 0 0 0.068 0 0.001805 
78293189 missense 17 c.A3101T:p.K1034M rs55996424 0.34 0.189451 0.541746 0.160946 0.1667 
78293222 missense 17 c.C3134T:p.S1045L NA 0 0 0.496412 0.002146 0.005415 
78298872 missense 18 c.C3067T:p.R1023W NA 0 0 0.001 0.002146 0 
78298926 missense 18 c.G3121A:p.A1041T rs61359568 0.04 0.051029 0.007 0.072957 0.04815 
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78302157 missense 20 c.C3397A:p.Q1133K rs8082521 0.56 0.700832 0 0.270336 0.3315 
78302164 missense 20 c.C3404T:p.A1135V NA 0 0 0.223 0 0.00722 
78305871 missense 21 c.G3583A:p.V1195M rs10782008 0.52 0.59067 0.73 0.329691 0.3662 
78305896 missense 21 c.C3608T:p.S1203L NA 0 0 0.154 0 0.00361 
78305962 missense 21 c.A3674G:p.D1225G NA 0 0 0.919 0.002146 0 
78305989 missense 21 c.A3701G:p.Q1234R rs116722283 0.02 0 0.493 0.002146 0 
78306102 missense 21 c.G3814C:p.E1272Q rs9913636 0.37 0.386553 0.69 0.49327 0.469 
78306107 missense 21 c.G3819C:p.E1273D NA 0 0 0 0 0.001805 
78306280 missense 21 c.A3992G:p.D1331G rs8074015 0.6 0.703241 0.002 0.273071 0.3259 
78307917 missense 22 c.G4156A:p.D1386N rs113139767 0.0023 0.002847 0.154 0 0.001805 
78310056 missense 23 c.G4405C:p.V1469L rs116694967 0.01 0.010293 0.908 0.002146 0 
78313074 missense 26 c.C4907T:p.T1636M NA 0.0023 0 0.96 0.008584 0.00361 
78313281 missense 26 c.C5114A:p.T1705K NA 0.0032 0.007008 1 0.025747 0.007246 
78313329 missense 26 c.C5162T:p.P1721L NA 0.0014 0 0.877 0.002146 0.00361 
78313622 missense 26 c.C5455T:p.R1819C NA 0 0 0.999 0 0.001805 
78313697 missense 26 c.G5530A:p.A1844T NA 0 0 0.041 0.004292 0.005415 
78313763 missense 26 c.A5596G:p.T1866A NA 0 0 0.77 0.006438 0 
78316974 missense 27 c.T6032C:p.M2011T rs78457838 0.01 0.011841 0.004 0.002146 0 
78318782 missense 29 c.G6647A:p.R2216Q NA 0 0 0.66 0.002146 0 
78319114 missense 29 c.A6979G:p.N2327D NA 0.0009 0.000923 0.049 0.004292 0 
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78319115 missense 29 c.A6980G:p.N2327S NA 0 0 0.094 0.002146 0.001805 
78319136 missense 29 c.G7001A:p.S2334N rs9674961 0.57 0.660464 0 0.300419 0.3466 
78319447 missense 29 c.C7312T:p.R2438C NA 0 0.000077 0.655 0.002146 0 
78320611 missense 29 c.G8476A:p.A2826T NA 0 0 1 0.002146 0 
78320710 missense 29 c.A8575G:p.T2859A NA 0 0 0.012 0 0.001805 
78321046 missense 29 c.A8911G:p.N2971D NA 0 0 0.012 0 0.00361 
78321108 missense 29 c.T8973G:p.D2991E NA 0 0.000231 0.528 0.002146 0.001805 
78321157 missense 29 c.T9022C:p.C3008R rs61600413 0.08 0.113409 0.803 0.062231 0.03889 
78321560 missense 29 c.T9425C:p.V3142A NA 0 0 0.998 0 0.001805 
78321697 missense 29 c.G9562A:p.V3188M NA 0 0 0.96 0.002146 0 
78321844 missense 29 c.C9709A:p.Q3237K NA 0 0 0.264 0.006438 0 
78321941 missense 29 c.G9806A:p.R3269Q NA 0 0.000077 1 0 0.00361 
78323570 splicing 30 c.A9952G:p.I3318V NA 0.0018 0.002153 1 0.002146 0.001805 
78328364 missense 36 c.C10850T:p.A3617V NA 0 0 0.555 0 0.001805 
78336958 frameshift_dele
tion 
40 c.11413delC:p.P3805fs NA 0 0 1 0.004292 0.001805 
78337058 missense 40 c.G11512C:p.V3838L rs35332090 0.13 0.154698 0.329 0.145955 0.1029 
78337440 missense 41 c.C11600T:p.T3867M NA 0 0.000154 0.504 0 0.005415 
78337584 missense 41 c.A11744G:p.E3915G rs61740658 0.07 0.085807 0.243 0.111619 0.07581 
78343401 missense 45 c.G12255C:p.E4085D NA 0 0 0 0 0.001805 
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78345744 missense 47 c.G12496A:p.D4166N NA 0 0.000923 1 0.002146 0 
78346840 missense 49 c.G12817A:p.D4273N NA 0.0023 0.003537 1 0.008584 0.009025 
78346870 missense 49 c.C12847A:p.L4283I rs62077764 0.04 0.05436 0.264 0.051505 0.06137 
78346877 missense 49 c.G12854A:p.S4285N NA 0 0.000077 0.024 0.002146 0 
78348389 splicing 50 c.G13074A:p.K4358K NA 0 0 1 0.002146 0 
78350110 missense 52 c.G13195A:p.A4399T NA 0.02 0.006689 0.906 0.004292 0.009025 
78350767 splicing 53 c.13510+4A>G NA 0.0009 0.004998 1 0.010726 0.005415 
78353451 missense 55 c.T13577C:p.I4526T NA 0 0 0.290848 0.006438 0 
78354656 missense 56 c.G13666A:p.G4556S NA 0 0 0.998 0.002146 0.00361 
78355462 missense 57 c.C13913T:p.T4638I NA 0 0.001 0.995 0.006438 0.001805 
78355494 missense 57 c.C13945G:p.L4649V rs61745599 0.05 0.074273 0.996 0.075105 0.08845 
78356830 missense 58 c.G14030T:p.W4677L rs61741961 0.01 0.014301 0.997 0.006438 0.02347 
78357478 splicing 59 c.A14072G:p.H4691R rs12944088 0.02 0.019914 1 0.036484 0.01625 
78357600 missense 59 c.A14194G:p.K4732E rs12944385 0.0032 0.007766 0.087 0.006438 0.005415 
78363054 missense 65 c.G15082A:p.V5028I rs8072774 0.1 0.156005 0.011 0.079399 0.08664 
78363707 missense 66 c.G15275A:p.R5092Q NA 0 0.000077 0.998 0.002146 0 
78367225 missense 68 c.A15551C:p.E5184A rs61429875 0.05 0.069276 0.734 0.002146 0 
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Table S6. Cochran-Armitage trend test on 38 polymorphic SNPs in RNF213 loci 
CHR SNP A1 A2 AFF UNAFF CHISQ DF P 
17 rs7217421 A G 248/256 1722/1996 1.478 1 0.2241 
17 rs4889968 G A 12/484 117/3513 0.8884 1 0.3459 
17 rs9916351 C T 221/287 1757/1969 2.436 1 0.1186 
17 rs12947578 A G 202/306 1583/2139 1.444 1 0.2295 
17 rs9913317 A G 0/502 1/3733 0.1345 1 0.7138 
17 rs7219131 C T 224/280 1780/1940 2.13 1 0.1444 
17 rs12601730 G T 12/496 113/3615 0.6745 1 0.4115 
17 rs7220465 T C 128/374 1092/2636 3.117 1 0.0775 
17 rs11869363 C T 136/370 1173/2545 4.732 1 0.0296 
17 rs12937242 T C 77/431 687/3037 3.324 1 0.06827 
17 rs8068939 T G 125/383 1004/2728 1.193 1 0.2747 
17 rs12451223 C T 120/388 935/2795 0.501 1 0.4791 
17 rs8081176 C T 159/349 1265/2467 1.327 1 0.2494 
17 rs6565666 A G 119/389 649/3085 11.29 1 0.00078 
17 rs7225029 A G 45/461 280/3450 1.255 1 0.2626 
17 rs4889843 G A 246/262 1681/2045 1.996 1 0.1577 
17 rs9907978 A G 146/362 1243/2487 4.172 1 0.0411 
17 rs9908583 G A 143/359 1232/2456 4.754 1 0.02923 
17 rs4890008 T G 27/481 151/3577 1.791 1 0.1807 
17 rs10782008 G A 173/335 1393/2331 2.139 1 0.1436 
17 rs8072917 C T 173/335 1393/2331 2.148 1 0.1428 
17 rs4890009 G A 144/358 1242/2484 4.266 1 0.03889 
17 rs4890010 C T 173/335 1393/2327 2.209 1 0.1372 
17 NeuroX_chr17:78319717 T C 0/508 2/3732 0.2724 1 0.6018 
17 rs11150856 C T 68/440 544/3188 0.4948 1 0.4818 
17 rs12051723 T G 98/410 545/3183 7.603 1 0.005829 
17 rs11655038 T G 40/468 337/3391 0.7355 1 0.3911 
17 rs7216493 G A 128/380 1086/2642 3.345 1 0.0674 
17 rs8078251 G A 170/338 1230/2490 0.03161 1 0.8589 
17 rs4078429 G A 28/478 198/3532 0.04479 1 0.8324 
17 rs6565681 A G 76/430 610/3114 0.5957 1 0.4402 
17 rs4889848 C T 75/433 608/3124 0.7565 1 0.3844 
17 rs7224239 G A 249/259 1622/2112 5.759 1 0.01641 
17 rs12944385 G A 3/505 22/3712 1.44E-05 1 0.997 
17 rs4890018 C T 31/477 210/3516 0.1718 1 0.6785 
17 rs8072774 T C 40/466 324/3406 0.3454 1 0.5567 
17 rs3185057 A G 51/457 312/3418 1.541 1 0.2144 
17 rs8359 T C 42/466 332/3400 0.2201 1 0.6389 
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Appendix 5: Supplemental material for Chapter 3.3 
 
Supplementary figures 
 
Figure S1. Quantile-quantile plot of case-control logistic regression analysis 
 
 
Figure S2. Manhattan plot showing the result of the initial trend test 
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Figure S3. Regional validation of 13 previous GWAS associated loci  
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Supplementary tables  
 
Table S1. FBAT-O result of 50 FHIT variants with significant association (p<0.05) in Nunavik 
Inuit 
Marker chr pos afreq fam# S-E(S) Var(S) Z P Offset 
rs780365 3 59761789 0.377 14 6.842 5.254 2.985 0.002839 0.231 
rs17361653 3 59771515 0.462 18 -6.903 5.489 -2.946 0.003216 0.203 
rs9809480 3 60448671 0.23 14 5.032 3.155 2.833 0.004615 0.277 
rs1597104 3 60453227 0.23 14 5.032 3.155 2.833 0.004615 0.277 
rs7621114 3 60418721 0.205 13 4.663 3.003 2.691 0.007123 0.257 
rs2255772 3 60557852 0.207 10 4.039 2.519 2.545 0.010928 0.245 
rs2687189 3 60423009 0.438 18 4.701 3.768 2.422 0.015436 0.095 
rs445057 3 60447369 0.433 18 4.701 3.768 2.422 0.015436 0.095 
rs424675 3 60448261 0.433 18 4.701 3.768 2.422 0.015436 0.095 
rs17061176 3 59755841 0.179 11 4.311 3.188 2.414 0.015763 0.224 
rs13092167 3 59772342 0.293 10 4.244 3.148 2.392 0.016762 0.212 
rs3920477 3 60733152 0.328 15 4.425 3.484 2.371 0.017762 0.154 
rs9861525 3 60004908 0.398 15 4.756 4.157 2.332 0.019677 0.268 
rs241700 3 60516256 0.311 13 4.01 3.005 2.313 0.020728 0.235 
rs10451993 3 60566492 0.321 13 4.01 3.005 2.313 0.020728 0.235 
rs17669257 3 60566161 0.412 17 4.626 4.158 2.269 0.023295 0.271 
rs17609699 3 60487578 0.48 18 -5.16 5.188 -2.265 0.023496 0.27 
rs49413 3 59757484 0.418 20 5.311 5.546 2.255 0.024112 0.264 
rs993000 3 59745585 0.158 10 2.989 1.815 2.218 0.026535 0.4 
rs1683346 3 59749703 0.158 10 2.989 1.815 2.218 0.026535 0.4 
rs17061173 3 59754178 0.156 10 2.989 1.815 2.218 0.026535 0.4 
rs994931 3 59741758 0.319 15 -4.661 4.506 -2.196 0.028127 0.451 
rs780366 3 59762116 0.347 15 -4.661 4.506 -2.196 0.028127 0.451 
rs11130733 3 59767786 0.347 15 -4.661 4.506 -2.196 0.028127 0.451 
rs17361780 3 59772328 0.347 15 -4.661 4.506 -2.196 0.028127 0.451 
rs1627302 3 60658608 0.473 17 -4.48 4.468 -2.119 0.034058 0.27 
rs721207 3 60607896 0.468 16 -5.031 5.672 -2.112 0.034649 0.372 
rs780354 3 59772460 0.366 15 -4.505 4.578 -2.106 0.035223 0.478 
rs2682931 3 60631936 0.359 19 -4.939 5.68 -2.072 0.038225 0.261 
rs6766789 3 60090013 0.468 20 -4.352 4.463 -2.06 0.039397 0.349 
rs10780042 3 60090402 0.468 20 -4.352 4.463 -2.06 0.039397 0.349 
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rs9881736 3 60487247 0.139 11 3.056 2.21 2.055 0.039836 0.5 
rs6786100 3 60351746 0.402 17 4.528 5.083 2.008 0.04461 0.302 
rs2142301 3 60095070 0.396 19 -3.978 4.074 -1.971 0.048745 0.18 
rs2885865 3 60610341 0.381 19 -4.741 5.811 -1.967 0.049201 0.292 
rs2363670 3 60611613 0.372 19 -4.741 5.811 -1.967 0.049201 0.292 
rs7633853 3 60613659 0.38 19 -4.741 5.811 -1.967 0.049201 0.292 
rs11926787 3 60615310 0.368 19 -4.741 5.811 -1.967 0.049201 0.292 
rs6762641 3 60616153 0.356 19 -4.741 5.811 -1.967 0.049201 0.292 
rs10510852 3 60616790 0.356 19 -4.741 5.811 -1.967 0.049201 0.292 
rs12637393 3 60620284 0.368 19 -4.741 5.811 -1.967 0.049201 0.292 
rs2856058 3 60625598 0.36 19 -4.741 5.811 -1.967 0.049201 0.292 
rs1735448 3 60647540 0.36 19 -4.741 5.811 -1.967 0.049201 0.292 
rs1716709 3 60657213 0.349 19 -4.741 5.811 -1.967 0.049201 0.292 
rs1716714 3 60660179 0.349 19 -4.741 5.811 -1.967 0.049201 0.292 
rs1735443 3 60662282 0.349 19 -4.741 5.811 -1.967 0.049201 0.292 
rs1735444 3 60664075 0.348 19 -4.741 5.811 -1.967 0.049201 0.292 
rs1716722 3 60681361 0.349 19 -4.741 5.811 -1.967 0.049201 0.292 
rs1735457 3 60683737 0.349 19 -4.741 5.811 -1.967 0.049201 0.292 
rs1735468 3 60703616 0.36 19 -4.741 5.811 -1.967 0.049201 0.292 
 
 
Table S2. 68 genes with exonic variants of FC exome cohort in 13 previously GWAS identified 
loci 
Loci Gene Number of exonic 
variants 
MAC in each gene P-value std error 
(SE) 
permutations 
1q23.1 IQGAP3             10 219 0.516484 0.376007 1000 
1q23.1 TTC24              9 123 0.380619 0.475192 1000 
1q23.1 APOA1BP            6 62 0.0527894 0.583171 5000 
1q23.1 GPATCH4            5 48 0.064787 0.521149 5000 
1q23.1 BCAN               9 131 0.979021 0.379929 1000 
1q23.1 NES                15 643 0.15984 0.395594 1000 
1q23.1 ISG20L2            3 16 0.576424 0.385064 1000 
1q23.1 RRNAD1             3 4 0.505495 0.432044 1000 
1q23.1 PRCC               4 66 0.00359928 0.368741 5000 
1q23.1 SH2D2A             3 104 0.300699 0.372431 1000 
1q23.1 INSRR              18 72 0.0115977 0.408737 5000 
1q23.1 NTRK1              13 207 0.495504 0.550519 1000 
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1q23.1 PEAR1              19 479 0.147852 0.539598 1000 
1q23.1 LRRC71             8 269 0.253746 0.404279 1000 
1q23.1 ARHGEF11           10 294 0.297702 0.398201 1000 
1q23.1 ETV3L              10 261 0.873127 0.419813 1000 
1q23.1 ETV3               2 29 0.127872 0.398124 1000 
1q23.1 FCRL5              6 22 0.0677864 0.501448 5000 
2q23.3 MMADHC             3 42 0.293706 0.411939 1000 
3p25.2 CAND2              25 832 0.330669 0.37951 1000 
3p25.2 RPL32              2 6 0.906094 0.421056 1000 
3p25.2 IQSEC1             15 60 1 0.412235 1000 
3p25.2 NUP210             25 1325 0.612388 0.359059 1000 
3p25.2 FBLN2              28 584 0.214785 0.615247 1000 
4q31.22 EDNRA              2 132 0.994006 0.486694 1000 
4q31.22 ARHGAP10           6 9 0.956044 0.408415 1000 
4q31.22 PRMT10             2 10 0.618382 0.437471 1000 
5q31.1 HSPA4              7 95 0.158841 0.361348 1000 
5q31.1 FSTL4              7 100 0.873127 0.363665 1000 
6q24.2 EPM2A              7 183 0.297702 0.338059 1000 
6q24.2 FBXO30             8 250 0.0103979 0.361532 5000 
6q24.2 SHPRH              8 60 0.608392 0.391281 1000 
7p21.2 AGMO               8 19 0.222777 0.434542 1000 
7p21.2 MEOX2              2 4 0.270729 0.410235 1000 
7p21.2 FERD3L             2 72 0.539461 0.386999 1000 
7p21.2 TWISTNB            3 11 0.0641872 0.406677 5000 
8q11.23 RGS20              2 2 0.724276 0.401227 1000 
8q11.23 LYPLA1             4 5 0.872128 0.433138 1000 
8q11.23 SOX17              3 5 0.0825835 0.409256 5000 
8q11.23 RP1                17 614 0.498501 0.387365 1000 
9p21.3 MTAP               3 142 0.511489 0.385122 1000 
9p21.3 DMRTA1             6 99 0.458541 0.361992 1000 
9q31.3 ACTL7B             7 225 0.0243951 0.357704 5000 
9q31.3 ACTL7A             3 15 0.877123 0.39043 1000 
9q31.3 IKBKAP             25 532 0.277722 0.439947 1000 
9q31.3 CTNNAL1            3 148 0.917083 0.412994 1000 
9q31.3 TMEM245            2 2 0.707293 0.415635 1000 
10q24.32 TMEM180            4 271 0.793207 0.372718 1000 
10q24.32 SUFU               4 28 0.953047 0.381939 1000 
10q24.32 TRIM8              2 2 0.696304 0.428279 1000 
10q24.32 WBP1L              6 164 0.863137 0.344598 1000 
10q24.32 CYP17A1            4 208 0.84016 0.36976 1000 
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10q24.32 AS3MT              2 24 0.874126 0.409238 1000 
10q24.32 C10orf32-
AS3MT     
2 24 0.866134 0.400477 1000 
10q24.32 CNNM2              4 161 0.0875825 0.358167 5000 
10q24.32 NT5C2              3 154 0.704296 0.383839 1000 
10q24.32 INA                5 27 0.00279944 0.455156 5000 
10q24.32 TAF5               3 85 0.833167 0.381828 1000 
10q24.32 PDCD11             16 322 0.306693 0.356928 1000 
10q24.32 CALHM2             6 18 0.04979 0.434441 5000 
10q24.32 CALHM1             6 241 0.537463 0.433275 1000 
13q13.1 PDS5B              3 117 0.47952 0.342009 1000 
13q13.1 KL                 12 278 0.401598 0.388544 1000 
13q13.1 STARD13            10 360 0.00079984 0.351073 5000 
18q11.2 GATA6              2 2 0.731269 0.441789 1000 
18q11.2 CTAGE1             6 174 0.0753849 0.371797 5000 
18q11.2 RBBP8              6 43 0.0585883 0.376427 5000 
18q11.2 CABLES1            3 68 0.00559888 0.356104 5000 
i 
 
i 
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